Mitochondrial DNA prostate cancer marker and related systems and methods

ABSTRACT

There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of the patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a national phase application under 35 U.S.C. § 371 of International Application No. PCT/CA2017/000139 filed Jun. 2, 2017, which claims the benefit of priority of U.S. Provisional Patent Application No. 62/344,723 filed Jun. 2, 2016, the entire contents of which are incorporated herein by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 28, 2022, is named UCLA_P0101US_Sequence_Listing.txt and is 8,301 bytes in size.

FIELD OF INVENTION

The present disclosure relates generally to a prostate cancer biomarker signature. More particularly, the present disclosure relates to a mitochondrial DNA for the prognosis of prostate cancer outcomes, which can inform treatment decisions and guide therapy.

BACKGROUND

Prostate cancer remains the most prevalent non-skin cancer in men¹ and exhibits a remarkably quiet mutational profile². Exome sequencing studies of localized tumours have revealed few recurrent somatic single nucleotide variants (SNVs)^(3,4), while whole-genome sequencing studies have not identified highly recurrent driver non-coding SNVs or genomic rearrangements (GRs)⁵⁻⁸. Although strong mutagenic field effects have been observed^(9,10), their underlying mechanisms and to what extent they drive tumour initiation or progression are unknown. Nevertheless, promising molecular diagnostics predictive of aggressive disease have been created using supervised machine-learning techniques, both from RNA abundance data^(11,12) and from DNA copy number data¹³, showing strong linkage between molecular features of prostate tumour cells and patient outcome.

Most studies of the prostate cancer genome have focused on mutations occurring in the nuclear genome, and have ignored the other genome of the cell: the mitochondrial genome. Mitochondria are maternally inherited and play critical roles in pathways dysregulated in cancer cells, including energy production, metabolism and apoptosis¹⁴. While mitochondrial mutations have been observed in several tumour types¹⁵⁻¹⁷, including prostate cancer¹⁸⁻²², their global frequency and clinical impact have not yet been comprehensively characterized. Previous studies have found that mitochondrial mutations are associated with increased serum prostate-specific antigen (PSA) levels²¹, have suggested that mtDNA mutations increase cancer cell tumourigenicity²⁰, and indicate that overall mitochondrial mutation burden is correlated with higher Gleason Scores²².

SUMMARY OF INVENTION

In an aspect, there is provided a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

In an aspect, there is provided a computer-implemented method of prognosing or predicting disease progression in a patient with prostate cancer, the method comprising: a) receiving, at at least one processor, sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); b) comparing, at the at least one processor, said sequencing data to corresponding control or reference sequences to determine mitochondrial single nucleotide variations (mtSNVs); d) determining, at the at least one processor, a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

In an aspect, there is provided a computer program product for use in conjunction with a general-purpose computer having a processor and a memory connected to the processor, the computer program product comprising a computer readable storage medium having a computer mechanism encoded thereon, wherein the computer program mechanism may be loaded into the memory of the computer and cause the computer to carry out the method described herein.

In an aspect, there is provided a computer readable medium having stored thereon a data structure for storing the computer program product described herein.

In an aspect, there is provided a device for prognosing or predicting disease progression in a patient with prostate cancer, the device comprising: at least one processor; and electronic memory in communication with the at one processor, the electronic memory storing processor-executable code that, when executed at the at least one processor, causes the at least one processor to: a) receive sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); b) compare said sequencing data to corresponding control or reference sequences to determine mitochondrial single nucleotide variations (mtSNVs); and c) determining, at the at least one processor, a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1. In some embodiments, the processor further displays the prostate cancer prognosis on a user display.

In an aspect, there is provided a kit for prognosing or predicting disease progression in a patient with prostate cancer, the kit comprising primer sequences that permit the sequencing of a mitochondrial genome to determine mtSNVs in ATP8, OHR, ND4L and CSB1.

Other aspects and features of the present disclosure will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments in conjunction with the accompanying figures.

BRIEF DESCRIPTION OF FIGURES

Embodiments of the present disclosure will now be described, by way of example only, with reference to the attached Figures and Tables.

FIG. 1 shows panorama of mitochondrial mutations in prostate cancer. (a) The top panel displays the number of mtSNVs per patient sorted first by T-Category and then by the number of mtSNVs; histogram bars are coloured by the average difference in the heteroplasmy fraction (ΔHF) between tumour and normal samples, light-blue 20-40%, medium-blue 40-60%, dark-blue ≥60%. A heatmap showing the location of each mtSNV on the mitochondrial genome (middle), where the colour of each dot represents ΔHF. The mitochondrial genome is represented on the left. The bottom panel shows the clinical covariates for all 384 patients: Age, Gleason Score, PSA and T-Category. Bottom right: Associations between the covariates and number of mtSNVs. (b) Frequency and distribution of single nucleotide variants (SNVs) within the mitochondrial genome. Mutation frequency normalized by dividing the number of mutations per locus of each patient by (length of the locus (kbp)×MCN). (c) Distribution of mtSNVs across the mitochondrial genome. mtSNVs were fairly evenly distributed across the genome (black bars) and recurrent mutation positions are indicated by the histogram.

FIG. 2 shows the difference in mitochondrial mutational frequency and copy number with age. (a) Association of nuclear (green) and mitochondrial (yellow) mutation SNV/Mbp rates with patient age. Mitochondrial mutation rate normalized by MCN. (b) Distribution of mtSNVs in EOPC (red) and LOPC (blue) patients. The histogram indicates presence and frequency of a mtSNV. The most recurrent mtSNV was at position 16093. (c) The fraction of patients by number of mtSNVs, EOPC (gray bars), LOPC (black bars). (d) Tumour mitochondrial copy number (MCN) for both patient age groups. EOPC: n=164; LOPC: n=220.

FIG. 3 shows associations between mitochondrial and nuclear genome mutations. (a) Correlations of mitochondrial features with nuclear genome features. The size and colour of the dot represents the Spearman correlation and the background shading represents the p-value. Nuclear features: SNVs, CTXs, INVs, kataegis data available for 172 patients; Chromothripsis: n=159; CNAs: MYC, NKX3-1 (n=203); CDH1, CDKN1B, CHD1, PTEN, RB1, TP53 (n=194); Methylation: n=104. Mitochondrial features: 216 patients. (b) Mutations in OHR are associated with CNAs in MYC. Heatmap showing those patients with CNA gains (red) in MYC and those with mtSNVs in OHR, CSB1, the control region and ATP6, mtSNV colour represents the ΔHF. Since CSB1 is a subregion within OHR, mutations in CSB1 are also considered as OHR mtSNVs, similarly, mtSNVs in OHR are also within the control region (n=203). The barplot on the right shows the fraction of patients with or without a MYC CNA that have a specific mtSNV. (c) Kaplan-Meier plot of 165 patients with OHR and MYC mutations. Patients were grouped according to whether they had neither MYC CNAs nor OHR SNVs (black line), a MYC CNA or an OHR mtSNV (blue) or had both (red line). The group that had a CNA gain in MYC and an mtSNV in the OHR region had significantly worse outcomes than those without the mutations. Biochemical RFR (Biochemical relapse-free rate).

FIG. 4 shows clinical impact of mitochondrial mutations in prostate cancer. (a) The associations of biochemical recurrence (BCR) and 21 mitochondrial features: 19 mitochondrial genes or regions, MCN (median-dichotomized), and mtSNV count (0 vs. 1+) were calculated using Cox models in 165 LOPC patients. Hazard ratios (HRs) are shown in the middle panel and p-values from the log-rank test in the right panel. The change in the 10 year survival for patients with mutations in each mitochondrial region is indicated (left panel). The colour of the bars indicate the average ΔHF for mtSNVs in that region; light-blue 20-40%, medium-blue 40-60%, dark-blue ≥60%. (b) Kaplan-Meier plots of mtSNVs occurring within HV1 and (c) OHR. (d) Kaplan-Meier plot of results of leave-one-out cross-validation predictions (p-value from log-rank test).

FIG. 5 shows the experimental design/experimental workflow for the project. Whole genome sequencing was performed on 333 CPC-GENE and EOPC samples. In addition, 51 publicly available samples with whole genome sequences were included in the dataset and realigned. Mitochondrial reads were extracted and the mitochondrial analysis tool MToolBox was run on the resulting BAM files. Heteroplasmic fractions (HF) were calculated for each nucleotide and only those positions that differed by ≥0.2 HF between the tumour and matched normal were included in the list of mtSNVs.

FIG. 6 shows MCN association with clinical variables. Tumour MCN categorized by age (a), T-category (b), and Gleason score (c). EOPC patients are indicated by red dots, LOPC by blue dots. (d) MCN of the matched normal samples show a significant difference between the two age groups.

FIG. 7 shows PCR validation confirms predicted mtSNVs. A comparison of chromatograms after PCR amplification and Sanger sequencing from (a) normal and (b) tumour samples from patient CPCG0196 for the mtDNA region: 187-208 (SEQ ID NOs: 41 and 42 respectively). Arrow indicates position 195 which has significant heteroplasmy in tumour.

FIG. 8 shows mtSNVs chosen for PCR validation. The 25 mtSNVs validated by PCR amplification and Sanger sequencing had varying levels in the difference in heteroplasmy (ΔHF) between tumour and normal samples. Light blue 20-40%, medium blue 40-60% and dark blue 60% ΔHF. mtDNA position on x-axis. Labels in red indicate those mtSNVs that failed PCR validation.

FIG. 9 shows frequency of mutations by patient and mitochondrial loci. Heatmap showing the distribution of mutations in the different mitochondrial regions (y-axis) by patients (x-axis). The difference in heteroplasmy fraction between tumour and normal sample (ΔHF) is indicated by colour, white: no mutation; light-blue: 20-40%; blue: 40-60% and dark blue ≥60%. Patients with more than one mtSNV in a particular mtDNA region are indicated by gray dots. Note: CSB1 and OHR are overlapping regions with the mtDNA Control region, mtSNVs in CSB1 are necessarily mtSNVs in OHR and both are mtSNVs within the Control region.

FIG. 10 shows distributions of mtSNV fractions by mitochondrial genome loci for EOPC and LOPC patients. The fraction of total mtSNVs per loci for EOPC and LOPC cohorts, those 50 years old (164 patients) and those >50 year old (220 patients) respectively.

FIG. 11 shows correlations between nuclear and mitochondrial features as a function of heteroplasmy fraction. Spearman's p (a) and p-values (b) were calculated using increasing ΔHF cutoffs for mtSNVs for several nuclear and mitochondrial features: MYC CNAs and OHR mtSNVs, the non-coding SNV chr4:39684557 and ND2 mtSNVs, TP53 SNVs and ND5 mtSNVs, and MYC CNAs and RNR2 mtSNVs. (c) The total number of mtSNVs for 384 patients at each ΔHF threshold (unadjusted).

FIG. 12 shows prognostic synergy between mitochondrial and nuclear mutations. Kaplan-Meier plots of patients with (a) methylation events in miR129-2 and mtSNVs in HV1 or (b) ND5; (c) NKX3-1 CNAs and OHR mtSNVs; (d) mtSNVs in HV1 and methylation events in TCERG1L-5′ or (e) TUBA3C; and (f) MYC CNAs and HV2 mtSNVs. Patients were grouped according to whether they had no mutations (black line), either a mtSNV or nuclear genomic mutation (blue) or had both (red line).

FIG. 13 shows signature flow chart and subset signature. (a) Flowchart showing details of the leave-one-out cross validation method. (b) Mitochondrial signature using three genes (HV1, OHR, CO3).

FIG. 14 shows mitochondrial signature in intermediate risk patients. Only patients classified as NCCN-intermediate risk were used with the mtSNV signature and were separated into three risk-prediction groups, ‘high’ (red line), ‘intermediate’ (black line), and ‘low’ (blue line).

FIG. 15 shows suitable configured computer device, and associated communications networks, devices, software and firmware to provide a platform for enabling one or more embodiments as described herein.

Table 1 shows results of PCR validation of 25 mtSNVs. The table includes the mtSNV position, which PCR primers were used to validate, the heteroplasmy fraction (adjusted by cellularity) of the major allele for both tumour and normal and the results of the PCR amplification and Sanger sequencing.

Table 2 shows results from univariate Cox proportional modeling. Hazard ratios were calculated for the different mitochondrial loci individually, the table includes the HR and 95% CI, p-values, the change in 10 year survival and the number of patients with a mtSNV in that loci.

Table 3 shows the sequence and mtDNA targeted region of 20 forward and reverse PCR primers.

Table 4 shows clinical and sequencing data per patient. The data includes patient age at treatment, Gleason Score, T-category, PSA (ng/mL) level, tumour cellularity, number of mtSNVs and the mean coverage depth, mitochondrial copy number for both normal and tumour sample and the aligner used for each wgs. The presence or absence of mutations in each of 20 mitochondrial regions and MYC and NKX3-1 copy number aberrations is indicated for each sample and the amount of DNA that was sent for sequencing for the CPC-GENE samples are included.

Table 5 shows 293 somatic mtSNVs. List of mtSNVs, including heteroplasmic fractions (HF), reference allele nucleotide, identity of tumour and normal major alleles and major allele heteroplasmy fractions (both adjusted and unadjusted by tumour cellularity), tumour and normal coverage at each position, the mtDNA gene or region and pathogenicity scores from MutPred and Polyphen2 obtained from MToolBox.

Table 6 shows mitochondrial mutation recurrence for 41 nuclear genomic features. The table includes the number of patients that had a specific nuclear genome CNA, GR, methylation event or SNV and of those patients the number that also harbours an mtSNV in any of 22 mtDNA features.

Table 7 shows mtSNVs with ΔHF values between 0.1 and 0.2. List of 265 mtSNVs, that had ΔHF values greater than 0.1, but less than 0.2. The table includes heteroplasmic frequencies, reference allele nucleotide, identity of tumour and normal major alleles and major allele heteroplasmy fractions, tumour and normal coverage at each position and the mtDNA gene or region.

DETAILED DESCRIPTION

Nuclear mutations are well-known to drive tumour incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally-inherited mitochondrial genome are poorly understood. To characterize the mitochondrial mutation landscape of prostate cancer, we analyzed the mitochondrial genomes of 384 adenocarcinomas of the prostate across all National Comprehensive Cancer Network (NCCN) defined risk categories, including 164 early-onset prostate cancers (EOPCs, age at diagnosis less than 50). We identified a median of one mitochondrial single nucleotide variant (mtSNV) per patient.

We identify recurrent mutational hotspots in the mitochondrial genome, which included recurrently mutated bases or recurrently mutated genes or regions. We also confirm increasing mutation burden with patient age²³⁻²⁶, identify interactions between nuclear and mitochondrial mutation profiles and reveal specific mitochondrial mutations enriched in aggressive prostate tumours. For example certain control region mtSNVs co-occur with gain of the MYC oncogene, and these mutations are jointly associated with patient survival.

These data demonstrate frequent mitochondrial mutation in prostate cancer, and suggest interplay between nuclear and mitochondrial mutational profiles in prostate cancer.

The methods described herein are useful for prognosing the outcome of a subject that has, or has had, a cancer associated with the prostate. The cancer may be prostate cancer or a cancer that has metastasized from a cancer of the prostate.

In an aspect, there is provided a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

The term “subject” as used herein refers to any member of the animal kingdom, preferably a human being and most preferably a human being that has, has had, or is suspected of having prostate cancer.

The term “sample” as used herein refers to any fluid (e.g. blood, urine, semen), cell, tumor or tissue sample from a subject which can be assayed for the biomarkers described herein.

The term “genetic material” used herein refers to materials found/originate in the nucleus, mitochondria and cytoplasm, which play a fundamental role in determining the structure and nature of cell substances, and capable of self-propagating and variation. In the context of the present methods, the genetic material is any material from which one can measure the biomakers described herein. The genetic material is preferably DNA.

The term “prognosis” as used herein refers to the prediction of a clinical outcome associated with a disease subtype which is reflected by a reference profile such as a biomarker reference profile. The prognosis provides an indication of disease progression and includes an indication of likelihood of death due to cancer. The prognosis may be a prediction of metastasis, or alternatively disease recurrence. In one embodiment the clinical outcome class includes a better survival group and a worse survival group. The term “prognosing or classifying” as used herein means predicting or identifying the clinical outcome of a subject according to the subject's similarity to a reference profile or biomarker associated with the prognosis. For example, prognosing or classifying comprises a method or process of determining whether an individual has a better or worse survival outcome, or grouping individuals into a better survival group or a worse survival group, or predicting whether or not an individual will respond to therapy.

The term “biomarker profile” as used herein refers to a dataset representing the state or expression level(s) of one or more biomarkers. A biomarker profile may represent one subject, or alternatively a consolidated dataset of a cohort of subjects, for example to establish a reference biomarker profile as a control.

As used herein, the term “control” refers to a specific value or dataset that can be used to prognose or classify the value e.g the measured biomarker or reference biomarker profile obtained from the test sample associated with an outcome. In one embodiment, a dataset may be obtained from samples from a group of subjects known to have cancer having different tumor states and/or healthy individuals. The state or expression data of the biomarkers in the dataset can be used to create a control value that is used in testing samples from new patients. In some embodiments, a cohort of subjects is used to obtain a control dataset. A control cohort patients may be a group of individuals with or without cancer. In a particularly embodiment, the control is a patient's own matched normal profile (e.g. from blood or normal tissue).

As used herein, “overall survival” refers to the percentage of or length of time that people in a study or treatment group are still alive following from either the date of diagnosis or the start of treatment for a disease, such as cancer. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works.

As used herein, “relapse-free survival” refers to, in the case of caner, the percentage of or length of time that people in a study or treatment group survive without any signs or symptoms of that cancer after primary treatment for that cancer. In a clinical trial, measuring the relapse-free survival is one way to see how well a new treatment works. It is defined as any disease recurrence or relapse (local, regional, or distant).

The term “good survival” or “better survival” as used herein refers to an increased chance of survival as compared to patients in the “poor survival” group. For example, the biomarkers of the application can prognose or classify patients into a “good survival group”. These patients are at a lower risk of death after surgery and can also be categorized into a “low-risk group”.

The term “poor survival” or “worse survival” as used herein refers to an increased risk of disease progression or death as compared to patients in the “good survival” group. For example, biomarkers or genes of the application can prognose or classify patients into a “poor survival group”. These patients are at greater risk of death or adverse reaction from disease or surgery, treatment for the disease or other causes, and can also be categorized into a “high-risk group”.

A person skilled in the art would understand how to implement differing cut-offs for good survival vs. worse survival, depending on the clinical outcome one is predicting and the biomarkers being assayed.

In some embodiments, the at least 1 patient biomarker, is at least 2, 3 or 4 patient biomarkers.

In some embodiments, the prostate cancer is localized prostate cancer, preferably non-indolent localized prostate cancer.

In some embodiments, the method further comprises building a patient biomarker profile from the determined or measured patient biomarkers.

In some embodiments, the prostate cancer prognosis is the likelihood of disease recurrence, preferably measured by biochemical relapse.

In some embodiments, the method further comprises classifying the patient into a high risk group if the likelihood of disease recurrence is relatively high or a low risk group if the likelihood of disease recurrence is relatively low.

In some embodiments, the method further comprises treating the patient with more aggressive therapy if the patient is in the high risk group. Preferably, the more aggressive therapy comprises adjuvant therapy, preferably hormone therapy, chemotherapy or radiotherapy.

In some embodiments, the patient biomarkers further comprise 002, CO3 and ND4L. Preferably, the at least 1 biomarker is at least 5, 6 or all 7 biomarkers. Further preferably, the at least 1 biomarker is all 7 biomarkers.

In some embodiments, the subject is classified as low risk if there exists mtSNVs in CO2, CO3, and HV1 and high risk if there exists mtSNVs in ATPS, OHR, ND4L and CSB1.

In some embodiments, the mtSNVs are the mtSNVs identified in Table 5. [NTD: Please confirm]

The present system and method may be practiced in various embodiments. A suitably configured computer device, and associated communications networks, devices, software and firmware may provide a platform for enabling one or more embodiments as described above. By way of example, FIG. 15 shows a generic computer device 100 that may include a central processing unit (“CPU”) 102 connected to a storage unit 104 and to a random access memory 106. The CPU 102 may process an operating system 101, application program 103, and data 123. The operating system 101, application program 103, and data 123 may be stored in storage unit 104 and loaded into memory 106, as may be required. Computer device 100 may further include a graphics processing unit (GPU) 122 which is operatively connected to CPU 102 and to memory 106 to offload intensive image processing calculations from CPU 102 and run these calculations in parallel with CPU 102. An operator 107 may interact with the computer device 100 using a video display 108 connected by a video interface 105, and various input/output devices such as a keyboard 115, mouse 112, and disk drive or solid state drive 114 connected by an I/O interface 109. In known manner, the mouse 112 may be configured to control movement of a cursor in the video display 108, and to operate various graphical user interface (GUI) controls appearing in the video display 108 with a mouse button. The disk drive or solid state drive 114 may be configured to accept computer readable media 116. The computer device 100 may form part of a network via a network interface 111, allowing the computer device 100 to communicate with other suitably configured data processing systems (not shown). One or more different types of sensors 135 may be used to receive input from various sources.

The present system and method may be practiced on virtually any manner of computer device including a desktop computer, laptop computer, tablet computer or wireless handheld. The present system and method may also be implemented as a computer-readable/useable medium that includes computer program code to enable one or more computer devices to implement each of the various process steps in a method in accordance with the present invention. In case of more than computer devices performing the entire operation, the computer devices are networked to distribute the various steps of the operation. It is understood that the terms computer-readable medium or computer useable medium comprises one or more of any type of physical embodiment of the program code. In particular, the computer-readable/useable medium can comprise program code embodied on one or more portable storage articles of manufacture (e.g. an optical disc, a magnetic disk, a tape, etc.), on one or more data storage portioned of a computing device, such as memory associated with a computer and/or a storage system.

In an aspect, there is provided a computer-implemented method of prognosing or predicting disease progression in a patient with prostate cancer, the method comprising: a) receiving, at at least one processor, sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); b) comparing, at the at least one processor, said sequencing data to corresponding control or reference sequences to determine mitochondrial single nucleotide variations (mtSNVs); d) determining, at the at least one processor, a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

In some embodiments, the method further comprises displaying the prostate cancer prognosis on a user display.

In an aspect, there is provided a computer program product for use in conjunction with a general-purpose computer having a processor and a memory connected to the processor, the computer program product comprising a computer readable storage medium having a computer mechanism encoded thereon, wherein the computer program mechanism may be loaded into the memory of the computer and cause the computer to carry out the method described herein.

In an aspect, there is provided a computer readable medium having stored thereon a data structure for storing the computer program product described herein.

In an aspect, there is provided a device for prognosing or predicting disease progression in a patient with prostate cancer, the device comprising: at least one processor; and electronic memory in communication with the at one processor, the electronic memory storing processor-executable code that, when executed at the at least one processor, causes the at least one processor to: a) receive sequencing data of mitochondrial genetic material from prostate cancer cells of the patient, the sequencing data reflecting at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); b) compare said sequencing data to corresponding control or reference sequences to determine mitochondrial single nucleotide variations (mtSNVs); and c) determining, at the at least one processor, a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1. In some embodiments, the processor further displays the prostate cancer prognosis on a user display.

As used herein, “processor” may be any type of processor, such as, for example, any type of general-purpose microprocessor or microcontroller (e.g., an Intel™ x86, PowerPC™, ARM™ processor, or the like), a digital signal processing (DSP) processor, an integrated circuit, a field programmable gate array (FPGA), or any combination thereof.

As used herein “memory” may include a suitable combination of any type of computer memory that is located either internally or externally such as, for example, random-access memory (RAM), read-only memory (ROM), compact disc read-only memory (CDROM), electro-optical memory, magneto-optical memory, erasable programmable read-only memory (EPROM), and electrically-erasable programmable read-only memory (EEPROM), or the like. Portions of memory 102 may be organized using a conventional filesystem, controlled and administered by an operating system governing overall operation of a device.

As used herein, “computer readable storage medium” (also referred to as a machine-readable medium, a processor-readable medium, or a computer usable medium having a computer-readable program code embodied therein) is a medium capable of storing data in a format readable by a computer or machine. The machine-readable medium can be any suitable tangible, non-transitory medium, including magnetic, optical, or electrical storage medium including a diskette, compact disk read only memory (CD-ROM), memory device (volatile or non-volatile), or similar storage mechanism. The computer readable storage medium can contain various sets of instructions, code sequences, configuration information, or other data, which, when executed, cause a processor to perform steps in a method according to an embodiment of the disclosure. Those of ordinary skill in the art will appreciate that other instructions and operations necessary to implement the described implementations can also be stored on the computer readable storage medium. The instructions stored on the computer readable storage medium can be executed by a processor or other suitable processing device, and can interface with circuitry to perform the described tasks.

As used herein, “data structure” a particular way of organizing data in a computer so that it can be used efficiently. Data structures can implement one or more particular abstract data types (ADT), which specify the operations that can be performed on a data structure and the computational complexity of those operations. In comparison, a data structure is a concrete implementation of the specification provided by an ADT.

In an aspect, there is provided a kit for prognosing or predicting disease progression in a patient with prostate cancer, the kit comprising primer sequences that permit the sequencing of a mitochondrial genome to determine mtSNVs in ATPS, OHR, ND4L and CSB1.

In some embodiments, the primers further permit sequencing of CO2, CO3 and ND4L.

The above listed aspects and/or embodiments may be combined in various combinations as appreciated by a person of skill in the art. The advantages of the present disclosure are further illustrated by the following examples. The examples and their particular details set forth herein are presented for illustration only and should not be construed as a limitation on the claims of the present invention.

EXAMPLES

Methods/Materials

Patient Cohort

We collected 384 prostate cancer tumour samples with matched normal samples (381 blood, 3 tissue-derived). The samples had Gleason Scores ranging from 3+3 to 5+4. The 165 patients from the Canadian Prostate Cancer Genome Network (CPC-GENE) underwent either radical prostatectomy or image-guided radiotherapy as detailed in Fraser et al. (2017)⁷. In addition, 51 samples from publicly available datasets were included in the somatic mutation analysis and correlations with clinical variables, age, Gleason Score and T-category^(4-6,8), three of TOGA samples had tissue-derived normal samples as opposed to blood-normals. All samples were manually macro-dissected and were assessed by an expert urological pathologist to have tumour cellularity >70%. All tumour specimens were taken from the index lesion. Publicly available tumour tissues were obtained and used following University Health Network Research Ethics Board (REB) approved study protocols (UHN 06-0822-CE, UHN 11-0024-CE, CHUQ 2012-913:H12-03-192). Local REB and ICGC guidelines were used to collect whole blood and informed consent from CPC-GENE patients at the time of clinical follow-up.

EOPC Patient Cohort and Sample Processing

We collected 168 tumour samples from EOPC patients. Informed consent and an ethical vote (institutional reviewing board) were obtained according to the current ICGC guidelines. The patients did not receive any neo-adjuvant radiotherapy, androgen deprivation therapy, or chemotherapy prior to the surgical removal of tumor tissue. Tumor samples and a normal blood control were frozen at −20° C. and subsequently stored at −80° C.

EOPC DNA Library Preparation, Sequencing and Alignment

DNA library preparation and whole-genome sequencing was performed on Illumina sequencers with the raw length of the reads displaying a median of 101 bp. Reads were aligned to the hg19 reference genome using BWA-MEM version 0.7.8-r455 [arXiv:1303.3997v2] and duplicates were removed using Picard (available on the World Wide Web at broadinstitute.github.io/picard). Mitochondrial reads were extracted using SAMtools³⁹.

Nuclear Mutation Calling

Recurrent nuclear genomic features were obtained from Fraser et al. (2017)⁷, which included five recurrent coding SNVs from commonly mutated genes in prostate cancer; the six most recurrent noncoding SNVs; CNAs from eight commonly mutated prostate cancer genes; the 10 GRs included the five most recurrent translocations and the four most recurrent inversions plus a recurrent inversion containing the PTEN gene; the TMPRSS-ERG fusion; presence or absence of kataegis events; chromothripsis; 3 metrics of mutation density (median dichotomized PGA estimates, number of SNVs and number of GRs); six methylation events were identified through univariate CoxPH modelling as associated with disease progression. Nuclear somatic single nucleotide variants were predicted by SomaticSniper (v1.0.2)³⁸, (n=172 samples) setting the mapping quality threshold to 1, otherwise with default parameters. Nuclear SNVs were filtered using SAMtools (v0.1.6)³⁹ and SomaticSniper (v1.0.2) provided filters, as well as a mapping quality filter and false positive filter from bam-readcount (downloaded Jan. 10, 2014). Nuclear SNVs were then annotated by ANNOVAR (v2015-06-17)⁴⁰. The nuclear mutation rate was obtained by dividing the number of SNVs after filtering by the number of callable loci. Copy number aberrations were analyzed by Affymetrix OncoScan microarrays (n=194) and methylation data was generated by Illumina Infinium Human Methylation 450k BeadChip kits (n=104). Genomic rearrangements were called using Delly (v0.5.5)⁴¹ (n=172). Chromothripsis scores (n=159) were calculated by ShatterProof (v0.14)⁴² and subsequently dichotomized with a 0.517 threshold. Sample processing, whole genome sequencing and whole genome sequencing data analysis are as described in detail by Fraser et al. (2017)⁷.

Mitochondrial SNV Calling

Reads mapped to the mitochondria during whole genome alignment were extracted using BAMQL (v1.1)⁴³ using the command:

bamql -I -o out_mito_reads.bam -f input_wgs.bam ‘(chr(M) & mate_chr(M)) |(chr(Y) & after(59000000) & mate_chr(M))’;

The second part of the query statement collects reads where one of the pair mapped to chrM and the other unmapped which in our data was also assigned to an unresolved region in chrY.

The output files from BAMQL were used as input barn files for the mitochondrial genome analysis program MToolBox (v0.2.2)⁴⁴. The versions of the various system requirements were: Python v2.7.2; gmap v.2013-07-20⁴⁵; samtools v0.1.18³⁹; java v1.7.0_72; picard v1.92 (available on the World Wide Web at broadinstitute.github.io/picard); muscle v3.8.31⁴⁶. We used default parameters for MToolBox and used the default RSRS⁴⁷ as the reference genome. The default parameters include a minimum base quality score of 25, samples that failed the MToolBox program using default parameters, but successfully completed at a lower base quality parameter setting of 20, were nonetheless removed from the analysis.

MToolBox_v0.2.2/MToolBox.sh bam -r RSRS -M -I -m′-D genome_index/-H hg19RSRS -M chrRSRS′-a′-r genome_fasta/-F -P -C′

The predicted mitochondrial genome for each tumour sample and the number of reads supporting each base were compared to the corresponding normal sample if available, from each patient. Positions where the absolute difference in heteroplasmy fraction (ΔHF) was greater than 0.2 were considered to be mitochondrial SNVs (mtSNVs). While this does not preclude the possibility of tissue-specific heteroplasmy being mislabeled as somatic mutations, this allowed us to identify somatic variants as well as ignore those positions that could be called population variants, reducing the number of potentially false positive variant calls. Heteroplasmy fraction estimates were adjusted to account for tumour cellularity using cellularity values calculated by qpure⁴⁸. Tumour HF values were adjusted with the following equation: Tumour HF_(cellularity)=(Tumour HF_(MToolBox)−(1−cellularity)*Normal HF_(MToolBox))/cellularity

If there were no cellularity values available we assumed cellularity=1.0. Those values of Tumour HF_(cellularity) that were less than zero or greater than one were rounded to zero and one respectively.

In the mitochondrial reference genome there are three positions encoded as ‘N’ to preserve historical numbering, (523, 524 and 3107), in addition position 310 is located within a homopolymer region and is a common variant²⁸. These four positions can result in misalignments⁴⁹, therefore they were filtered out of our analyses, as in previous studies⁵⁰. We also filtered out those positions with relatively low coverage of less than 100 read depth. Positions of mitochondrial genes and subregions of the noncoding control region were obtained from the World Wide Web at mitomap.org. Pathogenicity scores from MutPred⁵¹, PolyPhen-2⁵² and SiteVar⁵³ were obtained from the MToolBox output. Mutations in tRNA genes were compared to the Mamit-tRNA database⁵⁴.

We chose to a threshold of 0.2 ΔHF in order to balance removing false positives without excluding a large number of mtSNVs unnecessarily (FIG. 11c ). As part of this assessment, we looked at four correlations between different nuclear and mitochondrial features using mtSNVs assessed at increasing ΔHF cutoffs from 0.1-0.6 (FIG. 11, Table 7). In each of these four cases, raising ΔHF from 0.1 to 0.2 led to increasing correlation coefficients between the two features. Three of the correlations that were not significant at 0.1 ΔHF, became significant at higher ΔHF, suggesting that some mtSNVs with lower HF values may be either false positives or low-level tissue specific heteroplasmies. Any further increases in ΔHF had differing effects on the four correlations.

mtDNA Copy Number

Mitochondrial copy number per cell (MCN) was calculated using the equation: (mitochondrial coverage/nuclear coverage) ×2, using nuclear coverage data from the whole genome alignment⁷ and mitochondrial coverage data calculated by bedtools genomecov (v2.24.0)⁵⁵. The mitochondrial mutation rate per megabase DNA was calculated by dividing the number of mtSNVs by the tumour MCN multiplied by the number of callable bases, 16565, accounting for the 4 positions that were removed.

Survival and Statistical Analyses

The mtSNV data were compared to patient clinical features in the R statistical environment (v3.2.3). Binomial regression (age, PSA) and Chi-square tests (T-category, Gleason Score) were used to identify associations between the clinical variables and mtSNVs for all 384 patients. Survival analyses were performed on 165 patients due to survival data availability. Cox proportional hazards models were used to calculate HRs for mtSNVs in the different mitochondrial features such as genes or MCN, with verification of the proportional hazards assumption. The mitochondrial feature MT-ND4L was removed from this analysis as only one patient in the 165 cohort had a mtSNV in this gene. Change in 10 year percent survival was calculated using survival rates. Kaplan-Meier plots were created comparing biochemical recurrence with the presence or absence of mutations in certain mitochondrial loci, (genes or noncoding regions) or median-dichotomized tumour MCN. Nuclear genomic features were chosen based on recurrence in a previous prostate cancer study⁷. Data was visualized using the R-environment and lattice (v0.20-31), latticeExtra (v0.6-26) and circos (v0.67-4)⁵⁶. Associations between nuclear and mitochondrial genome features were calculated using Spearman's correlation.

PCR Validation

Single nucleotide variants in mitochondrial DNA were validated by Sanger re-sequencing, as previously reported⁷. Briefly, 10 ng of total genomic DNA (including mitochondrial DNA) was subjected to PCR amplification using primer pairs flanking SNVs identified from whole-genome sequencing (Table 3). Sequence data surrounding the region of interest was obtained from the World Wide Web at mitomap.org/bin/view.pl/MITOMAP/HumanMitoSeq. The amplicon sequence generated by the in silico PCR was then entered into the NCBI genome BLAST search engine to identify non-mitochondrial sequences that were similar. This was done to ensure that there were some differences between the designed primers and nuclear sequences, as well as to identify any sequence regions that could confound downstream analyses. The genome used for the BLAST search was GRCh38.p2 reference assembly top-level. These web pages were used on Aug. 20 and 21, 2015 and verified on Sep. 13, 2016. PCR reactions were purified using the QIAquick PCR purification kit (Qiagen, Toronto, Canada). Sanger re-sequencing was performed using amplicon-specific primers on an ABI 3730XL capillary electrophoresis instrument (Thermo Fisher Scientific, Burlington, Canada) at The Centre for Applied Genomics, Hospital for Sick Children, Toronto, Canada.

Data Availability Statement

Sequencing data is available at the European Genotype-Phenotype Archive (EGA) repository under accession EGAS00001001782.

Results

Mitochondrial Genome Sequence Analysis

We collected 384 tumours from patients with localized prostate cancer, comprising 164 EOPCs and 220 late-onset prostate cancers (LOPC; Table 4; FIG. 5). The LOPC patients represented the three NCCN risk groups: 19 low-risk, 151 intermediate-risk and 36 high-risk. The average sequencing depth of the mitochondrial genome was 13,577x, allowing extremely sensitive mutation detection. This cohort does not include any nuclear whole genome duplication events, as demonstrated by SNP microarray analysis⁷. We first evaluated the mitochondrial copy number (MCN) for each sample from the sequencing coverage of the mitochondrial and nuclear genomes. MCN ranged from 75 to 1405 (mean: 431) across the cohort, and was strongly associated with age (linear model, p=1.67×10⁻²⁶), as well with clinical indices such as T-category (ANOVA, p=6.01×10⁻³) and Gleason Score (GS; ANOVA, p=6.46×10⁻³; FIG. 6).

We next conservatively identified mitochondrial SNVs (mtSNVs) as those positions that had an absolute difference in their heteroplasmy fraction (ΔHF) between purity-adjusted tumour and paired-normal samples of at least 0.20 (FIG. 5). Because the number of identified mtSNVs is dependent on the heteroplasmy fraction threshold, we chose to balance false positives and false negatives with an intermediate value. There were 293 mtSNVs across all patients, with 47.4% of tumours (182/384) harbouring at least one and 6.8% (26/384) harbouring three or more FIG. 1a ; Table 5). Proportions of patients with 0, 1, 2, ≥3 mtSNVs are 202/384 (52.6%), 110/384 (28.6%), 46/384 (12.0%) and 26/384 (6.8%), respectively. The number of patients with no mtSNVs was greater than expected by chance, suggesting significant variability in mtSNV burden (permutation test; p=3.4×10⁻⁵). Tumours with a larger number of mitochondria were more likely to have an mtSNV (generalized linear model (GLM) family binomial; p=8.38×10⁻⁷). mtSNVs were associated with tumour size (T-category; x² test; p=2.47×10⁻⁴), but not other clinical prognostic indices like pre-treatment PSA and GS (FIG. 1a ). PCR followed by Sanger sequencing validated 18/25 predicted mtSNVs (FIG. 7; FIG. 8; Table 1), suggesting precision of ˜75%, comparable to somatic indel detection accuracy²⁷.

Frequently Mutated Mitochondrial Loci

The noncoding control region of the mitochondria (mtDNA positions: 1-576 and 16024-16569), was the most frequently mutated region with 15.4% (59/384) of tumours harbouring mutations in that region (Table 5; FIG. 9). The control region comprises several elements, including the heavy- and light-strand promoters, as well as the origins of replication for the heavy strand (OHR), two hypervariable regions (HV1, HV2) and three conserved sequence blocks (CSB1, CSB2, CSB3). All functional locations were defined from mitmap.org²⁸. Of these regions, HV1 was the most frequently mutated (mtDNA positions: 16024-16383). Overall, mutation rates were generally consistent across regions of the mitochondrial genome (FIG. 1b ).

There were 157 mtSNVs in the 13 protein coding genes, 82% (129/157) of which were nonsynonymous, including 6 premature stop codons and two mutated stop codons. The most frequently mutated protein coding gene was ND5 (30/157). We identified 21 specific positions mutated in at least two patients (FIG. 1c ): ten within the control region, eight in protein-coding regions and three in rRNA subunits. Of the coding mutations, seven were non-synonymous and one introduced a premature stop codon. In the control region, position 16093—a common site of tissue specific heteroplasmy^(29,30)—was the most frequently mutated position (nine patients; FIG. 1c ). Of protein-coding genes, ND1 was frequently mutated, with two patients having G3946A mutations (ΔHF: 0.63, 0.24), leading to a structure-disrupting E214K amino acid change, resulting in a reduction of complex assembly³¹. A second mutation, G4142A was found in two patients (ΔHF: 1.0, 0.21; R279Q) and a third mutation, G3842A, in three patients (ΔHF: 0.45, 0.21, 0.95; premature stop codon).

There were 22 mutations within mitochondrial tRNA genes, and eight of these were located within anticodon stems. In CO1 there were non-synonymous mutations at G5910A (A2T in one patient; ΔHF: 0.84) and T6664C (1254T in one patient; ΔHF: 0.46), two amino acids previously observed to be mutated in prostate cancer cells²⁰. Two patients with mutations at position 6419 were detected within the CO1 gene (ΔHF: 0.2, 0.23), although these two showed heteroplasmy within the normal samples and homoplasmy in the tumour suggesting that these mtSNVs represent either tissue-specific heteroplasmy³² or mutations that have gone to fixation in the tumour. Overall CO1 was mutated in 4.7% (18/384) of patients, markedly lower than the 11% rate previously reported²⁰.

Age Effect on the Distribution of mtSNVs in Prostate Cancer

As expected, the occurrence of mitochondrial mutations was strongly associated with patient age (GLM family binomial; p=5.88×10⁻⁹; FIG. 1a )²³⁻²⁶. The mitochondrial mutation rate was significantly lower than that of the nuclear genome mutation rate (FIG. 2a ; p=0.040, F-test), which may in part be explained by differential mutation detection accuracy in the two genomes. To further understand the association of mtSNVs with age, we separated patients into those 50 and under years of age (EOPC; n=164) and those over 50 (LOPC; n=220). The median ages of the EOPC and LOPC cohorts were 47 and 63.5 years old, respectively. Patients with EOPC were significantly more likely to have no mitochondrial mutations, 117/164 (71.3%), than those with LOPC (85/220, 38.6%; p=4.22×10⁻¹⁰, proportion test; FIG. 2b, c ). Despite this difference in mutational load, the two groups have similar distributions of mtSNVs across the mitochondrial genome, with the highest fraction of mtSNVs within the control region (FIG. 10). EOPC patients had about 224 fewer copies of the mitochondria than LOPC patients (Mann-Whitney test; p=4.56×10⁻³⁰; FIG. 2d ). This effect was inverted in the normal samples with EOPC patients having 86 more copies (Mann-Whitney; p=1.54×10⁻¹⁴; FIG. 6d ), consistent with the decline in lymphocyte MCN with age³³.

Associations Between mtSNVs and Nuclear Genomic Mutations

Intriguingly, mutations in the large rRNA subunit (RNR2) were significantly correlated with mutations in the mitochondrial gene ND4 (Spearman's p=0.19; p=0.00015), suggesting to us an inter-play between different mutational types. To rigorously assess this phenomenon, we studied mutational associations between the nuclear and mitochondrial genomes. We exploited a set of 40 candidate nuclear somatic driver events recently identified through recurrence analyses, including five measures of mutation density, six methylation events, six non-coding SNVs, five coding SNVs, five measures of mutational density, ten genomic rearrangements and eight copy number aberrations (CNAs)⁷. The SNVs included recurrent coding SNVs in genes that are commonly mutated in prostate cancer, as well as the six most recurrent non-coding SNVs. To characterize per-region mtSNVs, we defined 22 mutational features representing the broad functional aspects of the mitochondria, 13 protein coding genes, 2 rRNAs, tRNAs (treated as one group), the control region and 3 subregions within the control region, along with mtSNV number and MCN. For each of the nuclear features, we evaluated their correlation to 22 mitochondrial mutational features in 194 LOPCs with nuclear mutational data (Table 6). We detected multiple nuclear-mitochondrial mutational associations (FIG. 3a ). For example, SNVs in FOXA1 were significantly positively correlated with multiple mitochondrial features, as were SNVs in MED12. Nuclear-mitochondrial correlations were weakly dependent on the ΔHF threshold used to call mtSNVs (FIG. 11, Table 7).

One prominent nuclear-mitochondrial mutational interactions was co-occurrence of MYC copy number gain and mtSNVs within the OHR (FIG. 3b ). Mutations within the OHR may dysregulate mtDNA replication, while MYC induces mitochondrial biogenesis by activating genes required for mitochondrial function³⁴ and influences metabolic plasticity in cancer stem cells³⁵. Risk of biochemical failure (BCR) after primary definitive treatment by radiotherapy or surgery was significantly higher for patients whose tumours harboured both MYC CNAs and OHR mtSNVs relative to those with neither or one of these two mutations, suggesting a synergistic mitochondrial-nuclear effect on disease aggression (FIG. 3c ). Several other similar instances of apparent synergistic mitochondrial-nuclear effects on disease aggression were observed (FIG. 12a-e ), suggesting that this is a common phenomenon in prostate cancer. While we have used the region defined as OHR (mtDNA positions: 110-441) as the mitochondrial feature, this subregion of the Control Region significantly overlaps with a region defined as HV2 (mtDNA positions: 57-372). We confirmed that HV2 mtSNVs show the same synergistic effect with MYC CNAs as mtSNVs defined as OHR (FIG. 12f ). Interestingly, MYC CNAs were more common in LOPCs (14.5%; 29/200) than in EOPCs (8.4%; 10/119) making it impossible to assess if the same nuclear-mitochondrial interactions occur in both disease states. Further evaluation of changes in nuclear-mitochondrial associations across disease progression will be revealing.

Clinical Impact of mtSNVs in Prostate Cancer

The recurrence of mitochondrial mutations in specific regulatory regions and their association with prognostic nuclear mutations strongly suggested their ability to drive disease aggression. We therefore systematically evaluated the association of individual mitochondrial somatic mutational features with disease aggression in 165 patients with clinical follow-up using Cox proportional hazards modeling. Of our 22 mitochondrial mutational features (FIG. 3a ), four were significantly associated with biochemical relapse rates (FIG. 4a ; Table 2): mutations in CSB1, OHR, ATP8 and HV1. We should note that MT-ND4L was not included in this analysis as only one patient of the 165 had a mtSNV in this gene. To evaluate if these mutations were independent prognostic variables, we employed multivariable modeling to adjust for age, pre-treatment PSA, T-category and GS. After adjustment, mtSNVs in HV1 were associated with better patient outcome (FIG. 4b ; Hazard Ratio, HR=0.28, 95% CI=0.08-0.9, p=0.032, Wald test), while mtSNVs in OHR were associated with significantly worse patient outcome (FIG. 4c ; HR=2.47, 95% CI=1.13-5.38, p=0.023, Wald test).

These data suggested that mtSNVs might comprise a novel way to predict patient outcome. We therefore assessed the ability of a multi-mtSNV signature to identify patients at elevated risk for biochemical failure (who therefore might benefit from treatment intensification) and those at low risk (who might therefore be appropriate for surveillance protocols). Using leave-one-out cross-validation and univariate feature-selection, we created a three-class signature that separated patients into three distinct risk groups for biochemical failure (FIG. 13a ). The signature identified both patients at elevated risk (FIG. 4d ; HR=3.41, 95% CI=1.71-6.80, p=0.0005, Wald test) and patients at low-risk (HR=0.23, 95% CI=0.08-0.65, p=0.005, Wald test). These effects are independent of clinical features: when we considered only the clinically-homogeneous NCCN intermediate risk group, the same mtSNV signature again separated three groups with distinct risk profiles (FIG. 14). The cross-validation method identified seven genes (CO2, CO3, ATP8, HV1, OHR, CSB1, ND4L) as informative for classification. Patients with mtSNVs in (CO2, CO3, HV1) were classified as low-risk and patients with mtSNVs in (ATP8, OHR, ND4L, CSB1) were classified as high-risk. To show that this does not lead to over-fitting, we chose the three most frequently mutated regions of the seven (CO3, HV1, OHR) which also clearly separated patients into three groups (FIG. 13b ).

Discussion

The mitochondrial mutational landscape of cancer has been relatively unexplored. Previous work has shown a large-scale mtDNA deletion has predictive value in the prostate biopsy outcomes³⁶, suggesting the feasibility of mtDNA-based molecular tests. We identify a large number of mtSNVs in localized prostate cancer. These mutations show complex interplay with nuclear mutational characteristics, and appear to work together to drive tumour aggressiveness.

Mitochondrial mutations also show associations with risk of biochemical relapse. Interestingly, mtSNVs within the control region can have conflicting outcomes, however when separated into the different noncoding subregions (HV1, OHR) we found that certain loci were associated with better outcomes and others with worse outcomes. The overlap of the OHR and HV2 within the control region and their association with MYC CNAs highlight the need for better understanding of the functions of the control region³⁷. In future, treating the control region as distinct regulatory regions may provide further insight into the roles of these regions, as well as any contribution they may make towards tumour aggression. We note that the number of pairs of nuclear-mitochondrial mutational features tested may elevate false-positive rates, and it will be key to perform validation studies in larger cohorts to verify their effect-sizes and biological significance.

The differences observed in the mitochondrial mutational profiles of EOPC and LOPC patients show a need to better understand the association between mtSNVs and aging and how this may relate to the development of prostate cancer. While the mitochondrial copy number of matched-normal samples decreases with patient age, a previously observed trend³³, tumour MCN estimates were significantly higher in older patients which could account for the higher frequency of mtSNVs in these patients. However, since the majority of the samples of each age group come from different research centres, this striking difference in tumour MCN will require further investigation to exclude any confounding effects.

Further studies will be needed to assess when different mtSNVs occur during tumour evolution, their timing relative to common nuclear mutations and the effects of these mutations on mitochondrial function. This will more clearly identify the mitochondrial mutations that are important for mitochondrial-nuclear communication and how they may interact to drive tumour formation. Localized prostate cancer remains the most diagnosed non-skin cancer in men, and identification of aggressive disease remains an urgent clinical dilemma. Addition of mtSNVs to prognostic biomarkers may be an effective way of improving prediction of patient outcome, supporting triage of patients with low-risk disease to surveillance protocols and with high-risk disease to adjuvant therapy regimens.

All documents disclosed herein, including those in the following reference list, are incorporated by reference. Although preferred embodiments of the invention have been described herein, it will be understood by those skilled in the art that that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

REFERENCES

-   1. Lozano, R. et al. Global and regional mortality from 235 causes     of death for 20 age groups in 1990 and 2010: a systematic analysis     for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128     (2012). -   2. Barbieri, C. E. et al. The mutational landscape of prostate     cancer. Eur. Urol. 64, 567-576 (2013). -   3. Barbieri, C. E. et al. Exome sequencing identifies recurrent     SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44,     685-689 (2012). -   4. Cancer Genome Atlas Research Network. The Molecular Taxonomy of     Primary Prostate Cancer. Cell 163, 1011-1025 (2015). -   5. Baca, S. C. et al. Punctuated evolution of prostate cancer     genomes. Cell 153, 666-677 (2013). -   6. Berger, M. F. et al. The genomic complexity of primary human     prostate cancer. Nature 470, 214-220 (2011). -   7. Fraser, M. et al. Genomic hallmarks of localized, non-indolent     prostate cancer. Nature 541, 359-364 (2017). -   8. Weischenfeldt, J. et al. Integrative genomic analyses reveal an     androgen-driven somatic alteration landscape in early-onset prostate     cancer. Cancer Cell 23, 159-170 (2013). -   9. Boutros, P. C. et al. Spatial genomic heterogeneity within     localized, multifocal prostate cancer. Nat. Genet. 47, 736-745     (2015). -   10. Cooper, C. S. et al. Analysis of the genetic phylogeny of     multifocal prostate cancer identifies multiple independent clonal     expansions in neoplastic and morphologically normal prostate tissue.     Nat. Genet. 47, 367-372 (2015). -   11. Erho, N. et al. Discovery and validation of a prostate cancer     genomic classifier that predicts early metastasis following radical     prostatectomy. PloS One 8, e66855 (2013). -   12. Wu, C.-L. et al. Development and validation of a 32-gene     prognostic index for prostate cancer progression. Proc. Natl. Acad.     Sci. U.S.A 110,6121-6126 (2013). -   13. Lalonde, E. et al. Tumour genomic and microenvironmental     heterogeneity for integrated prediction of 5-year biochemical     recurrence of prostate cancer: a retrospective cohort study. Lancet     Oncol. 15,1521-1532 (2014). -   14. Wallace, D. C. Mitochondria and cancer. Nat. Rev. Cancer     12,685-698 (2012). -   15. Kumimoto, H. et al. Frequent somatic mutations of mitochondrial     DNA in esophageal squamous cell carcinoma. Int. J. Cancer     108,228-231 (2004). -   16. Larman, T. C. et al. Spectrum of somatic mitochondrial mutations     in five cancers. Proc. Natl. Acad. Sci. U.S.A 109,14087-14091     (2012). -   17. McMahon, S. & LaFramboise, T. Mutational patterns in the breast     cancer mitochondrial genome, with clinical correlates.     Carcinogenesis 35,1046-1054 (2014). -   18. Chen, J. Z., Gokden, N., Greene, G. F., Mukunyadzi, P. &     Kadlubar, F. F. Extensive somatic mitochondrial mutations in primary     prostate cancer using laser capture microdissection. Cancer Res.     62,6470-6474 (2002). -   19. Gómez-Zaera, M. et al. Identification of somatic and germline     mitochondrial DNA sequence variants in prostate cancer patients.     Mutat. Res. 595,42-51 (2006). -   20. Petros, J. A. et al. mtDNA mutations increase tumorigenicity in     prostate cancer. Proc. Natl. Acad. Sci. U.S.A 102,719-724 (2005). -   21. Kloss-Brandstätter, A. et al. Somatic mutations throughout the     entire mitochondrial genome are associated with elevated PSA levels     in prostate cancer patients. Am. J. Hum. Genet. 87,802-812 (2010). -   22. McCrow, J. P. et al. Spectrum of mitochondrial genomic variation     and associated clinical presentation of prostate cancer in South     African men. Prostate 76,349-358 (2016). -   23. Cortopassi, G. A. & Arnheim, N. Detection of a specific     mitochondrial DNA deletion in tissues of older humans. Nucleic Acids     Res. 18,6927-6933 (1990). -   24. Corral-Debrinski, M., Shoffner, J. M., Lott, M. T. &     Wallace, D. C. Association of mitochondrial DNA damage with aging     and coronary atherosclerotic heart disease. Mutat. Res. 275, 169-180     (1992). -   25. Zhang, C. et al. Differential occurrence of mutations in     mitochondrial DNA of human skeletal muscle during aging. Hum. Mutat.     11, 360-371 (1998). -   26. Michikawa, Y., Mazzucchelli, F., Bresolin, N., Scarlato, G. &     Attardi, G. Aging-dependent large accumulation of point mutations in     the human mtDNA control region for replication. Science 286, 774-779     (1999). -   27. Alioto, T. S. et al. A comprehensive assessment of somatic     mutation detection in cancer using whole-genome sequencing. Nat.     Commun. 6, 10001 (2015). -   28. Lott, M. T. et al. mtDNA Variation and Analysis Using Mitomap     and Mitomaster. Curr. Protoc. Bioinforma. 44, 1.23.1-26 (2013). -   29. Krjutškov, K. et al. Tissue-specific mitochondrial heteroplasmy     at position 16,093 within the same individual. Curr. Genet. 60,     11-16 (2014). -   30. Samuels, D. C. et al. Recurrent tissue-specific mtDNA mutations     are common in humans. PLoS Genet. 9, e1003929 (2013). -   31. Kervinen, M. et al. The MELAS mutations 3946 and 3949 perturb     the critical structure in a conserved loop of the ND1 subunit of     mitochondrial complex I. Hum. Mol. Genet. 15, 2543-2552 (2006). -   32. He, Y. et al. Heteroplasmic mitochondrial DNA mutations in     normal and tumour cells. Nature 464, 610-614 (2010). -   33. Ding, J. et al. Assessing Mitochondrial DNA Variation and Copy     Number in Lymphocytes of ˜2,000 Sardinians Using Tailored Sequencing     Analysis Tools. PLoS Genet. 11, e1005306 (2015). -   34. Li, F. et al. Myc stimulates nuclearly encoded mitochondrial     genes and mitochondrial biogenesis. Mol. Cell. Biol. 25, 6225-6234     (2005). -   35. Sancho, P. et al. MYC/PGC-1a Balance Determines the Metabolic     Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell     Metab. 22, 590-605 (2015). -   36. Robinson, K. et al. Accurate prediction of repeat prostate     biopsy outcomes by a mitochondrial DNA deletion assay. Prostate     Cancer Prostatic Dis. 13, 126-131 (2010). -   37. Nicholls, T. J. & Minczuk, M. In D-loop: 40 years of     mitochondrial 7S DNA. Exp. Gerontol. 56, 175-181 (2014). -   38. Larson, D. E. et al. SomaticSniper: identification of somatic     point mutations in whole genome sequencing data. Bioinformatics 28,     311-317 (2012). -   39. Li, H. et al. The Sequence Alignment/Map format and SAMtools.     Bioinformatics 25, 2078-2079 (2009). -   40. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation     of genetic variants from high-throughput sequencing data. Nucleic     Acids Res. 38, e164 (2010). -   41. Rausch, T. et al. DELLY: structural variant discovery by     integrated paired-end and split-read analysis. Bioinformatics 28,     i333-i339 (2012). -   42. Govind, S. K. et al. ShatterProof: operational detection and     quantification of chromothripsis. BMC Bioinformatics 15, 78 (2014). -   43. Masella, A. P. et al. BAMQL: a query language for extracting     reads from BAM files. BMC Bioinformatics 17, 305 (2016). -   44. Calabrese, C. et al. MToolBox: a highly automated pipeline for     heteroplasmy annotation and prioritization analysis of human     mitochondrial variants in high-throughput sequencing. Bioinformatics     30, 3115-3117 (2014). -   45. Wu, T. D. & Watanabe, C. K. GMAP: a genomic mapping and     alignment program for mRNA and EST sequences. Bioinformatics 21,     1859-1875 (2005). -   46. Edgar, R. C. MUSCLE: multiple sequence alignment with high     accuracy and high throughput. Nucleic Acids Res. 32, 1792-1797     (2004). -   47. Behar, D. M. et al. A ‘Copernican’ reassessment of the human     mitochondrial DNA tree from its root. Am. J. Hum. Genet. 90, 675-684     (2012). -   48. Song, S. et al. qpure: A Tool to Estimate Tumor Cellularity from     Genome-Wide Single-Nucleotide Polymorphism Profiles. PLOS ONE 7,     e45835 (2012). -   49. Guo, Y. et al. The use of Next Generation Sequencing Technology     to Study the Effect of Radiation Therapy on Mitochondrial DNA     Mutation. Mutat. Res. 744, 154-160 (2012). -   50. Ju, Y. S. et al. Origins and functional consequences of somatic     mitochondrial DNA mutations in human cancer. eLife 3, (2014). -   51. Li, B. et al. Automated inference of molecular mechanisms of     disease from amino acid substitutions. Bioinformatics 25, 2744-2750     (2009). -   52. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting     functional effect of human missense mutations using PolyPhen-2.     Curr. Protoc. Hum. Genet. 7, Unit7.20 (2013). -   53. Rubino, F. et al. HmtDB, a genomic resource for     mitochondrion-based human variability studies. Nucleic Acids Res.     40, D1150-1159 (2012). -   54. Pütz, J., Dupuis, B., Sissler, M. & Florentz, C. Mamit-tRNA, a     database of mammalian mitochondrial tRNA primary and secondary     structures. RNA 13, 1184-1190 (2007). -   55. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of     utilities for comparing genomic features. Bioinformatics 26, 841-842     (2010). -   56. Krzywinski, M. I. et al. Circos: An information aesthetic for     comparative genomics. Genome Res. (2009).

TABLE 1 Results of PCR validation of 25 mtSNVs HF - HF - Sample Position Amplicon Validated? Tumour Normal CPCG0196 195 1 Y 0.58T 1.0T CPCG0242 234 1 Y 1.0G 1.0A CPCG0189 650 2 Y 0.69C 1.0T CPCG0248 988 3 N 0.64A 1.0G CPCG0324 3079 5 N 1.0A 1.0G CPCG0233 3946 6 N 0.63A 1.0G CPCG0407 4770 7 N 0.98A 1.0G CPCG0242 5511 9 Y 1.0C 1.0T CPCG0189 6270 10 N 0.66G 1.0G CPCG0251 6276 10 Y 1.0A 0.55G CPCG0331 6856 11 Y 1.0C 1.0T CPCG0345 8391 12 N 0.59G 1.0G CPCG0196 8433 12 Y 0.58T 1.0T CPCG0340 10866 14 Y 1.0T 0.5C CPCG0410 11814 15 Y 1.0C 1.0T CPCG0352 12700 16 Y 0.87A 1.0C CPCG0236 12763 16 Y 1.0A 1.0G CPCG0217 13913 17 Y 1.0C 1.0T CPCG0410 13918 17 Y 1.0C 0.97T CPCG0340 14846 18 Y 1.0A 1.0G CPCG0412 15045 18 N 0.51G 1.0G CPCG0412 15708 19 Y 0.58A 1.0G CPCG0269 15731 19 Y 0.83A 1.0G CPCG0269 15817 19 Y 0.91G 0.83A CPCG0356 15884 19 Y 1.0A 0.84G

TABLE 2 Results from univariate Cox proportional modeling 10 year number of lower upper p-value p-value survival patients with Loci HR 95% CI 95% CI (wald test) (logrank test) difference mitoSNV 1 Control 0.79 0.429 1.45 0.447 0.446 0.01 35 Region 2 RNR1 1.48 0.671 3.28 0.329 0.326 −0.29 12 3 RNR2 1.25 0.538 2.91 0.603 0.602 −0.11 15 4 tRNAs 0.80 0.285 2.22 0.663 0.662 0.24 9 5 ND1 1.28 0.508 3.24 0.597 0.596 −0.03 10 6 ND2 1.27 0.507 3.16 0.613 0.613 −0.18 12 7 ND3 1.24 0.171 9.02 0.832 0.831 0.11 3 8 ND4 1.19 0.476 2.98 0.709 0.709 0.02 12 9 ND5 1.74 0.825 3.67 0.145 0.140 −0.24 16 10 ND6 1.69 0.234 12.25 0.601 0.597 −0.06 2 11 CO1 0.66 0.239 1.82 0.422 0.419 −0.02 12 12 CO2 0.00 0.000 Inf 0.997 0.196 0.45 3 13 CO3 0.25 0.035 1.80 0.168 0.136 0.35 9 14 ATP6 0.57 0.079 4.11 0.577 0.572 0.11 4 15 ATP8 4.25 1.014 17.84 0.048 0.031 −0.23 3 16 CYB 0.44 0.132 1.47 0.181 0.172 0.24 11 17 HV1 0.26 0.080 0.82 0.022 0.013 0.32 18 18 CSB1 4.52 1.410 14.46 0.011 0.005 −0.57 3 19 OHR 2.73 1.294 5.74 0.008 0.006 −0.41 12 20 MCN 1.50 0.918 2.46 0.105 0.103 −0.15 165 21 mtSNV 0.87 0.525 1.43 0.574 0.574 −0.047 105

TABLE 3 PCR primers Primer Targets Region: Seq ID NO.  1F tctatcaccctattaaccacactcacg  10-385 1  1R aggctggtgttagggttctttg 2  2F aaaaatttccaccaaaccccc 287-718 3  2R actggaacggggatgcttg 4  3F acgggaaacagcagtgattaac  809-1103 5  3R agggctaagcatagtggggt 6  4F cagcaaaccctgatgaaggc 1273-1710 7  4R tggtagtaaggtggagtgggt 8  5F taccctagggataacagcgca 2927-3171 9  5R gggaaggcgctttgtgaagt 10  6F tactcctgccatcatgaccct 3828-4067 11  6R gttcaggggagagtgcgtc 12  7F ataccccgaaaatgttggttatac 4434-4927 13  7R ggcttacgtttagtgagggagag 14  8F ctgacatccggcctgctt 4840-5171 15  8R caggtgcgagatagtagtagggtc 16  9F catcgcccttaccacgctac 5457-5742 17  9R cggcgggagaagtagattga 18 10F cataaacaacataagcttctgactcttacct 6192-6586 19 10R ggtctcctcctccggcg 20 11F tatcctaccaggcttcggaat 6642-6957 21 11R acctacggtgaaaagaaagatga 22 12F accacagtttcatgcccatc 8194-8482 23 12R ggtgagggaggtaggtggtag 24 13F caaaaaggccttcgatacggg 9433-9876 25 13R tagttggcggatgaagcagat 26 14F tgggcctagccctactagtctc 10688-10939 27 14R gggtcggaggaaaaggttgg 28 15F tacgaacgcactcacagtcg 11760-11988 29 15R tgtagagggagtatagggctgt 30 16F atctcgaactgacactgagcc 12524-12894 31 16R aaggcgaggatgaaaccgat 32 17F ctaacaacatttcccccgcatc 13743-14056 33 17R ggtggagatttggtgctgtg 34 18F cccaccccatccaacatctc 14811-15111 35 18R caagcaggaggataatgccg 36 19F ggcgtccttgccctattact 15615-16051 37 19R acccaaatctgctttcccat 38 20F atggggaagcagatttgggt 16032-16298 39 20R gggtgggtaggtttgttggt 40

TABLE 4 Clinical and sequencing data per patient Normal mito- Normal Tumour Tumour Age chondrial mito- mito- mito- At T PSA mean chondrial chondrial chondrial Treat- Gleason cate- (ng/ coverage copy mean copy mtSNVs/ MT- Patient ment Score gory mL) mitoSNVs d num coverage nu Mb DLOOP Baca-P03-1426 69 4 + 3 T2c 13.9 1 9973.43 528.32 9639.89 430.02 0.14 0 Baca-P05-1657 47 3 + 4 T2b 9.3 1 5301.26 541.65 13952.8 455.87 0.132 0 Baca-PR-05-3595 64 3 + 4 T2c 7.2 2 7848.46 366.84 13517.9 378.68 0.319 1 Baca-P05-3852 62 4 + 3 T3a 12.5 2 9535.11 517.82 14571 483.77 0.25 0 Baca-PR-06-1749 60 4 + 3 T2c 6.7 1 3687.29 518.5 22823.8 543.38 0.111 0 Baca-PR-06-3199 54 4 + 3 T3a 25 1 7265.49 374.58 13011.3 320.31 0.188 1 Baca-PR-07-4610 69 3 + 4 T3a 5.6 1 5986.71 206.44 6899.3 181.05 0.333 1 Baca-P07-4941 57 3 + 3 T2c 4.1 1 9583.63 505.45 11448.7 231.43 0.261 0 Baca-P07-5037 68 4 + 3 T3a 11 0 12286.3 703.49 12188.3 349.15 0 0 Baca-PR-08-4154 58 3 + 4 T4 36 1 7155.13 381.71 13066.7 322.03 0.187 0 Baca-P08-716 59 3 + 4 T3a 4.1 0 13055.6 648.03 13959 466.2 0 0 Baca-P09-37 76 3 + 4 T3b 9 1 5974.65 316.06 9801.68 388.03 0.156 0 Baca-PR-0410 60 3 + 3 T2c 4.5 0 808.985 48.58 17039.6 653.48 0 0 Baca-PR- 62 3 + 4 T3a 6 1 2953.47 150.82 17440.3 452.67 0.133 0 STID0000002872 Berger-PR-0508 57 3 + 4 T2c 7.8 3 2664.78 143.98 11557.9 601.49 0.301 0 Berger-PR-0581 69 4 + 5 T3b 9.2 0 794.518 59.07 7999.43 460.05 0 0 Berger-PR-1701 62 3 + 4 T3a 2.1 0 2023.96 94.9 9496.81 447.2 0 0 Berger-PR-1783 66 4 + 4 T2c 9.8 0 1856 104.29 11199 634.19 0 0 Berger-PR-2832 66 3 + 4 T2c 6.6 0 1630.41 84.31 13476.4 682.17 0 0 Berger-PR-3027 66 4 + 4 T3b 10.2 1 1624.68 97.23 5624.32 314.53 0.192 0 Berger-PR-3043 69 3 + 4 T2c 7.2 3 1969.11 106.24 14276.4 776.69 0.233 0 CPCG0001 69.4 3 + 4 T2b 7.7 1 2010.51 91.23 15343.8 536.19 0.113 1 CPCG0003 71.8 3 + 4 T2a 10 1 1592 98.23 16387.8 563.25 0.107 0 CPCG0004 76.5 4 + 4 T2b 14.1 0 2360.43 76.6 21736 504.1 0 0 CPCG0005 72.5 3 + 3 T2a 5.4 1 1954.36 105.73 14676.7 428.18 0.141 0 CPCG0006 73.5 4 + 3 T2b 8.4 0 11969.9 368.42 19269.2 631.66 0 0 CPCG0007 65.9 4 + 4 T1c 8.4 0 2622.67 107.85 19394.9 618.46 0 0 CPCG0008 74.3 3 + 4 T2a 4.7 0 8033.1 216.69 8220.56 487.07 0 0 CPCG0015 70 4 + 4 T2a 5.6 0 2445.52 123.29 11664.1 338.77 0 0 CPCG0019 71.4 4 + 5 T2a 7.3 1 1855.12 103.89 7508.09 235.48 0.256 0 CPCG0020 70.8 3 + 4 T1c 16 1 2152.74 102.61 15986.9 451.44 0.134 0 CPCG0022 70.3 3 + 3 T1c 12.6 0 6126.42 191.2 27763.9 427.62 0 0 CPCG0027 64.6 3 + 3 T1c 5 2 2309.34 124.47 18997.1 540.68 0.223 0 CPCG0030 73.1 4 + 4 T1c 8 2 1860.72 88.54 24737.1 435.4 0.277 0 CPCG0036 75.9 3 + 4 T2a 5.3 0 1546.25 83.47 21118.1 641.24 0 0 CPCG0040 71.5 3 + 4 T1c 9 3 2234.77 109.46 12738.2 385.35 0.47 1 CPCG0042 75.5 4 + 3 T2b 5.6 0 2661.75 127.13 12385.6 394.09 0 0 CPCG0046 79.4 4 + 3 T1c 5.1 5 1944.65 106.17 23558.9 1020.68 0.296 1 CPCG0047 71.9 4 + 3 T2c 13.2 0 1773.42 87.23 6868.3 181.08 0 0 CPCG0048 74.3 3 + 3 T2b 5.1 0 1965.81 100.43 18063.2 630.52 0 0 CPCG0050 75.8 3 + 3 T1c 7.7 1 2326.01 107.27 35390.2 922.94 0.065 0 CPCG0057 70.4 3 + 3 T2a 10 1 2814.45 142.84 7928.7 270.69 0.223 0 CPCG0063 68.6 4 + 3 T2a 3.8 2 2644.85 126.2 16387.6 538.02 0.224 0 CPCG0067 62 3 + 4 T2b 10 4 2540.37 113.15 26440.2 1255.88 0.192 0 CPCG0070 67.3 3 + 3 T2a 5.9 2 3288.57 130.51 23488.5 703.48 0.172 1 CPCG0071 74.9 4 + 3 T1c 14.7 2 2038.28 100.32 13083.5 407.14 0.297 0 CPCG0072 75.7 4 + 5 T2a 9.3 1 2087.05 114.92 18531.3 566.05 0.107 0 CPCG0073 71.6 4 + 3 T1c 10.3 2 2207.67 104.47 17129.6 500.64 0.241 1 CPCG0075 70.8 4 + 4 T2a 4.1 0 2219.17 110.59 11392.5 303.91 0 0 CPCG0076 76.6 3 + 3 T2a 12.7 1 1742.35 84.34 19549.5 531.43 0.114 0 CPCG0078 61 4 + 3 T2b 3.3 2 1105.04 49.32 14594.2 581.48 0.208 1 CPCG0081 75 4 + 3 T2a 17.8 2 2160.59 98.52 37008.6 1033.84 0.117 1 CPCG0082 70.3 4 + 3 T2a 7.8 1 1857.84 88.02 17730.5 440.85 0.137 0 CPCG0083 61.5 3 + 4 T2b 12.7 1 2672.43 109.97 13413.7 477.54 0.126 0 CPCG0084 70.8 3 + 3 T2b 7 1 2455.36 211.71 19898.8 557.13 0.108 1 CPCG0087 72.8 3 + 4 T1c 9.4 0 2124.21 90.43 10965.7 378.22 0 0 CPCG0089 73.9 4 + 4 T1c 4.8 1 6316.55 109.74 9884.38 579.96 0.104 0 CPCG0090 77.6 3 + 3 T1c 11.2 2 3146.06 107.25 26497.8 601.53 0.201 0 CPCG0094 77.6 4 + 3 T2b 16.41 0 1772.67 85.84 9333.85 270.47 0 0 CPCG0095 68.5 4 + 3 T2a 4 1 3226.28 116.97 9627.27 284.66 0.212 0 CPCG0096 71.2 3 + 3 T1c 6.1 1 2354.53 112.19 10526 336.77 0.179 0 CPCG0097 75.1 3 + 3 T1c 13.7 2 3186.24 114.53 15025 437.56 0.276 1 CPCG0098 80.7 4 + 3 T1c 7.5 4 3141.66 92.39 19866.5 675.49 0.357 1 CPCG0099 66.2 3 + 4 T2c 6.96 0 3088.28 123.68 20339.1 619.84 0 0 CPCG0100 55.3 4 + 5 T2c 5.56 2 1592.37 65.62 11999.8 325.79 0.371 1 CPCG0102 58.1 4 + 3 T3b 8.65 1 3756.32 117.24 19274.1 553.3 0.109 0 CPCG0103 65 3 + 4 T3b 5.2 2 3051.27 95.84 27103.1 669.18 0.18 0 CPCG0114 67.7 4 + 3 T2b 4.4 4 13818.6 425.97 3370.65 95.95 2.517 1 CPCG0117 71.3 3 + 4 T2a 10.1 1 2116.03 93.89 17318.3 1057.43 0.057 0 CPCG0120 73.1 4 + 5 T2a 14.79 1 4556 79.41 17038.8 1040.35 0.058 0 CPCG0121 63.5 3 + 4 T1c 7.2 0 1819.09 81.46 16843.6 507.7 0 0 CPCG0122 65.6 3 + 3 T1c 6.4 0 1587.25 73.44 26709.7 655.79 0 0 CPCG0123 70.7 3 + 4 T2a 8.8 1 2153.44 93.95 14680.6 408.31 0.148 0 CPCG0124 72 4 + 3 T2a 72 2 1693.03 103.91 16616.7 471.18 0.256 0 CPCG0126 70 3 + 3 T2a 6.1 0 2146.19 112.82 16857.3 511.86 0 0 CPCG0127 54.4 3 + 4 T2a 29.9 1 1410.98 82.03 22778.4 687.22 0.088 0 CPCG0128 70.2 3 + 4 T1c 30.3 2 1895.38 94.61 19629.6 527.03 0.229 1 CPCG0154 55.4 3 + 3 T2a 13.8 0 1661.73 94.48 12384.6 411.8 0 0 CPCG0158 70.3 3 + 4 T1c 10 1 1543.38 107.49 9261.13 444.37 0.136 1 CPCG0166 74 3 + 4 T2a 6.8 5 2756.4 101.74 15269.5 449.28 0.672 1 CPCG0182 57 4 + 3 T2c 7.64 0 2366.95 101.87 14861.1 429.06 0 0 CPCG0183 64.3 4 + 3 T3a 5.67 2 2002.32 89.43 24135.9 654.71 0.184 1 CPCG0184 51.8 4 + 3 T3a 5.53 0 2836.72 106.41 20155.2 504.67 0 0 CPCG0185 60 3 + 4 T3a 4.49 1 1921.47 79.18 15534.6 452.91 0.133 0 CPCG0187 72.4 4 + 4 T1c 13 1 2078.85 119.32 22991.9 828.01 0.073 1 CPCG0188 59 4 + 5 T2c 7.23 0 2202.35 89.99 25035.8 638.01 0 0 CPCG0189 57.4 3 + 4 T2b 6.52 5 2523.89 102.02 26654.4 775.6 0.389 1 CPCG0190 74.1 3 + 4 T3a 4.3 1 3002.16 117.98 23557.5 623.93 0.097 0 CPCG0191 60.7 4 + 3 T3a 11.1 0 1834.4 94.75 21490.7 646.17 0 0 CPCG0194 69.8 3 + 4 T1c 8.7 0 1901.55 196.32 7805.15 255.37 0 0 CPCG0196 52.5 4 + 3 T3b 4.88 2 3327.15 151.6 12536 343.95 0.351 1 CPCG0198 60.7 3 + 4 T2a 5.2 1 3099.65 146.67 29684.5 829.49 0.073 1 CPCG0199 74.2 4 + 3 T2a 6.3 0 2826.11 107.59 21647.3 676.99 0 0 CPCG0201 63.4 4 + 3 T1c 1.6 2 3002.98 97.47 39114.2 1120.3 0.108 0 CPCG0204 75.7 3 + 4 T1b 9.7 3 3464.6 105.94 10867.3 270.65 0.669 1 CPCG0205 65 3 + 4 T2a 20.4 1 1544.7 101.98 17086.3 532.21 0.113 1 CPCG0206 66.9 4 + 3 T1c 8 1 2110.22 103.11 19211.1 687.44 0.088 1 CPCG0208 60.4 3 + 4 T2c 5.7 0 2030.64 102.22 27846.3 833.35 0 0 CPCG0210 51.4 4 + 3 T2c 3.51 0 2301.46 125.14 13751.7 428.21 0 0 CPCG0211 75.2 3 + 4 T2a 4.5 3 1966.24 89.91 20019.9 601.45 0.301 0 CPCG0212 71.2 3 + 4 T1c 7 1 1851.09 99.03 9954.72 600.39 0.101 0 CPCG0213 67.2 3 + 4 T2a 9.3 3 2302.15 113.57 11806.2 356.88 0.507 0 CPCG0217 61.5 3 + 3 T3b 6.5 3 2862.32 126.84 22997.4 613.9 0.295 0 CPCG0232 71.6 3 + 4 T3a 8.15 1 1888.72 96.56 16843.7 497.16 0.121 0 CPCG0233 70.3 4 + 3 T3a 4.63 2 2754.55 124.79 31553 914.29 0.132 0 CPCG0234 70.1 3 + 4 T1c 5.7 2 2178.87 107.66 12593.3 446.63 0.27 0 CPCG0235 59.2 4 + 4 T3a 8.04 0 3220.53 123.34 37607.4 1206.8 0 0 CPCG0236 59.1 4 + 3 T3a 10.92 1 2509.78 114.9 30744.4 900.49 0.067 0 CPCG0237 60.4 3 + 3 T2a 10.7 1 1916.74 100.66 21603.4 479.47 0.126 0 CPCG0238 55.6 3 + 4 T3a 7.92 0 2171.64 86.06 14799.9 386.3 0 0 CPCG0241 66.6 3 + 4 T3a 5.64 0 1392.4 81.71 19837 522.61 0 0 CPCG0242 56 4 + 3 T3a 4 3 2229.79 104.54 21398 618.51 0.293 1 CPCG0243 63.7 3 + 3 T2b 13.6 0 2108.3 101.41 27303.7 705.69 0 0 CPCG0246 60.6 3 + 3 T2c 5.64 0 3078.8 106.59 21908.6 586.08 0 0 CPCG0248 54.2 3 + 4 T3a 5.1 1 2177.55 87.09 13487.4 357.01 0.169 0 CPCG0249 66.1 3 + 4 T3b 7.1 2 1341.68 70.87 23315.6 637.4 0.189 0 CPCG0250 62 3 + 3 T2c 4.23 1 2919.61 104.25 14478.6 435.33 0.139 1 CPCG0251 52.1 3 + 4 T2c 13.41 1 2438.75 116.04 26111.1 713.14 0.085 0 CPCG0255 72 3 + 3 T2c 6.9 0 1692.11 105.24 47617 1404.64 0 0 CPCG0256 63.9 3 + 4 T3a 7.32 3 2237.41 94.99 18998.2 574.56 0.315 1 CPCG0257 75.3 3 + 3 T2a 8 0 1875.56 96.61 30453.9 801.83 0 0 CPCG0258 49.2 3 + 3 T2c 5.13 0 2816.13 137.62 27975 645.84 0 0 CPCG0259 55.9 3 + 3 T3a 11.65 1 2343.37 112.81 25185.2 787.31 0.077 1 CPCG0260 65.3 4 + 3 T2b 6.59 0 2215.3 114.94 16393.6 439.11 0 0 CPCG0262 63 3 + 4 T2c 5.7 2 1748.24 96.8 22867 665.8 0.181 0 CPCG0263 66.4 3 + 3 T2a 13.9 1 2153.77 90.92 14025.9 376.94 0.16 1 CPCG0265 63.2 3 + 3 T3a 9.34 1 2865.36 125.95 24767.3 746.34 0.081 0 CPCG0266 66.1 3 + 4 T2c 1.74 1 1989.51 109.53 12392.6 357.7 0.169 0 CPCG0267 44.5 3 + 4 T2c 17.1 1 2632.29 102.84 12520.1 321.02 0.188 0 CPCG0268 59.3 3 + 3 T3a 12.35 1 1783.77 89.65 20844.9 632.34 0.095 0 CPCG0269 68.3 3 + 3 T2c 13.21 4 1862.44 75.85 20396.5 578.59 0.417 1 CPCG0324 64.7 3 + 4 T3a 12.1 2 1627.2 96.53 15641.5 461.67 0.262 0 CPCG0331 69.9 3 + 4 T3a 11.08 3 2214.28 118.64 22194.1 685.07 0.264 0 CPCG0334 53.7 3 + 4 T3a 7.41 0 2205.65 120.17 17649.3 526.22 0 0 CPCG0336 60.9 3 + 3 T3a 9.08 1 2531.23 122.84 22760.1 619.98 0.097 0 CPCG0339 57.7 3 + 4 T3a 14.29 2 2439.27 109.25 21027.2 575.8 0.21 0 CPCG0340 62 3 + 4 T2c 4.41 2 3925.02 145.3 28167.6 940.05 0.128 0 CPCG0341 56.8 4 + 3 T2c 11.3 0 1780 96.57 13179.1 450.01 0 0 CPCG0342 52.2 4 + 3 T3a 6.3 1 2051.9 102.5 42684.1 1317.94 0.046 1 CPCG0344 60.9 3 + 3 T2c 5.5 1 2169.22 107.1 21245.2 644.68 0.094 1 CPCG0345 60.4 3 + 4 T3b 6.6 1 2076.81 85.49 23445.5 669.58 0.09 0 CPCG0346 59.7 3 + 4 T3a 6.5 2 3160.71 122.58 17265.9 361.98 0.334 0 CPCG0348 57 3 + 4 T3a 4.22 0 2469.37 105.23 19175.6 627.9 0 0 CPCG0349 61.8 4 + 4 T2c 7.1 1 3936.14 141.05 29956.4 876.02 0.069 0 CPCG0350 53.2 4 + 3 T3b 39.47 1 3186.42 175.12 16436.5 553.25 0.109 0 CPCG0352 55.5 4 + 3 T2c 9.1 2 4267.8 210.29 21746 629.93 0.192 1 CPCG0353 65.6 3 + 4 T3b 9 0 5165.99 171.98 15483 445.09 0 0 CPCG0354 61.4 3 + 4 T2c 6.7 0 10612.5 369.9 15967.2 479.46 0 0 CPCG0355 55.5 3 + 3 T2c 6.7 2 10942.8 413.22 24203.7 722.52 0.167 1 CPCG0356 51.6 4 + 3 T2c 8.49 3 5522.17 183.24 24184.8 758.82 0.239 0 CPCG0357 59.1 3 + 4 T2c 3.11 0 2936.46 144.62 13756 432.86 0 0 CPCG0358 68.8 3 + 4 T2a 5.88 1 11783.1 558.8 19095.4 640.92 0.094 0 CPCG0360 66.2 3 + 4 T3b 14 0 2459.98 102.12 20880.2 626.95 0 0 CPCG0361 70.1 3 + 4 T3a 4.6 1 4085.15 171.45 23547.5 424.85 0.142 0 CPCG0362 57.6 3 + 4 T3b 8.77 0 5073.01 232.26 16830.4 543.17 0 0 CPCG0363 56.6 3 + 4 T2c 4.27 0 3803.3 134.64 22238.6 676.72 0 0 CPCG0364 63.2 3 + 3 T3a 8.11 0 2119.11 90.51 32021.9 585.73 0 0 CPCG0365 71.7 3 + 3 T2c 4.23 0 2595.34 108 20792.3 560.3 0 0 CPCG0366 60.5 3 + 4 T3a 15 0 2832.85 118.99 10542.6 284.93 0 0 CPCG0368 63.7 3 + 3 T2c 4.39 1 3212.27 136.26 26323.3 795.63 0.076 1 CPCG0369 63.7 3 + 4 T3a 7.18 0 4818.33 216.57 21784.1 636.84 0 0 CPCG0371 60.7 3 + 4 T3a 7.52 0 6744.86 304.1 15628.5 492.43 0 0 CPCG0372 60.2 3 + 4 T2c 4 1 3635.5 178.11 22791.2 726.25 0.083 0 CPCG0373 59.8 3 + 4 T2c 4.9 0 6165.27 290.47 15628.5 478.66 0 0 CPCG0374 63.6 3 + 3 T2c 4.7 1 5552.69 251.7 30129 839.05 0.072 0 CPCG0375 70.2 3 + 3 T2c 7.01 0 5556.59 228.69 30332 1023.21 0 0 CPCG0377 76.9 4 + 4 T2c 6.9 1 5674.91 238.24 24080.1 701.87 0.086 0 CPCG0378 69.1 3 + 4 T3b 8.7 1 6663.66 277.53 25862.6 756.27 0.08 0 CPCG0379 68.6 3 + 4 T3a 14.6 1 3991.82 194.66 16985.8 471.18 0.128 0 CPCG0380 58.1 3 + 4 T2c 6.29 1 3479.34 177.05 23339.2 716.88 0.084 0 CPCG0381 64.9 3 + 4 T2c 5.76 0 4173.25 180.55 18670.6 576.26 0 0 CPCG0382 71.1 4 + 4 T2c 6.8 0 3774.09 157.43 35627.8 1141.52 0 0 CPCG0387 67.1 4 + 3 T2c 4.52 2 6376.56 286.84 18213.4 529.95 0.228 0 CPCG0388 54.5 3 + 4 T3a 2.5 1 2485.18 106.06 22595.6 707.36 0.085 0 CPCG0391 60.8 3 + 3 T2c 5.3 0 6416.64 265.25 17324.3 438.19 0 0 CPCG0392 61.4 3 + 4 T3b 19.5 0 1868.71 87.57 18631.4 511.01 0 0 CPCG0401 58.1 3 + 4 T2c 36 0 4357.69 191.91 17145.6 532.82 0 0 CPCG0404 56.2 3 + 4 T2c 36 1 5948.57 243.78 40464.9 1098.8 0.055 1 CPCG0407 57.9 3 + 4 T2a 11.5 2 3378.68 206.76 17177.2 477.4 0.253 0 CPCG0408 67.9 4 + 4 T2c 3.47 0 6495.59 276.71 22309.9 641.83 0 0 CPCG0409 59.1 3 + 4 T3a 6.3 1 2922.04 173.92 28278 742.69 0.081 0 CPCG0410 62 3 + 4 T2c 5 3 5203.82 217.73 26133.8 741.72 0.244 0 CPCG0411 45.7 4 + 3 T2c 10.55 0 4019.65 163.77 14003 424.03 0 0 CPCG0412 58.7 4 + 3 T2a 3.36 3 2780.6 164.49 15645.1 479.17 0.378 0 CPCG0413 59.1 3 + 4 T2c 6.89 0 3915.74 186.91 21079.7 737.96 0 0 CPCG0414 43.8 4 + 3 T2c 5.4 0 3877.37 172.59 15891.4 508.01 0 0 Weischenfeldt- 46 3 + 4 T2c 6 2 3077.42 136 8577.51 368.3 0.328 0 EOPC-010 Weischenfeldt- 48 3 + 4 T2c 4.8 0 1839.24 123 4632.61 299.45 0 0 EOPC-011 Weischenfeldt- 51 3 + 4 T2c 23.8 0 3352.84 200.42 5115.26 370.21 0 0 EOPC-02 Weischenfeldt- 46 5 + 4 T3a 12 1 3258.08 237.37 17967.1 528.61 0.114 0 EOPC-03 Weischenfeldt- 51 4 + 3 T3b 72 2 5386.42 163.11 6291.77 427.88 0.282 1 EOPC-04 Weischenfeldt- 50 3 + 4 T3a 5 1 1840.62 119.72 4111.36 258.28 0.234 1 EOPC-05 Weischenfeldt- 38 3 + 4 T3b 18.2 0 2104.12 103.53 4020.19 193.78 0 0 EOPC-06 Weischenfeldt- 49 3 + 4 T2c 5.4 4 1995.09 130.76 5886.36 375.09 0.644 0 EOPC-07 Weischenfeldt- 44 3 + 4 T2c 7.8 0 3107.47 196.85 7331.15 347.3 0 0 EOPC-08 Weischenfeldt- 48 3 + 4 T2c 5.1 0 4594.3 228.69 6755.4 408.36 0 0 EOPC-09 ICGC_PCA001 45 3 + 4 T3a 30 0 2827.22 128.51 9654.26 459.73 0 0 ICGC_PCA012 48 3 + 4 T2c 4.8 0 1901.03 126.74 4799.33 309.63 0 0 ICGC_PCA013 45 3 + 4 T2c NA 1 4499.82 243.23 17577.1 491.46 0.123 0 ICGC_PCA014 45 3 + 4 T2a NA 0 3804.42 234.55 11582.8 254.76 0 0 ICGC_PCA015 48 3 + 4 T3b NA 1 4139.76 232.51 7798.35 183.08 0.33 1 ICGC_PCA016 44 3 + 4 T2a NA 0 3967.64 227.96 7782.91 217.1 0 0 ICGC_PCA017 48 3 + 4 T2c 13.2 0 4965.55 264.69 4464.28 233.37 0 0 ICGC_PCA018 49 3 + 3 T2c 4.6 0 7169.97 300.19 3978.88 198.99 0 0 ICGC_PCA019 46 3 + 4 T2c 6.74 0 4594.35 256.45 4238.89 224.99 0 0 ICGC_PCA020 49 3 + 3 T3a NA 0 2643.11 166.23 11609.6 317.25 0 0 ICGC_PCA021 45 3 + 4 T2c 5.35 0 4498.3 208.64 4629.81 208.88 0 0 ICGC_PCA022 49 3 + 4 T2c 5.88 0 5958.51 222.46 4028.03 195.82 0 0 ICGC_PCA023 50 3 + 4 T2c 2.56 1 7928.37 330.28 10306.4 373.49 0.162 0 ICGC_PCA024 43 3 + 4 T2c 11.7 0 2382.34 115.03 4937.3 219.63 0 0 ICGC_PCA025 47 3 + 4 T2c 9.79 0 1837.06 111.03 4018.61 211.56 0 0 ICGC_PCA026 48 3 + 3 T2c 3.8 1 2183.34 127.53 5286.37 267.53 0.226 0 ICGC_PCA027 49 3 + 4 T2c NA 0 3878.45 187.36 4240.61 224.61 0 0 ICGC_PCA028 40 3 + 4 T2c NA 0 4063.62 213.65 4881.5 229.56 0 0 ICGC_PCA029 48 4 + 3 T3b 15.5 3 4670.4 178.6 5589.59 213.38 0.849 0 ICGC_PCA030 48 4 + 3 T3b 62.4 0 4655.41 178.99 9524.12 361.17 0 0 ICGC_PCA031 48 3 + 4 T2c 22.5 1 5953.36 222.93 6554.49 230.1 0.262 1 ICGC_PCA032 44 3 + 4 T2a 4.23 5 3258.41 177.67 3955.93 NA NA 1 ICGC_PCA033 43 3 + 4 T2c 5 0 2815.95 163.29 4980.66 NA NA 0 ICGC_PCA034 46 3 + 4 T2c 5.27 0 2350.99 119.31 6313.81 278.94 0 0 ICGC_PCA035 49 4 + 3 T3b 70.43 0 4548.29 245.85 13510.3 773.12 0 0 ICGC_PCA036 57 3 + 4 T3a 6.52 2 4422.45 175.49 9231.92 362.04 0.333 0 ICGC_PCA037 50 3 + 4 T3a 6.98 0 3709.63 NA 15562.3 884.22 0 0 ICGC_PCA038 49 3 + 4 T2c 3.99 0 6205.3 250.06 5214.15 244.34 0 0 ICGC_PCA040 50 3 + 3 T2c 6.13 0 6296.73 263.24 5967.76 246.35 0 0 ICGC_PCA041 48 5 + 4 T4 58 1 4421.8 231.63 3387.42 149.19 0.405 0 ICGC_PCA043 47 4 + 5 NA NA 0 2911.35 169.46 8698.75 373.5 0 0 ICGC_PCA044 48 4 + 3 T2c 12 0 4142.43 244.97 9927.41 377.83 0 0 ICGC_PCA045 47 3 + 4 T2c 7.65 0 4123.21 245.79 8784.67 374.29 0 0 ICGC_PCA046 49 3 + 4 T2c 9.36 0 3982.15 229.12 6158.4 185.33 0 0 ICGC_PCA048 50 3 + 3 T2a 8.2 1 5147.5 253.07 5545.16 212.13 0.285 0 ICGC_PCA049 48 3 + 3 T2c 6.09 0 5441.71 196.27 7249.09 272.27 0 0 ICGC_PCA050 48 3 + 4 T2c NA 0 3497.67 145.98 6475.02 261.19 0 0 ICGC_PCA051 41 3 + 4 T2c NA 1 2606.4 108.46 5413.56 230.22 0.262 0 ICGC_PCA052 40 3 + 4 T2c NA 0 6947.3 264.31 5799.31 233.8 0 0 ICGC_PCA053 48 4 + 3 T2c 9.9 0 6203.75 230.88 6614 259.63 0 0 ICGC_PCA054 50 3 + 4 T2c 6.4 0 4053.86 213.7 5865.11 232.88 0 0 ICGC_PCA055 48 3 + 4 T2c 6.15 0 4154.49 242.1 6373.99 292.45 0 0 ICGC_PCA056 47 3 + 4 T2c NA 0 4748.29 193.29 6807.71 319.99 0 0 ICGC_PCA057 50 3 + 4 T2c 5.07 1 4296.18 220.09 6351.99 288.2 0.209 0 ICGC_PCA058 47 3 + 4 T2c 5.4 0 4131.73 204.29 7484.18 298.12 0 0 ICGC_PCA059 47 3 + 4 T2c 14.1 0 2733.23 113.62 5098.51 228.84 0 0 ICGC_PCA060 41 3 + 3 T2c 5.74 1 7267.63 285.01 9625.05 360.89 0.167 0 ICGC_PCA061 47 3 + 4 T2a 6.47 0 6088.55 256.58 5563.43 213.36 0 0 ICGC_PCA062 45 3 + 4 T2c 8.21 0 5973.57 232.62 10047.6 405.8 0 0 ICGC_PCA063 46 3 + 4 T2c 13 0 3077.46 177.38 8342.93 352.02 0 0 ICGC_PCA064 47 3 + 3 T2a 5.3 0 6441.14 398.83 10255.3 420.64 0 0 ICGC_PCA065 48 3 + 4 T2c 8.9 2 1325.05 75.46 11750 619.56 0.195 1 ICGC_PCA068 50 3 + 4 T2c 12.9 1 5040.31 276.33 5742.06 236.93 0.255 0 ICGC_PCA069 50 4 + 3 T3a 6.45 0 2451.17 143.26 5556.66 262.17 0 0 ICGC_PCA070 47 3 + 4 T2c 5.2 1 3953.56 231.81 5395.4 260.33 0.232 0 ICGC_PCA071 49 4 + 3 T2c 24.5 1 3776.54 223.33 6539.71 301.58 0.2 1 ICGC_PCA072 49 3 + 4 T2c 11 0 4492.12 269.55 6647.67 314.24 0 0 ICGC_PCA074 42 3 + 4 T2c 5.7 0 3321.15 251.03 5395.89 300.36 0 0 ICGC_PCA075 40 3 + 3 T2a 5.4 2 5151.89 266.66 5965.86 338.87 0.356 0 ICGC_PCA076 49 3 + 4 T2c NA 0 3491.55 192.11 3316.82 213.37 0 0 ICGC_PCA077 44 4 + 3 T2a 5.48 0 7752.06 405.76 8308.19 337.25 0 0 ICGC_PCA078 47 3 + 4 T2c 16 0 4355.82 237.7 3346.03 133.55 0 0 ICGC_PCA079 46 3 + 4 T2c 6.3 0 6685.66 343.82 2601.73 105.83 0 0 ICGC_PCA081 50 4 + 5 T3b 13 1 2714.44 116.32 4814.68 183.35 0.329 0 ICGC_PCA082 41 5 + 4 T3b 7.5 0 6940.57 290.7 5926.09 232.03 0 0 ICGC_PCA083 45 3 + 4 T2c 16 1 11499.2 500.95 3934.47 165.31 0.365 0 ICGC_PCA084 45 5 + 4 T3b NA 0 5001.32 177.57 5497.65 205.17 0 0 ICGC_PCA085 47 3 + 4 T2c NA 0 3163.24 117.88 5796.65 222.73 0 0 ICGC_PCA086 50 4 + 3 T3b NA 1 2093.52 79.68 7527.37 284.86 0.212 0 ICGC_PCA087 45 3 + 3 T2c NA 0 4426.2 173.41 6051.99 237.24 0 0 ICGC_PCA088 43 3 + 3 T2c NA 0 4838.29 172.92 4928.1 189.51 0 0 ICGC_PCA089 48 3 + 4 T2c NA 0 3071.35 125.49 5624.6 219.75 0 0 ICGC_PCA090 40 3 + 4 T2c NA 0 3773.1 133.25 7026.47 285.17 0 0 ICGC_PCA091 50 3 + 4 T2c NA 1 7940.39 357.03 6353.35 326.23 0.185 0 ICGC_PCA094 45 3 + 4 T2c NA 0 1580.49 110.87 4981.62 249.77 0 0 ICGC_PCA095 50 3 + 3 T2c NA 1 2460.92 179.24 5146.51 196.13 0.308 0 ICGC_PCA096 49 3 + 3 T2a NA 0 2575.05 190.82 6107.44 232.27 0 0 ICGC_PCA097 48 3 + 3 T2a 8.5 1 3853.91 280.28 8780.53 391.46 0.154 1 ICGC_PCA098 45 4 + 5 T3a NA 3 4548.38 376.83 6023.84 308.36 0.587 1 ICGC_PCA102 48 3 + 3 T2c NA 0 3897.72 304.27 6101.24 299.3 0 0 ICGC_PCA103 48 3 + 3 T2c NA 1 3976.32 300.1 7233.16 338.95 0.178 0 ICGC_PCA104 44 3 + 4 T2a NA 0 3427.5 247.03 5674.02 243.73 0 0 ICGC_PCA105 49 3 + 4 T2c NA 0 4097.07 175.58 7762.64 289.33 0 0 ICGC_PCA106 43 3 + 4 T2c NA 0 8923.14 375 5921.86 250.34 0 0 ICGC_PCA107 47 3 + 3 T2c NA 0 4825.85 196.81 6644.75 252.32 0 0 ICGC_PCA108 50 3 + 4 T3a NA 0 6116.57 213.75 8639.65 317.23 0 0 ICGC_PCA110 48 3 + 3 T2c NA 0 5878.11 243.55 4948.4 329.78 0 0 ICGC_PCA111 43 3 + 4 T2c NA 0 7863.32 459.98 7416.78 309.48 0 0 ICGC_PCA112 47 4 + 3 T3b NA 0 2980.66 168.21 5585.02 262.95 0 0 ICGC_PCA113 48 4 + 5 T3b NA 0 2915.6 229.57 4126.11 223.7 0 0 ICGC_PCA116 46 3 + 4 T3a NA 0 4955.88 254.74 7505.96 283.24 0 0 ICGC_PCA118 50 3 + 3 T2c NA 1 3994.34 192.73 8046.52 337.81 0.179 1 ICGC_PCA121 44 3 + 4 T2c NA 0 5487.62 190.05 7985.31 261.26 0 0 ICGC_PCA122 50 4 + 3 T3b NA 1 4089.29 139.16 16881.6 274.74 0.22 0 ICGC_PCA123 46 3 + 4 T3a NA 1 6229.33 201.83 23838.9 390.26 0.155 0 ICGC_PCA124 46 3 + 4 T3a NA 0 3088.17 103.27 18666.6 289.76 0 0 ICGC_PCA125 44 5 + 4 T4 NA 3 6218.51 206.29 37206.4 513.19 0.353 1 ICGC_PCA126 47 4 + 3 T3b NA 0 4562.1 264.16 18594.5 589.83 0 0 ICGC_PCA127 49 3 + 4 T2c NA 0 3722.96 213.53 9790.9 314.37 0 0 ICGC_PCA129 49 4 + 5 T2c NA 0 4966.04 279.15 13371.3 395.19 0 0 ICGC_PCA130 46 3 + 4 T3a NA 0 1157.65 64.66 10770.6 318.28 0 0 ICGC_PCA131 50 3 + 4 T2c NA 0 3322.29 180.76 9669.45 304.17 0 0 ICGC_PCA132 48 3 + 4 T3b NA 0 2513.39 153.77 8557.46 261.06 0 0 ICGC_PCA133 49 3 + 3 T2c NA 0 4382.32 287.84 11193.9 325.5 0 0 ICGC_PCA134 48 3 + 4 T2c NA 0 3757.47 228.28 6793.07 225.09 0 0 ICGC_PCA135 47 3 + 4 T2c NA 0 3768.45 222.46 13255.5 269.37 0 0 ICGC_PCA136 47 3 + 4 T2c NA 0 2273.13 136.73 7783.32 234.65 0 0 ICGC_PCA137 49 3 + 4 T2c NA 0 2698.04 168.42 9615.6 308.54 0 0 ICGC_PCA138 48 3 + 4 T2c NA 0 2118.75 133.68 4218.26 91.54 0 0 ICGC_PCA140 45 3 + 3 T2c NA 1 5669.67 169.93 8477.17 179.01 0.337 0 ICGC_PCA141 49 3 + 4 T2c NA 0 3703.42 235.29 3519.06 75.73 0 0 ICGC_PCA142 46 5 + 4 T4 NA 1 6249.11 397.65 14694.7 479.36 0.126 0 ICGC_PCA143 48 3 + 4 T3a NA 0 4739.26 144.27 10439.3 324.05 0 0 ICGC_PCA144 46 3 + 4 T2c NA 0 9066.31 138.77 6515.96 203.56 0 0 ICGC_PCA145 32 3 + 3 T2a NA 0 2457.97 155.08 6448.05 207.27 0 0 ICGC_PCA148 46 3 + 4 T3a NA 0 2547.86 139.34 7361.85 134.36 0 0 ICGC_PCA149 45 4 + 3 T2c NA 0 2529.97 148.52 7028.07 222.41 0 0 ICGC_PCA150 40 3 + 3 T2c NA 0 3151.92 193.85 8846 287.53 0 0 ICGC_PCA151 49 3 + 4 T3a NA 0 2056.8 131.17 6984.15 214.76 0 0 ICGC_PCA152 45 3 + 4 T2c NA 0 4032.42 251.71 9519.33 318 0 0 ICGC_PCA153 50 3 + 4 T2c NA 0 2467.2 149.3 9858.98 310.71 0 0 ICGC_PCA154 48 3 + 4 T2c NA 0 2957.33 171.59 9626.51 308.59 0 0 ICGC_PCA155 45 3 + 4 T2a NA 1 917.007 53.64 9799.51 306.62 0.197 0 ICGC_PCA156 45 3 + 4 T2c NA 1 4236.17 251.78 10226.1 408.15 0.148 0 ICGC_PCA157 44 3 + 3 T3a NA 0 3006.29 197.59 9086.25 313.43 0 0 ICGC_PCA158 45 4 + 3 T3a NA 0 4184.84 226.94 9004.93 281.4 0 0 ICGC_PCA159 44 4 + 3 T2c NA 0 4889.47 341.56 10928.6 327.3 0 0 ICGC_PCA160 50 4 + 3 T2c NA 0 2034.2 133.7 12007.2 363.41 0 0 ICGC_PCA161 48 4 + 5 T3b NA 2 1916.61 124.46 5272.41 182.18 0.663 0 ICGC_PCA162 50 3 + 4 T2c NA 0 3516.02 220.23 7845.21 239.88 0 0 ICGC_PCA163 45 3 + 4 T2c NA 1 3013.52 175.46 8769.99 268.11 0.225 0 ICGC_PCA164 50 3 + 4 T3a NA 0 4510.1 265.14 5838.26 354.37 0 0 ICGC_PCA165 48 3 + 4 T2c NA 0 2058.3 125.77 12277.9 379.59 0 0 ICGC_PCA166 47 4 + 3 T2a NA 2 2459.89 154.71 6601.8 206.31 0.585 1 ICGC_PCA167 43 3 + 4 T2c NA 0 3481.01 216.01 11925.1 357.9 0 0 ICGC_PCA168 50 3 + 4 T2a NA 1 4869.54 314.27 12045.6 279.19 0.216 0 ICGC_PCA169 46 3 + 4 T3a NA 2 5858.35 390.84 17049.7 470.86 0.256 1 ICGC_PCA170 51 4 + 3 T2c NA 2 3144.62 246.06 17963.1 324.48 0.372 1 ICGC_PCA171 50 3 + 4 T2c NA 1 5702.95 322.93 12983.8 353.49 0.171 0 ICGC_PCA172 43 3 + 3 T2c NA 0 6141.82 341.59 6015.86 166 0 0 ICGC_PCA173 46 3 + 4 T2c NA 0 6063 355.91 17240.8 463.59 0 0 ICGC_PCA174 51 3 + 4 T3b NA 1 4700.36 278.37 9175.36 260.85 0.231 0 ICGC_PCA175 48 4 + 3 T3a NA 0 3023.26 179.85 8788.83 257.43 0 0 ICGC_PCA176 47 5 + 5 T4 NA 0 5185.27 302.08 4916.06 139.5 0 0 ICGC_PCA177 46 3 + 4 T3a NA 0 1713.44 98.87 6854.12 210.6 0 0 ICGC_PCA178 51 3 + 3 T2a NA 0 1792.49 105.66 8523.97 279.43 0 0 ICGC_PCA179 45 3 + 4 T2c NA 0 4142.21 236.83 9055.59 271.86 0 0 ICGC_PCA180 51 3 + 4 T2c NA 2 2446.26 139.43 12616 389.92 0.31 0 ICGC_PCA181 51 3 + 4 T2c NA 0 9884.16 557.48 7422.03 250.36 0 0 ICGC_PCA182 51 3 + 4 T2c NA 1 3777.99 213.81 13779.1 421.64 0.143 0 ICGC_PCA183 52 3 + 4 T3a NA 1 2994.8 167.45 5766.19 151.34 0.399 1 ICGC_PCA184 51 3 + 4 T2c NA 2 4889.25 277.56 8793.69 249.22 0.484 1 ICGC_PCA185 51 3 + 3 T2c NA 1 6046.69 350.23 10357 285.87 0.211 0 ICGC_PCA186 51 3 + 4 T2c NA 0 8935.55 150.08 16333.1 498.49 0 0 ICGC_PCA187 46 3 + 3 T2c NA 1 24761.9 420.19 8581.43 266.01 0.227 0 ICGC_PCA188 48 3 + 4 T2c NA 0 6424.8 115.1 3947.88 116.18 0 0 ICGC_PCA189 51 3 + 4 T2c NA 0 11625.9 211 9484.56 293.64 0 0 ICGC_PCA190 51 4 + 3 T2c NA 0 10871.4 206.33 5180.94 169.2 0 0 ICGC_PCA191 51 3 + 4 T2c NA 0 2626.94 150.24 7651.09 232.7 0 0 ICGC_PCA192 52 4 + 4 T3b NA 1 3697.6 215.29 5591.91 171.06 0.353 0 ICGC_PCA193 52 5 + 4 T3b NA 3 4695.07 262 8394.14 253.71 0.714 0 ICGC_PCA194 52 3 + 4 T2c NA 0 5640.21 314.13 16449.8 482.61 0 0 ICGC_PCA195 47 3 + 3 T2c NA 0 1946.43 109.94 6144.92 178.42 0 0 ICGC_PCA196 52 4 + 5 T3b NA 1 2681.47 146.21 4994.05 137.48 0.439 0 ICGC_PCA197 50 3 + 4 T3a NA 1 3413.79 183.69 10603.2 309.85 0.195 1 ICGC_PCA198 52 4 + 5 T3b NA 2 3070.23 172.58 10961.7 304.15 0.397 1 ICGC_PCA199 51 3 + 4 T2c NA 0 2438.98 141.68 13931.1 265.61 0 0 ICGC_PCA200 47 3 + 4 T2c NA 0 2912.99 178.33 25583.2 277.99 0 0 TCGA-CH-5750 72 3 + 4 T2c 13.2 2 4645.1 256.1 8771.03 332.78 0.363 0 TCGA-CH-5763 66 3 + 4 T3a 14.8 0 4837.75 275.63 9349.95 321.39 0 0 TCGA-CH-5771 63 4 + 3 T2c 8.1 0 4387.57 267.28 6988.53 222.02 0 0 TCGA-CH-5788 69 4 + 3 T3b 19.4 1 5554.92 288.62 21678.6 606.25 0.1 1 TCGA-CH-5789 61 3 + 4 T3a 5.7 0 7282.33 418.19 8021.94 306.89 0 0 TCGA-EJ-5503 50 5 + 3 T3a 18.4 0 5531.64 289.41 7616.2 237.24 0 0 TCGA-EJ-5506 67 5 + 3 T3b 7.2 2 4952.82 291.73 8754.14 336.74 0.359 1 TCGA-EJ-7791 67 3 + 4 T2c 4.5 0 2665.12 159.65 7271.3 244.69 0 0 TCGA-G9-6336 57 3 + 4 NA 10.6 2 2003.55 105.24 9463.51 334.99 0.36 0 TCGA-G9-6365 71 3 + 4 T4 11.6 0 2230.56 107.99 9664.85 342.25 0 0 TCGA-G9-6370 52 3 + 4 T3b 6.4 0 2373.22 120.83 8885.26 304.54 0 0 TCGA-G9-7522 49 3 + 4 T2c 6.8 0 1974.77 115.85 5812.83 211.12 0 0 TCGA-HC-7075 63 3 + 3 T2a 5.1 1 2362.13 136.21 8765.79 285.05 0.212 1 TCGA-HC-7079 51 3 + 4 T3a 5.5 0 2660.98 143.62 4529.49 170.1 0 0 TCGA-HC-7233 73 4 + 3 T2a 7.7 0 2402.06 119.2 6346.51 214.41 0 0 TCGA-HC-7737 55 3 + 4 T2c 18.1 0 3231.25 180.11 7132.52 264.64 0 0 TCGA-HC-7740 59 3 + 4 T2c 5.9 0 2747.27 170.09 6201.89 241.73 0 0 TCGA-HC-7744 46 4 + 3 T3b 4.4 0 3770.56 211 9518.19 327.16 0 0 TCGA-HC-8258 56 3 + 3 T2c 4.3 0 2585.8 143.5 9352.13 272.82 0 0 TCGA-HI-7169 55 3 + 4 T3a 2.2 0 1802.28 99.46 8035.46 278.59 0 0

sample_size (Amt_DNA. MT- MT- MT- MT- MT- MT- MT- MT- MT- MT- MT- MT- MT- MT- sent.for. MYC NKX3-1 CYB RNR1 RNR2 ND1 MTND2 ND3 ND4 ND4L ND5 ND6 CO1 CO2 CO3 ATP6 ATP8 OHR CSB1 HV1 HV2 bwa version sequencing CNA CNA cellularity 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 NA 0 0 NA 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 −1 NA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 1 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa/0.5.7 NA 1 0 NA 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 1 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 356.5 0 −1 0.85 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 226.2 1 −1 0.76 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 198 0 −1 0.84 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 222.32 0 0 0.78 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 121.16 1 −1 0.92 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 267.3 0 −1 0.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 129 1 0 0.89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 239.9 0 −1 0.24 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 399.82 0 0 0.26 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 232.5 0 0 0.89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 295.2 0 0 0.92 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 259 0 0 0.18 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 232.2 0 −1 0.88 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 227.34 0 0 NA 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 392.06 1 0 0.83 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 391.89 0 −1 0.88 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 228.64 0 0 0.89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 424.02 0 0 0.85 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 512.4 0 0 0.71 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 159.8 0 0 0.92 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 310.77 0 −1 0.63 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 bwa/0.5.7 513.84 1 −1 0.24 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.15 500 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 bwa-mem/0.7.12 270.96 0 0 0.85 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 308.14 0 0 0.85 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 bwa/0.5.7 663.36 1 −1 0.78 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa/0.5.7 500 1 −1 0.75 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 242.19 0 0 0.77 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 408.2 0 0 0.85 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 bwa/0.5.7 252.59 1 −1 0.59 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa/0.5.7 675.13 1 −1 0.41 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 bwa-mem/0.7.12 253.71 1 −1 0.86 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 299.1 1 −1 0.6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa-mem/0.7.12 664.9 0 0 0.87 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 275.1 0 −1 0.98 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 bwa-mem/0.7.12 250 0 0 0.83 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 300 0 0 0.8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 417.15 0 0 0.48 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 359.22 0 0 0.9 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 100 0 0 0.86 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 186.62 0 0 0.78 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 bwa/0.5.7 250.29 1 −1 0.78 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1093.12 0 −1 0.84 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa/0.5.7 318.32 1 −1 0.68 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa/0.5.7 642.75 0 0 NA 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 bwa-mem/0.7.10 552.6 0 0 NA 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 bwa/0.5.7 339.15 0 0 0.23 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 677.5 0 0 0.62 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 205.47 1 −1 0.79 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 952.8 0 −1 0.25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 937.68 0 0 0.8 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa/0.5.7 242.5 0 0 0.83 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 bwa/0.5.7 980.4 0 0 0.8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 177.25 0 −1 0.92 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 503.84 0 0 0.92 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 1098.8 0 −1 0.92 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 950.96 0 0 0.84 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa/0.5.7 848.68 0 0 0.62 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 1 bwa/0.5.7 150 0 0 0.23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 501.12 0 0 NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 586.8 0 −1 0.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 774.52 1 −1 0.66 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2064 0 −1 0.59 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 bwa/0.5.7 2901.44 1 −1 0.89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1510.32 0 −1 0.76 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 bwa/0.5.7 2036.8 0 −1 0.72 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2020.36 0 0 0.36 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1722.16 0 −1 0.62 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 522.09 0 −1 0.85 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 bwa/0.5.7 1513.8 0 0 0.89 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa-mem/0.7.12 262.8 0 0 0.88 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 259.5 0 0 0.35 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 271.2 0 −1 0.82 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa-mem/0.7.12 991.44 0 −1 0.88 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 bwa/0.5.7 203.44 0 −1 0.27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa/0.5.7 335.52 1 −1 0.16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2304.48 0 −1 0.83 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1001.2 0 −1 0.3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1000 0 −1 0.53 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1001.64 0 −1 0.85 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1515.8 0 −1 0.23 0 0 1 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 bwa/0.5.7 1002.56 0 0 0.2 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2006 0 −1 0.79 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2015.2 0 −1 0.63 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 bwa/0.5.7 500 0 0 0.93 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2000 1 −1 0.81 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 388.8 1 −1 0.51 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 635.75 0 0 0.88 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2000 0 0 0.6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2000 0 −1 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 1 0 1 bwa/0.5.7 618 1 −1 0.69 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 1498 0 0 0.87 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 339 0 0 0.15 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 394.8 0 −1 0.65 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 bwa/0.5.7 563.4 0 −1 0.64 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 1500 0 0 0.37 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa/0.5.7 1000 0 0 0.23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 259.2 0 0 0.64 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 1 1 bwa/0.5.7 429 0 −1 0.2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.12 1006.4 0 −1 0.86 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1500 0 −1 0.27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 279 0 0 0.16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1500 0 0 0.55 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 bwa/0.5.7 253.2 0 −1 0.81 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 85.2 0 −1 0.31 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 287.4 0 −1 0.76 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 bwa/0.5.7 306.6 0 −1 0.19 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 271.2 0 0 0.3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 268.4 0 0 0.22 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 bwa/0.5.7 110.4 0 −1 0.75 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 416.5 0 −1 0.31 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 bwa/0.5.7 312.2 0 −1 0.22 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 318.5 0 −1 0.66 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 445.9 0 0 0.23 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 342 1 0 0.23 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 588 0 −1 0.62 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 543.9 0 −1 0.53 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 310.1 0 0 0.27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 363.6 0 0 0.28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 bwa/0.5.7 489 1 1 0.78 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 484.2 0 0 0.26 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 246 0 −1 0.67 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 bwa/0.5.7 253 0 −1 0.61 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa/0.5.7 297.6 0 −1 0.79 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 271.2 0 −1 0.63 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 250.8 0 0 0.51 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 298 0 −1 0.25 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 256 0 0 0.15 1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 bwa/0.5.7 277.6 0 1 0.61 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 346.2 0 0 0.69 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 265.5 0 0 0.27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 252.8 0 −1 0.23 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 347.4 0 −1 0.31 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 330.4 0 0 0.38 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 277.2 0 0 0.32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 237.2 0 0 0.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 2361.68 0 0 0.13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1542 0 −1 0.6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 309.4 0 0 0.2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 294.6 1 −1 0.72 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 355.68 0 −1 0.61 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 bwa/0.5.7 304 0 0 0.28 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 350.4 0 0 0.33 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 309.6 0 0 0.19 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 428 0 0 0.47 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 315 0 −1 0.28 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 bwa/0.5.7 288 0 −1 0.63 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 536.2 1 −1 0.77 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 bwa/0.5.7 282.6 1 −1 0.55 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 280.8 0 0 0.26 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 598 1 1 0.69 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 348 0 0 0.49 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 673 0 −1 0.74 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 374.4 0 0 0.21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 1180 0 0 0.7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 603 0 0 0.15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 754 0 0 0.71 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 588 0 −1 0.77 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 326 0 −1 0.13 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 399 0 −1 0.31 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 392 0 −1 0.27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 445.2 0 0 0.12 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 422 0 −1 0.63 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 442.4 0 0 0.51 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 336 0 0 0.17 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 −1 NA 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 1 −1 NA 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 1 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 1 1 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 1 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 1 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 bwa-mem/0.7.8-r455 NA 1 0 NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 1 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 1 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 1 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 1 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 1 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 bwa-mem/0.7.8-r455 NA 0 0 NA 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa-mem/0.7.8-r455 NA NA NA NA 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 bwa/0.5.7 NA 0 −1 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 bwa/0.5.7 NA NA 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA NA 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 bwa/0.5.7 NA 0 0 NA

TABLE 5 Table of 293 somatic mtSNVs Position Tumour Cover- Locus nucleo- Re- Tu- Tu- Tu- Tu- Tumour.H. Nor- Nor- Nor- Nor- Covering agemt Difference tide.vari- Patient ference mour mour.H.F mour.HF mour.HF Normal mal.HF.A mal.HF.C mal.HF.G mal.HF.G Normal DNA in H ability.sco CPCG0187 60 T T 0 0.22 0 0.78 T 0 0 0 1 7399 1019 CR 0.22 0.00186 CPCG0078 72 T C 0 0.72 0 0.27 T 0 0 0 1 6109 427 CR 0.73 0.0925 CPCG0114 72 T T 0 0 0 1 C 0 1 0 0 1191 4684 CR 1 0.0925 CPCG0263 72 T T 0 0.5 0 0.5 T 0 0 0 1 5744 867 CR 0.5 0.0925 ICGC_PCA071 72 T C 0 0.89 0 0.11 T 0 0 0 1 3206 1797 CR 0.89 0.0925 CPCG0166 73 G A 0.75 0 0.25 0 A 0.99 0 0.01 0 157 1517 CR 0.24 0.941 CPCG0098 146 C C 0 0.7 0 0.3 T 0 0 0 1 7027 1946 CR 0.7 0.661 CPCG0100 146 C T 0 0.42 0 0.58 T 0 0.01 0 0.99 6441 961 CR 0.41 0.661 ICGC_PCA169 146 C C 0 0.69 0 0.31 T 0 0.2 0 0.8 7149 3256 CR 0.49 0.661 ICGC_PCA198 146 C T 0 0.18 0 0.82 C 0 0.83 0 0.17 6081 1906 CR 0.66 0.661 CPCG0206 152 C C 0 0.84 0 0.16 C 0 0.18 0 0.82 6953 1192 CR 0.66 0.841 Baca07-4610 152 C T 0 0.27 0 0.73 T 0 0 0 1 1429 3202 CR 0.27 0.841 ICGC_PCA032 152 C C 0 0.99 0 0.01 T 0 0 0 1 2545 1947 CR 0.99 0.841 CPCG-0204 183 A G 0.49 0 0.51 0 A 1 0 0 0 4619 2424 CR 0.51 0.0184 CPCG0073 195 C T 0 0.26 0 0.74 T 0 0 0 1 7698 1420 CR 0.26 0.721 CPCG0196 195 C T 0 0.37 0 0.63 T 0 0 0 1 7693 1938 CR 0.37 0.721 ICGC_PCA118 195 C C 0 0.56 0 0.43 T 0 0.11 0 0.89 3858 1854 CR 0.46 0.721 ICGC_PCA166 199 T C 0 0.86 0 0.14 T 0 0.15 0 0.85 3353 1316 CR 0.71 0.161 ICGC_PCA015 207 G G 0.2 0 0.8 0 A 0.71 0 0.29 0 3875 2173 CR 0.51 0.15 CPCG0098 215 A G 0.24 0 0.76 0 A 1 0 0 0 6941 1904 CR 0.76 0.0275 CPCG0205 227 A A 0.82 0 0.18 0 G 0.16 0 0.84 0 7020 1057 CR 0.67 0.017 CPCG0242 234 A G 0.19 0 0.81 0 A 1 0 0 0 5708 1313 CR 0.81 0.0218 ICGC_PCA031 234 A G 0.16 0 0.84 0 A 0.93 0 0.07 0 3788 3533 CR 0.77 0.0218 CPCG0070 248 A A 0.99 0 0.01 0 A 0.74 0 0.26 0 7301 1864 CR 0.24 0.00171 CPCG0256 255 G G 0.44 0.01 0.55 0 G 0 0 1 0 5127 836 CR 0.45 0.00081 CPCG0158 307 C C 0 0.64 0 0.36 C 0 1 0 0 3733 418 CR 0.36 0.00028 CPCG0081 309 C C 0 0.62 0 0.38 C 0 1 0 0 4648 833 CR 0.38 0.00196 Baca06-3199 309 C T 0 0.22 0 0.77 C 0 0.99 0 0 3321 2031 CR 0.77 0.00196 CPCG0344 499 G G 0.21 0 0.78 0 G 0 0 1 0 5510 767 CR 0.22 0.129 CPCG0046 564 G G 0.27 0.02 0.71 0 G 0 0 1 0 5136 1358 CR 0.29 0 CPCG0342 564 G A 0.88 0 0.12 0 G 0 0 1 0 7015 1140 CR 0.88 0 ICGC_PCA125 574 A A 0.83 0.17 0 0 A 0.62 0.38 0 0 2350 2351 CR 0.22 0.0064 CPCG0067 617 G G 0.49 0 0.51 0 G 0 0 1 0 4991 1353 TF 0.49 0 CPCG0189 650 T T 0 0.5 0 0.5 T 0 0 0 1 7069 1697 RNR1 0.5 0.00327 CPCG0189 690 T T 0 0.27 0 0.73 T 0 0 0 1 7749 1636 RNR1 0.27 0 CPCG0083 709 G A 0.56 0 0.44 0 G 0 0 1 0 7699 2079 RNR1 0.32 0.481 ICGC_PCA16 709 G A 0.61 0 0.39 0 G 0.29 0 0.71 0 4203 2359 RNR1 0.32 0.481 CPCG0073 719 G G 0.38 0 0.62 0 G 0 0 1 0 7538 1856 RNR1 0.38 0.0371 CPCG0019 933 G A 0.52 0 0.48 0 G 0 0 1 0 6070 1334 RNR1 0.52 0 CPCG0248 988 G G 0.42 0 0.58 0 G 0 0 1 0 7286 1825 RNR1 0.42 0.00217 CPCG0346 988 G G 0.38 0 0.62 0 G 0 0 1 0 7487 2850 RNR1 0.38 0.00217 EOPC-07 988 G G 0.36 0 0.64 0 G 0 0 1 0 2637 1193 RNR1 0.36 0.00217 CPCG0204 991 G A 0.66 0 0.34 0 G 0 0 1 0 6944 3211 RNR1 0.66 0 CPCG0211 1079 G G 0.26 0 0.74 0 G 0 0 0.99 0 7251 955 RNR1 0.26 0 ICGC_PCA057 1157 T C 0 0.53 0 0.47 T 0 0 0 1 5267 3788 RNR1 0.53 0 EOPC-04 1193 T T 0 0.1 0 0.9 T 0 0.32 0 0.68 4416 5078 RNR1 0.22 0.0184 CPCG0090 1199 G A 0.7 0 0.3 0 G 0 0 1 0 7220 1809 RNR1 0.7 0 ICGC_PCA192 1447 G G 0.32 0 0.68 0 G 0 0 1 0 3833 3210 RNR1 0.32 0 ICGC_PCA032 1452 T T 0 0 0 1 C 0 1 0 0 3591 2798 RNR1 1 0.00255 CPCG0185 1456 T T 0 0.46 0 0.54 T 0 0 0 1 6988 1393 RNR1 0.45 0 CPCG0412 1469 G A 0.51 0 0.49 0 G 0 0 1 0 7430 2608 RNR1 0.51 0 CPCG0268 1552 G G 0.22 0 0.78 0 G 0 0 1 0 7268 1827 RNR1 0.22 0 CPCG0097 1644 G G 0.25 0 0.74 0 G 0 0 1 0 7544 1857 TV 0.25 0 ICGC_PCA103 1659 T T 0 0.46 0 0.54 T 0 0 0 1 5490 3077 TV 0.46 0 ICGC_PCA032 1716 T T 0 0 0 1 C 0 1 0 0 3512 2843 RNR2 1 0.00071 ICGC_PCA161 1730 T C 0 0.73 0 0.27 T 0 0 0 1 4449 1742 RNR2 0.73 0 ICGC_PCA075 1770 G G 0.44 0 0.56 0 G 0 0 1 0 5071 4007 RNR2 0.44 0.00024 CPCG0339 1906 G A 0.59 0 0.41 0 G 0 0 1 0 4152 2079 RNR2 0.59 0 CPCG0098 1975 T C 0 0.77 0 0.23 T 0 0 0 1 7264 3250 RNR2 0.77 0 CPCG0100 2074 A G 0.35 0 0.65 0 A 0.99 0 0 0 6650 1492 RNR2 0.64 0 CPCG0027 2115 T T 0 0 0 1 T 0 0.25 0 0.75 7869 2386 RNR2 0.25 0 ICGC_PCA083 2269 G A 0.6 0 0.4 0 G 0 0 1 0 3888 7545 RNR2 0.6 0 Baca05-3852 2333 G A 0.91 0 0.09 0 G 0.03 0 0.97 0 5544 535 RNR2 0.88 0 CPCG0388 2478 G G 0.36 0 0.64 0 G 0 0 1 0 6248 1625 RNR2 0.35 0 CPCG0183 2487 A A 0.99 0 0 0 A 0.77 0.2 0.01 0.01 6505 980 RNR2 0.22 0 C2CG0081 2519 G A 0.64 0 0.36 0 G 0 0 1 0 7720 2093 RNR2 0.63 0 ICGC_PCA029 2571 G G 0.26 0 0.74 0 G 0 0 1 0 4628 3828 RNR2 0.26 0 CPCG0040 2607 T T 0 0.26 0 0.74 T 0 0 0 1 7075 2426 RNR2 0.26 0.00021 CPCG0358 2634 T T 0 0.41 0 0.59 T 0 0 0 1 7226 6151 RNR2 0.41 0 CPCG0005 2697 G G 0.48 0 0.52 0 G 0 0 1 0 7295 1990 RNR2 0.48 0 ICGC_PCA182 2737 T C 0 0.72 0 0.28 T 0 0 0 1 7240 3411 RNR2 0.72 0 TCGA-CH-5750 2817 G G 0.47 0 0.53 0 G 0 0 1 0 7221 4353 RNR2 0.47 0 ICGC_PCA068 2844 G G 0.5 0 0.5 0 G 0 0 1 0 5749 5208 RNR2 0.5 0.00027 CPCG0217 2894 T T 0 0 0 1 T 0 0.24 0 0.76 7556 2046 RNR2 0.24 0 ICGC_PCA070 2914 A A 0.69 0 0.31 0 G 0.22 0 0.78 0 5262 3922 RNR2 0.48 0 ICGC_PCA051 2916 G G 0.32 0 0.68 0 G 0 0 1 0 5144 2334 RNR2 0.32 0 ICGC_PCA163 2916 G G 0.44 0 0.56 0 G 0 0 1 0 6634 2865 RNR2 0.44 0 CPCG0331 2941 G A 0.61 0 0.39 0 G 0 0 1 0 7516 2137 RNR2 0.61 0 CPCG0410 3022 G G 0.25 0 0.75 0 G 0 0 1 0 6485 4343 RNR2 0.25 0 ICGC_PCA125 3063 G A 0.69 0 0.31 0 G 0 0 1 0 7482 5738 RNR2 0.69 0 CPCG0324 3079 G A 0.61 0 0.39 0 G 0 0 1 0 7139 1352 RNR2 0.61 0 CPCG0166 3174 T T 0 0.28 0 0.72 T 0 0 0 1 367 1680 RNR2 0.28 0 CPCG0212 3297 T T 0 0.23 0 0.77 T 0 0 0 1 5513 1785 TL1 0.23 0 CPCG0071 3492 A A 0.75 0.24 0 0.01 A 0.97 0.03 0 0 4204 1332 ND1 0.23 0.00194 CPCG0265 3496 G G 0.4 0 0.59 0 G 0 0 1 0 5814 1482 ND1 0.41 0.00248 TCGA-CH-5750 3526 G G 0.23 0 0.77 0 G 0 0 1 0 6324 3582 ND1 0.23 0 CPCG0120 3697 G G 0.35 0 0.65 0 G 0 0 1 0 3441 2086 ND1 0.35 0 CPCG0063 3842 G G 0.22 0 0.77 0 G 0 0 1 0 6812 2780 ND1 0.23 0 ICGC_PCA122 3842 G G 0.45 0 0.55 0 G 0 0 1 0 6541 3027 ND1 0.45 0 ICGC_PCA187 3842 G G 0.21 0 0.79 0 G 0 0 1 0 5568 7177 ND1 0.21 0 CPCG0127 3946 G G 0.22 0 0.78 0 G 0 0 1 0 6769 1093 ND1 0.22 0.00011 CPCG0233 3946 G G 0.4 0 0.6 0 G 0 0 1 0 5649 2007 ND1 0.4 0.00011 ICGC_PCA125 3959 G G 0.36 0 0.63 0 G 0 0 1 0 6863 4509 ND1 0.36 0 CPCG0213 3982 G G 0.22 0 0.78 0 G 0 0 1 0 7271 1878 ND1 0.22 0 Baca05-3852 4053 A G 0.34 0 0.65 0 A 0.96 0 0.03 0 3456 1689 ND1 0.62 0.00103 CPCG0027 4142 G A 0.59 0 0.41 0 G 0 0 1 0 6519 580 ND1 0.59 0 TCGA-EJ-5506 4142 G G 0.21 0 0.79 0 G 0 0 0.99 0 4987 2746 ND1 0.21 0 CPCG0003 4201 G G 0.24 0 0.76 0 G 0 0 1 0 6785 632 ND1 0.24 0 CPCG0067 4231 A G 0.58 0 0.42 0 A 1 0 0 0 2905 1230 ND1 0.42 0.00257 ICGC_PCA098 4233 T C 0 0.53 0 0.47 T 0 0 0 1 3721 2957 ND1 0.53 0.00147 CPCG0067 4407 G A 0.63 0 0.36 0 G 0 0 1 0 6634 1169 TM 0.64 0 CPCG0387 4436 C C 0 0.56 0 0.44 C 0 1 0 0 7674 4629 TM 0.44 0 CPCG0262 4482 G G 0.27 0 0.73 0 G 0 0 1 0 7254 1360 ND2 0.27 0 ICGC_PCA171 4491 G G 0.46 0 0.54 0 G 0 0 1 0 7144 4922 ND2 0.46 0.0858 CPCG0204 4596 G A 0.68 0 0.32 0 G 0 0 1 0 4280 1516 ND2 0.68 0.00408 CPCG0117 4648 T T 0 0.36 0 0.63 T 0 0 0 1 7586 1489 ND2 0.36 0 CPCG0407 4770 G A 0.75 0 0.25 0 G 0 0 1 0 7113 2902 ND2 0.75 0 EOPC-03 4831 G A 0.61 0 0.39 0 G 0 0 1 0 7611 2736 ND2 0.61 0 CPCG0409 4858 T C 0 0.6 0 0.4 T 0 0 0 1 7397 2673 ND2 0.6 0 CPCG0071 4887 T T 0 0.49 0 0.5 T 0 0 0 1 6739 2006 ND2 0.5 0 CPCG0339 4905 T C 0 0.67 0 0.33 T 0 0 0 1 7113 1937 ND2 0.67 0 CPCG0046 4920 G G 0.25 0 0.72 0.03 G 0 0 1 0 288 1559 ND2 0.28 0 ICGC_PCA142 4958 A A 0.96 0 0.04 0 A 0.74 0 0.26 0 7261 4736 ND2 0.22 0.0118 CPCG0201 5115 T C 0 0.9 0 0.1 T 0 0 0 1 7055 3046 ND2 0.9 0 CPCG0020 5195 C C 0.05 0.95 0 0 C 0.44 0.56 0 0 7404 1841 ND2 0.39 0.00086 CPCG0267 5227 G G 0.28 0 0.72 0 G 0 0 1 0 6248 1665 ND2 0.28 0 ICGC_PCA185 5301 A A 0.66 0 0.34 0 G 0.41 0 0.59 0 7102 4152 ND2 0.24 0.0256 CPCG0242 5511 T C 0 0.82 0 0.17 T 0 0 0 1 7001 2241 ND2 0.83 0 ICGC_PCA013 5521 G A 0.53 0 0.47 0 G 0 0 1 0 7020 3818 TW 0.53 0 ICGC_PCA140 5774 T C 0 0.61 0 0.39 T 0 0 0 1 6911 4936 OLR/TC 0.61 0.0118 EOPC-07 5814 T C 0 0.86 0 0.14 T 0 0 0 1 4007 1500 TC 0.86 0.0097 CPCG0350 5910 G A 0.67 0 0.33 0 G 0 0 1 0 6052 1047 CO1 0.67 0.0058 TCGA-G9-6336 5979 G G 0.48 0 0.52 0 G 0 0 1 0 6381 1569 CO1 0.48 0.00634 CPCG0356 6020 C C 0 0.91 0 0.09 T 0 0.42 0 0.57 7024 4267 CO1 0.48 0.00462 ICGC_PCA048 6046 T T 0 0.28 0 0.72 T 0 0 0 1 5163 4643 CO1 0.28 0 CPCG0050 6054 G G 0.21 0 0.79 0 A 0.87 0 0.13 0 5512 1528 CO1 0.66 0.00066 CPCG0189 6270 G G 0.24 0 0.76 0 G 0 0 1 0 7176 1576 CO1 0.24 0 CPCG0251 6276 G A 0.87 0 0.13 0 G 0.45 0 0.55 0 7014 1437 CO1 0.42 0 TCGA-G9-6336 6321 G A 0.5 0 0.5 0 G 0 0 1 0 7462 1839 CO1 0.5 0 CPCG0123 6419 A A 1 0 0 0 A 0.8 0.18 0.01 0.01 6441 1175 CO1 0.2 0 CPCG0211 6419 A A 1 0 0 0 A 0.77 0.21 0.01 0 6273 552 CO1 0.23 0 CPCG0102 6496 C T 0 0.42 0 0.58 C 0 1 0 0 6397 3188 CO1 0.58 0 CPCG0124 6664 T C 0 0.8 0 0.2 T 0 0.44 0 0.56 7058 1440 CO1 0.36 0 ICGC_PCA060 6718 G A 0.53 0 0.47 0 G 0 0 1 0 7205 7567 CO1 0.53 0 CPCG0096 6742 T C 0 0.66 0 0.34 T 0 0 0 1 6034 2223 CO1 0.66 0 CPCG0331 6856 T C 0 0.6 0 0.4 T 0 0 0 1 7235 1771 CO1 0.6 0 CPCG0090 6892 G A 0.51 0 0.49 0 G 0 0 1 0 6649 1932 CO1 0.51 0 CPCG0189 6944 T T 0 0.26 0 0.74 T 0 0 0 1 7555 1925 CO1 0.25 0.00103 ICGC_PCA155 7026 G G 0.4 0 0.6 0 G 0 0 1 0 6855 819 CO1 0.4 0 EOPC-010 7293 G G 0.25 0 0.75 0 G 0 0 1 0 7413 2975 CO1 0.25 0 ICGC_PCA029 7393 G G 0.24 0 0.76 0 G 0 0 1 0 3325 2640 CO1 0.24 0 EOPC-010 7554 G G 0.25 0 0.75 0 G 0 0 1 0 4490 1572 TD 0.25 0 CPCG0124 7772 A G 0.19 0 0.81 0 A 0.55 0 0.45 0 6491 1205 CO2 0.36 0.0011 ICCC_PCA156 7803 T T 0 0.37 0 0.63 T 0 0 0 1 7302 3926 CO2 0.37 0 CPCG0378 7919 G G 0.26 0 0.74 0 G 0 0 1 0 6772 5709 CO2 0.26 0 CPCG0266 7929 G G 0 0 0.98 0.02 G 0 0 0.75 0.25 7012 1479 CO2 0.23 0 ICGC_PCA123 7997 G A 0.59 0 0.41 0 G 0 0 1 0 7456 5877 CO2 0.58 0 ICGC_PCA023 8078 G G 0.24 0 0.76 0 G 0 0 1 0 6794 6873 CO2 0.24 0.00189 ICGC_PCA174 8348 A G 0.14 0 0.86 0 G 0.35 0 0.65 0 6855 3534 TK 0.21 0.00857 CPCG0345 8391 G G 0.32 0 0.68 0 G 0 0 1 0 7322 1822 ATP8 0.32 0 CPCG0103 8393 C T 0 0.2 0 0.8 C 0 0.99 0 0 6860 2618 ATP8 0.79 0.0246 CPCG0196 8433 T T 0 0.37 0 0.63 T 0 0 0 1 6447 2231 ATP8 0.37 0.00559 ICGC_PCA193 8547 T C 0 0.54 0 0.46 T 0 0 0 1 5751 3664 ATP8/ 0.54 0.00156 ATP6 CPCG0063 8643 C T 0 0.1 0 0.9 C 0 0.63 0 0.37 6261 2790 ATP6 0.53 0 ICGC_PCA029 8697 G G 0.32 0 0.68 0 G 0 0 1 0 5997 5168 ATP6 0.32 0.201 CPCG0082 8705 T C 0 0.97 0 0.03 T 0 0.49 0 0.51 7435 1975 ATP6 0.47 0.0283 CPCG0217 8843 T T 0 0 0 1 T 0 0.25 0 0.75 7444 2102 ATP6 0.25 0.0274 Berger3043 8999 T C 0 0.9 0 0.1 T 0 0 0 1 5909 1314 ATP6 0.9 0.00083 CPCG0380 9182 G A 0.62 0 0.38 0 G 0 0 1 0 7258 3467 ATP6 0.62 0.00511 ICGC_PCA026 9185 T T 0 0.21 0 0.79 T 0 0 0 1 5862 2491 ATP6 0.21 0.00053 ICGC_PCA166 9378 T T 0 0.41 0 0.59 T 0 0 0 1 6300 2166 CO3 0.41 0 CPCG0349 9380 G A 0.8 0 0.2 0 G 0.19 0 0.81 0 7132 3251 CO3 0.61 0.0812 CPCG0262 9504 G A 0.84 0 0.16 0 G 0 0 1 0 7125 1416 CO3 0.84 0 CPCG0234 9516 T T 0 0.34 0 0.66 T 0 0 0 1 4614 1440 CO3 0.34 0 CPCG0070 9628 G A 0.59 0 0.41 0 G 0 0 1 0 7552 3285 CO3 0.59 0 CPCG0089 9673 G G 0.12 0.09 0.79 0 G 0 0 1 0 1850 3343 CO3 0.21 0 CPCG0269 9786 G G 0.28 0 0.72 0 G 0 0 1 0 4745 1771 CO3 0.28 0 CPCG0356 9797 T T 0 0.22 0 0.78 C 0 0.59 0 0.41 7503 4975 CO3 0.37 0.00103 CPCG0072 9804 G G 0.27 0 0.73 0 A 0.8 0 0.2 0 7079 2208 CO3 0.53 0.0198 CPCG0249 9840 T C 0 0.78 0 0.22 T 0 0 0 1 7215 1259 CO3 0.78 0.00141 ICGC_PCA086 9891 T T 0 0.38 0 0.62 T 0 0 0 1 7088 2008 CO3 0.38 0.00197 ICGC_PCA095 9977 T T 0 0.4 0 0.6 T 0 0 0 1 5302 2570 CO3 0.4 0.00221 ICGC_PCA193 10014 G A 0.53 0 0.47 0 G 0 0 1 0 6772 4094 TG 0.53 0 CPCG0128 10029 A A 0.94 0 0.06 0 A 0.66 0 0.34 0 7724 1809 TG 0.27 0.002 ICGC_PCA036 10182 G A 0.76 0 0.24 0 G 0 0 1 0 6512 3122 ND3 0.76 0 CPCG0114 10277 A A 0.97 0.03 0 0 A 0.69 0.3 0 0 2378 238 ND3 0.28 0 CPCG0166 10277 A A 0.76 0.24 0 0 A 0.99 0.01 0 0 153 980 ND3 0.22 0 CPCG0211 10277 A A 0.99 0.01 0 0 A 0.78 0.2 0 0.01 6462 499 ND3 0.22 0 EOPC-07 10558 T T 0 0.4 0 0.6 T 0 0 0 1 5874 1890 ND4L 0.4 0 CPCG0407 10586 G A 0.77 0 0.23 0 G 0 0 1 0 6878 3234 ND4L 0.77 0.0365 CPCG0256 10790 T T 0 0.4 0 0.6 T 0 0 0 1 7519 2396 ND4 0.4 0.00812 CPCG0331 10800 T T 0 0 0.26 0.74 T 0 0 0 1 7132 2482 ND4 0.26 0 CPCG0340 10866 T T 0 0 0 1 C 0 0.5 0 0.5 7598 3995 ND4 0.5 0 CPCG0324 11150 G A 0.24 0 0.76 0 G 0 0 1 0 7196 1616 ND4 0.24 0.0111 CPCG0040 11343 T C 0 0.77 0 0.23 T 0 0 0 1 7313 2729 ND4 0.77 0 Berger0508 11493 G G 0.33 0 0.67 0 G 0 0 1 0 4134 2002 ND4 0.33 0 Berger0508 11592 G A 0.9 0 0.1 0 G 0 0 1 0 6491 2191 ND4 0.89 0.00028 CPCG0046 11651 G A 0.85 0 0.15 0 G 0.16 0 0.84 0 6313 1618 ND4 0.69 0 CPCG0377 11711 G C 0 0.72 0.28 0 G 0 0 1 0 6420 4942 ND4 0.72 0.00031 ICGC_PCA041 11711 G G 0.48 0 0.52 0 G 0 0 1 0 2870 4121 ND4 0.48 0.00031 ICGC_PCA032 11788 C T 0 0 1 1 C 0 1 0 0 3705 3293 ND4 1 0.00765 CPCG0410 11814 T C 0 0.54 0 0.46 T 0 0 0 1 7377 4888 ND4 0.54 0 CPCG0103 11852 G G 0.22 0 0.78 0 G 0 0 1 0 4684 2047 ND4 0.21 0.00133 CPCG0374 11878 T C 0 0.57 0 0.43 T 0 0 0 1 7671 5544 ND4 0.57 0.00517 ICGC_PCA081 11940 T C 0 0.54 0 0.46 T 0 0 0 1 4677 2560 ND4 0.54 0.00031 CPCG0095 11949 G G 0.27 0 0.73 0 G 0 0 1 0 7450 2951 ND4 0.27 0 CPCG0076 12028 T T 0 0.29 0 0.71 C 0 0.7 0 0.3 4736 1587 ND4 0.4 0.00362 Berger0508 12173 T C 0 0.86 0 0.14 T 0 0 0 1 6497 2589 TH 0.86 0.00019 CPCG0114 12276 G G 0 0 1 0 A 0.57 0 0.43 0 3186 5946 TL2 0.57 0 ICGC_PCA161 12291 T T 0 0.45 0 0.55 T 0 0.03 0 0.97 4292 1590 TL2 0.43 0 CPCG0201 12312 T C 0 0.68 0 0.32 T 0 0 0 1 7591 2761 TL2 0.68 0.00029 CPCG0361 12501 G G 0.26 0 0.74 0 G 0 0 1 0 7551 4234 ND5 0.26 0.1 BacaSTID 12634 A A 0.84 0 0.16 0 G 0.01 0 0.99 0 183 1474 ND5 0.83 0.015 0000002872 ICGC_PCA065 12648 A C 0.3 0.7 0 0 A 0.65 0.35 0 0 7408 1300 ND5 0.35 0.00279 CPCG0242 12651 G G 0.21 0 0.79 0 G 0 0 1 0 7601 2456 ND5 0.21 0.0141 CPCG0030 12698 T T 0 0.24 0 0.76 T 0 0 0 1 7622 1873 ND5 0.24 0 CPCG0352 12700 C A 0.55 0.45 0 0 C 0 1 0 0 7357 4405 ND5 0.55 0 CPCG0336 12758 T C 0 0.54 0 0.46 T 0 0 0 1 7419 2631 ND5 0.54 0 CPCG0030 12758 T T 0 0.24 0 0.76 T 0 0 0 1 7629 1932 ND5 0.24 0 CPCG0236 12763 G A 0.75 0 0.25 0 G 0 0 1 0 6877 2433 ND5 0.75 0 Baca09-37 12769 G A 0.76 0 0.24 0 G 0.01 0 0.99 0 6642 6007 ND5 0.75 0 IGGC_PCA168 12818 G G 0.28 0 0.72 0 G 0 0 1 0 6759 4656 ND5 0.28 0 Berger3043 12980 G G 0.46 0 0.54 0 G 0 0 1 0 5006 990 ND5 0.46 0 CPCG0232 13121 G A 0.58 0 0.42 0 G 0 0 1 0 6628 1541 ND5 0.58 0 CPCG0234 13143 T C 0 0.61 0 0.39 T 0 0 0 1 295 1454 ND5 0.61 0.00461 Baca06-1749 13227 C C 0 0.59 0 0.41 C 0 1 0 0 7251 3030 ND5 0.41 0.00031 ICGC_PCA036 13289 G A 0.76 0 0.24 0 G 0 0 1 0 6801 4156 ND5 0.76 0 CPCG0379 13368 G A 0.86 0 0.14 0 A 0.5 0 0.5 0 7201 3751 ND5 0.35 0.211 ICGC_PCA180 13463 G A 0.77 0 0.23 0 G 0 0 1 0 6979 2001 ND5 0.77 0 Baca05-3595 13466 G A 0.55 0 0.44 0 G 0 0 1 0 6961 2522 ND5 0.56 0.00236 CPCG0213 13484 T C 0 0.54 0 0.46 T 0 0 0 1 7171 2098 ND5 0.54 0 CPCG0166 13507 T T 0 0.22 0 0.78 T 0 0 0 1 7083 1554 ND5 0.22 0 CPCG0166 13543 T T 0 0.2 0 0.79 T 0 0 0 1 398 1424 ND5 0.21 0.0003 CPCG0046 13568 T T 0 0 0 1 T 0 0.35 0 0.65 6727 1402 ND5 0.35 0 ICGC_PCA075 13759 G A 0.75 0 0.25 0 G 0.5 0 0.5 0 3756 3035 ND5 0.25 0.114 ICGC_PCA170 13888 T T 0 0.23 0 0.77 T 0 0 0 1 7154 2599 ND5 0.23 0 CPCG0190 13895 T T 0 0.46 0 0.54 T 0 0 0 1 7560 2513 ND5 0.46 0.00027 CPCG0217 13913 T T 0 0.3 0 0.7 T 0 0 0 1 7275 1953 ND5 0.3 0 CPCG0410 13918 T C 0 0.79 0 0.21 T 0 0.03 0 0.97 7279 4769 ND5 0.76 0 Baca05-1657 13928 G A 0.62 0 0.38 0 G 0 0 1 0 6778 3786 ND5 0.62 0.186 CPCG0237 14002 A A 1 0 0 0 A 0.78 0 0.22 0 7437 1036 ND5 0.22 0.0164 Berger3043 14151 T C 0 0.88 0 0.12 T 0 0 0 1 6560 1893 ND6 0.41 0 CPCG0372 14172 T T 0 0.41 0 0.59 T 0 0 0 1 7566 3645 ND6 0.41 0 EOPC-07 14560 G G 0.1 0 0.9 0 A 0.7 0 0.3 0 4980 1721 ND6 0.6 0.0729 CPCG0249 14638 T C 0 0.76 0 0.24 T 0 0 0 1 7357 1129 ND6 0.76 0 Baca07-4941 14831 G G 0.29 0 0.71 0 G 0 0 1 0 3170 1959 CYB 0.29 0.0136 CPCG0340 14846 G A 0.88 0 0.12 0 G 0 0 1 0 7024 3083 CYB 0.88 0 CPCG0387 14889 G G 0.32 0 0.68 0 G 0 0 1 0 7477 5472 CYB 0.32 0 CPCG0346 14985 G G 0.25 0 0.75 0 G 0 0 1 0 4764 2409 CYB 0.25 0 CPCG0078 15039 T C 0 0.61 0 0.39 T 0 0 0 1 7038 1289 CYB 0.61 0.00033 CPCG0355 15045 G G 0.25 0 0.75 0 G 0 0 1 0 6335 1368 CYB 0.24 0.00031 CPCG0412 15045 G G 0.31 0 0.69 0 G 0 0 1 0 4519 2562 CYB 0.31 0.00031 Baca08-4154 15229 T T 0 0.07 0 0.93 C 0 0.71 0 0.28 221 5590 CYB 0.64 0.0067 ICGC_PCA198 15323 G A 0.66 0 0.34 0 G 0.01 0 0.99 0 7015 2528 CYB 0.65 0.0185 CPCG0067 15375 G G 0.24 0 0.76 0 G 0 0 1 0 4219 1679 CYB 0.24 0 Berger3027 15446 C T 0 0.13 0 0.87 C 0 0.52 0 0.48 4499 1352 CYB 0.39 0 Baca03-1426 15498 G G 0.25 0 0.75 0 G 0 0 1 0 6803 4209 CYB 0.25 0.00271 CPCG0057 15661 C T 0 0.27 0 0.73 C 0 1 0 0 7107 2735 CYB 0.73 0.003 CPCG0412 15708 G G 0.37 0 0.63 0 G 0 0 1 0 7517 2739 CYB 0.37 0 CPCG0269 15731 G A 0.62 0 0.38 0 G 0 0 1 0 7524 1818 CYB 0.62 0.00907 CPCG0213 15762 G G 0.28 0 0.72 0 G 0 0 1 0 7336 2332 CYB 0.28 0 CPCG0269 15817 A G 0.27 0 0.73 0 A 0.83 0 0.17 0 7399 1904 CYB 0.56 0.0137 CPCG0356 15884 G A 0.7 0 0.3 0 G 0.16 0 0.84 0 7391 5417 CYB 0.54 0.126 CPCG0098 15924 A A 0.97 0 0.03 0 A 0.76 0 0.24 0 7718 3054 TT 0.22 0.137 CPCG0233 15986 G A 0.81 0 0.19 0 G 0 0 1 0 7280 2657 TP 0.81 0 ICGC_PCA180 16000 G G 0.07 0 0.93 0 G 0.34 0 0.66 0 7261 2185 TP 0.28 0.00565 ICGC_PCA091 16008 T T 0 0.28 0 0.72 T 0 0 0 1 5566 6514 TP 0.28 0 ICGC_PCA193 16012 A G 0.39 0 0.61 0 A 1 0 0 0 5964 4106 TP 0.61 0 CPCG0404 16027 T C 0 0.84 0 0.15 T 0 0 0 1 6955 5096 CR 0.85 0 CPCG0001 16035 G G 0.23 0 0.77 0 G 0 0 1 0 5872 1725 CR 0.23 0 ICGC_PCA098 16035 G G 0.22 0 0.78 0 G 0 0 1 0 5399 4407 CR 0.22 0 CPCG0269 16048 G G 0.16 0 0.84 0 G 0.41 0 0.58 0 7225 1653 CR 0.25 0.0148 CPCG0250 16051 A G 0.44 0 0.56 0 A 0.77 0 0.23 0 6934 2719 CR 0.33 0.112 CPCG0040 16086 T C 0 0.69 0 0.3 C 0 1 0 0 7485 1734 CR 0.3 0.0679 CPCG0128 16092 T T 0 0.17 0 0.83 C 0 0.96 0 0.04 7595 1451 CR 0.79 0.0481 CPCG0189 16093 T C 0 0.72 0 0.28 C 0 0.96 0 0.04 7272 1972 CR 0.24 0.275 CPCG0368 16093 T C 0 0.72 0 0.28 C 0 0.99 0 0.01 7180 3200 CR 0.26 0.275 CPCG0097 16093 T T 0 0.03 0 0.97 T 0 0.45 0 0.55 6981 2403 CR 0.42 0.275 TCGA-CH-5788 16093 T T 0 0.16 0 0.84 C 0 0.93 0 0.07 7767 4952 CR 0.77 0.275 TCGA-EJ-5506 16093 T C 0 0.69 0 0.31 C 0 0.96 0 0.04 7178 4245 CR 0.27 0.275 TCGA-HC-7075 16093 T T 0 0.03 0 0.97 C 0 0.94 0 0.06 7451 2210 CR 0.91 0.275 ICGC_PCA097 16093 T C 0 0.56 0 0.44 C 0 0.94 0 0.06 7434 3754 CR 0.38 0.275 ICGC_PCA170 16093 T T 0 0.12 0 0.88 C 0 0.9 0 0.1 7134 2704 CR 0.79 0.275 ICGC_PCA184 16093 T T 0 0.2 0 0.8 C 0 0.98 0 0.02 7025 4272 CR 0.79 0.275 CPCG0183 16147 C C 0 0.77 0 0.23 C 0 0.99 0 0 6878 1782 CR 0.22 0.0331 EOPC-04 16148 C T 0 0.29 0 0.71 C 0 1 0 0 6318 6134 CR 0.71 0.0575 CPCG0046 16153 G A 0.84 0 0.16 0 G 0 0 1 0 5392 1447 CR 0.83 0.0425 CPCG0355 16162 A G 0.02 0 0.98 0 G 0.28 0 0.72 0 7034 2115 CR 0.26 0.0712 ICGC_PCA032 16169 C C 0 1 0 0 G 0 0 0.99 0 4047 3363 CR 0.99 0.0386 Baca05-3595 16182 A C 0.08 0.82 0.1 0 C 0.24 0.44 0.32 0 1937 421 CR 0.37 0.444 CPCG0256 16183 A A 0.59 0.41 0 0 A 0.95 0.05 0 0 4286 982 CR 0.36 0.831 CPCG0352 16184 C T 0 0.34 0 0.66 C 0 1 0 0 6912 3003 CR 0.66 0.0332 CPCG0084 16188 C C 0 0.77 0 0.23 C 0 1 0 0 6562 1739 CR 0.23 0.0562 CPCG0114 16189 C T 0 0.03 0 0.97 C 0 0.75 0 0.25 2572 6657 CR 0.72 0.756 CPCG0259 16192 C C 0 0.78 0 0.22 C 0 1 0 0 7485 2143 CR 0.22 0.185 CPCG0198 16192 C T 0 0.34 0 0.66 T 0 0.11 0 0.89 7328 3030 CR 0.23 0.185 ICGC_PCA197 16192 C T 0 0.42 0 0.58 T 0 0.1 0 0.9 6039 2439 CR 0.32 0.185 ICGC_PCA065 16213 G G 0.27 0 0.73 0 A 0.6 0 0.4 0 7620 1314 CR 0.33 0.0359 EOPC-05 16278 T T 0 0.5 0 0.5 C 0 1 0 0 4040 1831 CR 0.5 0.34 ICGC_PCA169 16304 T T 0 0.34 0 0.66 C 0 1 0 0 7178 3126 CR 0.66 0.264 ICGC_PCA098 16342 T C 0 0.85 0 0.15 C 0 0.57 0 0.43 4197 3207 CR 0.28 0.0315 ICGC_PCA183 16390 G A 0.86 0 0.14 0 G 0.23 0 0.76 0 3737 1891 CR 0.62 0.211 ICGC_PCA184 16465 C C 0 0.89 0 0.11 C 0 0.55 0 0.45 4483 2172 CR 0.34 0.0153 Tumour Tumour Tumour Tumour Tumour (Difference chan- MutPred.path- PolyPhen.2.HumDiv.Pro A HF C HF G HF T HF in HF adjusted ge.in.AA ogenicity.sco PolyPhen.2.HumDiv.Pred adju adju adjusted adju by cellularity NA 0 0.247191011 0 0.752808989 T 0.247191011 NA 0 1 0 0 C 1 NA 0 0 0 1 T 1 NA 0 1 0 0 C 1 NA NA 0 0.89 0 0.11 C 0.89 NA 0 0 1 0 G 0.99 NA 0 0.897435897 0 0.102564103 C 0.897435897 NA 0 0.612941176 0 0.387058824 C 0.602941176 NA NA 0 0.69 0 0.31 C 0.49 NA NA 0 0.18 0 0.82 T 0.65 NA 0 1 0 0 C 0.82 NA 0 0.27 0 0.73 T 0.27 NA NA 0 0.99 0 0.01 C 0.99 NA 0.420454545 0 0.579545455 0 G 0.579545455 NA 0 0.346666667 0 0.653333333 T 0.346666667 NA 0 0.415730337 0 0.584269663 T 0.415730337 NA NA 0 0.56 0 0.43 C 0.46 NA NA 0 0.86 0 0.14 G 0.71 NA NA 0.2 0 0.8 0 G 0.51 NA 0.025641026 0 0.974358974 0 G 0.974358974 NA 1 0 0 0 A 0.84 NA 0 0 1 0 G 1 NA NA 0.16 0 0.84 0 G 0.77 NA 1 0 0 0 A 0.26 NA 1 0.05 0 0 A 1 NA 0 0.419354839 0 0.580645161 T 0.580645161 NA 0 0.073170732 0 0.926829268 T 0.926829268 NA 0 0.22 0 0.77 T 0.77 NA 0.75 0 0.214285714 0 A 0.785714286 NA 0.303370787 0.02247191 0.674157303 0 G 0.325842697 NA 1 0 0 0 A 1 NA NA 0.83 0.17 0 0 A 0.21 NA 0.49 0 0.51 0 G 0.49 NA 0 0.694444444 0 0.305555556 C 0.694444444 NA 0 0.375 0 0.625 T 0.375 NA 0.933333333 0 0.066666667 0 A 0.933333333 NA NA 0.61 0 0.39 0 A 0.32 NA 0.506666667 0 0.493333333 0 A 0.506666667 NA 1 0 0 0 A 1 NA 0.646153846 0 0.353846154 0 A 0.646153846 NA 1 0 0 0 A 1 NA 0.36 0 0.64 0 G 0.36 NA 0.75 0 0.25 0 A 0.75 NA 0.490566038 0 0.518301887 0 G 0.471698113 NA NA 0 0.53 0 0.47 C 0.53 NA 0 0.1 0 0.9 T 0.22 NA 0.875 0 0.125 0 A 0.875 NA NA 0.32 0 0.68 0 G 0.32 NA NA 0 0 0 1 T 1 NA 0 0.779661017 0 0.220338983 C 0.779661017 NA 0.80952381 0 0.19047619 0 A 0.80952381 NA 1 0 0 0 A 1 NA 0.320512821 0 0.666666667 0 G 0.333333333 NA NA 0 0.46 0 0.54 T 0.46 NA NA 0 0 0 1 T 1 NA NA 0 0.73 0 0.27 C 0.73 NA NA 0.44 0 0.56 0 G 0.44 NA 1 0 0 0 A 1 NA 0 0.987179487 0 0.012820513 C 0.987179487 NA 0.048823529 0 0.955882353 0 G 0.941176471 NA 0 0 0 1 T 0.25 NA NA 0.6 0 0.4 0 A 0.6 NA 0.91 0 0.09 0 A 0.88 NA 0.486486486 0 0.513513514 0 G 0.486486486 NA 1 0 0 0 A 0.23 NA 1 0 0 0 A 1 NA NA 0.26 0 0.74 0 G 0.26 NA 0 0.313253012 0 0.686746988 T 0.313253012 NA 0 1 0 0 C 1 NA 0.615384615 0 0.384615385 0 A 0.615384615 NA NA 0 0.72 0 0.28 C 0.72 NA 0.47 0 0.53 0 G 0.47 NA NA 0.5 0 0.5 0 G 0.5 NA 0 0 0 1 T 0.24 NA NA 0.69 0 0.31 0 A 0.47 NA NA 0.32 0 0.68 0 G 0.32 NA NA 0.44 0 0.56 0 G 0.44 NA 1 0 0 0 A 1 NA 0.925925926 0 0.074074074 0 A 0.925925926 NA NA 0.69 0 0.31 0 A 0.69 NA 1 0 0 0 A 1 NA 0 1 0 0 C 1 NA 0 0.270588235 0 0.729411765 T 0.270588235 K62N 0.563 0.38 benign 0.711176471 0.277058824 0 0.011764706 A 0.258823529 A64T 0.354 0 benign 0.526315789 0 0.460526316 0 A 0.539473684 A747 0.618 0.879 possibly damaging 0.23 0 0.77 0 G 0.23 G131S 0.854 1 probably damaging 0.443037975 0 0.556962025 0 G 0.443037975 Premature NA 0.916666667 0 0.041666667 0 A 0.958333333 Stop Codon Premature NA NA 0.45 0 0.55 0 G 0.45 Stop Codon Premature NA NA 0.21 0 0.79 0 G 0.21 Stop Codon E214K 0.778 0.999 probably damaging 0.239130435 0 0.760869565 0 G 0.239130435 E214K 0.778 0.999 probably damaging 0.634920635 0 0.365079365 0 A 0.634920635 G218D 0.775 1 probably damaging 0.36 0 0.63 0 G 0.37 A226T 0.616 0.995 probably damaging 0.956521739 0 0.043478261 0 A 0.956521739 syn NA 0.34 0 0.65 0 G 0.62 R279Q 0.879 0.974 probably damaging 1 0 0 0 A 1 R279Q 0.879 0.974 probably damaging 0.21 0 0.79 0 G 0.2 A299T 0.632 0.04 benign 0.315789474 0 0.684210526 0 G 0.315789474 I309V 0.427 0 benign 0.58 0 0.42 0 A 0.42 syn NA NA 0 0.53 0 0.47 C 0.53 NA 0.63 0 0.36 0 A 0.64 NA 0 0.102040816 0 0.897959184 T 0.897959184 A5T 0.194 1 probably damaging 0.333333333 0 0.666666667 0 G 0.333333333 V8I 0.439 0 benign 0.46 0 0.54 0 G 0.46 V43I 0.366 0.006 benign 0.772727273 0 0.227272727 0 A 0.772727273 F60S 0.796 1 probably damaging 0 0.580645161 0 0.403225806 C 0.596774194 A101T 0.717 1 probably damaging 0.974025974 0 0.025974026 0 A 0.974025974 G121D 0.809 1 probably damaging 0.61 0 0.39 0 A 0.61 L130P 0.737 0.999 probably damaging 0 1 0 0 C 1 S140P 0.875 0.997 probably damaging 0 0.576470588 0 0.411764706 C 0.588235294 S146P 0.635 0.925 possibly damaging 0 1 0 0 C 1 V151M 0.499 0.072 benign 0.280898876 0 0.685393258 0.033707865 G 0.314606742 syn NA NA 0.96 0 0.04 0 A 0.22 F216L 0.676 0.221 benign 0 1 0 0 C 1 syn NA 0.001797753 0.998202247 0 0 C 0.438202247 G253D 0.851 1 probably damaging 0.933333333 0 0.066666667 0 A 0.933333333 I278V 0.311 0.005 benign 0.66 0 0.34 0 A 0.25 Stop NA 0 1 0 0 C 1 Codon->Q NA NA 0.53 0 0.47 0 A 0.53 NA NA 0 0.61 0 0.39 C 0.61 NA 0 0.86 0 0.14 C 0.86 A3T 0.239 0.012 benign 0.848101266 0 0.151898734 0 A 0.848101266 A26T 0.769 0.998 probably damaging 0.48 0 0.52 0 G 0.48 syn NA 0 1 0 0 C 0.57 L48P 0.785 0.973 probably damaging 0 0.28 0 0.72 T 0.28 D51N 0.715 0.998 probably damaging 0.152608696 0 0.847391304 0 G 0.717391304 Premature NA 0.333333333 0 0.666666667 0 G 0.333333333 Stop Codon G125S 0.926 1 probably damaging 1 0 0 0 A 0.55 Premature NA 0.5 0 0.5 0 G 0.5 Stop Codon K172N 0.701 1 probably damaging 1 0 0 0 A 0.2 K172N 0.701 1 probably damaging 1 0 0 0 A 0.23 S198F 0.672 1 probably damaging 0 0.42 0 0.58 T 0.58 I254T 0.708 0.673 possibly damaging 0 0.89 0 0.11 C 0.45 G272D 0.771 1 probably damaging 0.53 0 0.47 0 A 0.53 I280T 0.69 0.997 probably damaging 0 0.76744186 0 0.23255814 C 0.76744186 V318A 0.541 0.998 probably damaging 0 1 0 0 C 1 S330N 0.519 0.001 benign 0.6375 0 0.3625 0 A 0.6375 syn NA 0 0.361111111 0 0.638888889 T 0.361111111 A375T 0.675 1 probably damaging 0.4 0 0.6 0 G 0.4 A464T 0.34 0.999 probably damaging 0.25 0 0.75 0 G 0.25 G497E 0.356 1 probably damaging 0.24 0 0.76 0 G 0.24 NA 0.25 0 0.75 0 G 0.25 T63A 0.523 0.017 benign 0.1 0 0.9 0 G 0.45 L73P 0.768 1 probably damaging 0 0.37 0 0.63 T 0.37 D112N 0.634 1 probably damaging 0.412698413 0 0.587301587 0 G 0.412698413 G115V 0.544 0.989 probably damaging 0 0 1 0 C 0.25 V138I 0.609 0.798 possibly damaging 0.59 0 0.41 0 A 0.59 V165I 0.616 0 benign 0.24 0 0.76 0 G 0.24 NA NA 0.14 0 0.86 0 G 0.21 Premature NA 0.41025641 0 0.58974359 0 G 0.41025641 Stop Codon P10S 0.569 0.993 probably damaging 0 0.2 0 0.8 T 0.79 I23T 0.735 0.005 benign 0 0.415730337 0 0.584269663 T 0.415730337 L61P 0.304 0.988 probably damaging 0 0.54 0 0.46 C 0.54 syn NA 0 0 0 1 T 0.63 syn NA NA 0.32 0 0.68 0 G 0.32 M60T 0.202 0 benign 0 1 0 0 C 0.51 I106T 0.642 0.617 possibly damaging 0 0 0 1 T 0.25 V158A 0.704 0 benign 0 0.9 0 0.1 C 0.9 S219N 0.6 0.995 probably damaging 1 0 0 0 A 1 L220P 0.751 0.999 probably damaging 0 0.21 0 0.79 T 0.21 W58R 0.85 0.998 probably damaging 0 0.41 0 0.59 T 0.41 syn NA 1 0 0 0 A 0.81 A100T 0.674 0.999 probably damaging 1 0 0 0 A 1 S104P 0.732 0.997 probably damaging 0 0.365591398 0 0.634408602 T 0.365591398 G141E 0.872 1 probably damaging 0.694117647 0 0.305882353 0 A 0.694117647 R156Q/ 0.69/ 0.999/1.0 probably damaging/ 0.144578313 0.108433735 0.746987952 0 G 0.253012048 R156P 0.731 probably damaging G194S 0.893 1 probably damaging 0.373333333 0 0.626666667 0 G 0.373333333 syn NA 0 0 0 1 T 0.59 A200T 0.708 0.006 benign 0.120512821 0 0.879487179 0 G 0.679487179 S212P 0.636 0.997 probably damaging 0 1 0 0 C 1 S229P 0.606 0.003 benign 0 0.38 0 0.62 T 0.38 syn NA NA 0 0.4 0 0.6 T 0.4 NA NA 0.53 0 0.47 0 A 0.53 NA 0.964347826 0 0.035652174 0 A 0.304347826 D42N 0.742 0.999 probably damaging 0.76 0 0.24 0 A 0.76 L73F 0.543 1 probably damaging 1 0 0 0 A 0.31 L73F 0.543 1 probably damaging 0 1 0 0 C 0.99 L73F 0.543 1 probably damaging 1 0 0 0 A 0.22 L30P 0.874 1 probably damaging 0 0.4 0 0.6 T 0.4 syn NA NA NA 1 0 3.60462E−17 0 A 1 syn NA 1 1 0 0 C 1 L14R 0.752 0.999 probably damaging 0 0 1 0 G 1 I361 0.558 0.015 benign 0 0 0 1 T 0.5 A131T 0.65 0.035 benign 0.774193548 0 0.225806452 0 A 0.774193548 M195T 0.684 0.949 possibly damaging 0 0.927710843 0 0.072289157 C 0.927710843 R245H 0.822 0.999 probably damaging 0.33 0 0.67 0 G 0.33 R278Q 0.885 0.995 probably damaging 0.9 0 0.1 0 A 0.9 V298M 0.605 0.85 possibly damaging 0.935280899 0 0.064719101 0 A 0.775280899 A318P 0.765 1 probably damaging 0 1 0 0 C 1 A318T 0.602 0.999 probably damaging 0.48 0 0.52 0 C 0.48 syn NA NA 0 0 0 1 T 1 L352P 0.783 0.987 probably damaging 0 1 0 0 C 1 A365T 0.57 0.004 benign 0.22 0 0.78 0 G 0.22 syn NA 0 1 0 0 C 1 L394P 0.669 0.403 benign 0 0.54 0 0.46 C 0.54 G397E 0.87 1 probably damaging 0.3 0 0.7 0 G 0.3 syn NA 0 0.217647059 0 0.782352941 T 0.482352941 NA 0 0.86 0 0.14 C 0.86 NA NA NA NA 0 0 1 0 G 0.57 NA NA 0 0.45 0 0.55 T 0.42 NA 0 0.829268293 0 0.170731707 C 0.829268293 syn NA 0.838709677 0 0.161290323 0 A 0.838709677 I100V 0.381 0.925 possibly damaging 0.84 0 0.16 0 A 0.83 syn NA NA 0.3 0.7 0 0 C 0.35 syn NA 0.304347826 0 0.695652174 0 G 0.304347826 L121P 0.719 1 probably damaging 0 0.272727273 0 0.727272727 T 0.272727273 L122I 0.6 0.996 probably damaging 0.873015873 0.126984127 0 0 A 0.873015873 F141S 0.671 0.997 probably damaging 0 1 0 0 C 1 F141S 0.671 0.997 probably damaging 0 0.272727273 0 0.727272727 T 0.272727273 G143S 0.637 1 probably damaging 1 0 0 0 A 1 E145K 0.813 0.996 probably damaging 0.76 0 0.24 0 A 0.75 R161Q 0.801 0.997 probably damaging 0.28 0 0.72 0 G 0.28 G215D 0.769 1 probably damaging 0.46 0 0.54 0 G 0.46 R262H 0.77 0.999 probably damaging 0.734177215 0 0.265822785 0 A 0.734177215 syn NA 0 0.655913978 0 0.344086022 C 0.655913978 syn NA 0 0.59 0 0.41 C 0.41 G318D 0.781 1 probably damaging 0.76 0 0.24 0 A 0.76 syn NA 0.967532468 0 0.032467532 0 A 0.467532468 G376D 0.82 0.994 probably damaging 0.77 0 0.23 0 A 0.77 S377N 0.707 0.003 benign 0.55 0 0.44 0 A 0.56 M383T 0.631 0.452 benign 0 1 0 0 C 1 S391P 0.793 0.997 probably damaging 0 0.956521739 0 0.043478261 C 0.956521739 Y403H 0.651 0.008 benign 0 0.869565217 0 0.086956522 C 0.913043478 I411T 0.702 0.001 benign 0 0 0 1 T 0.35 A475P 0.472 0.101 benign 0.75 0 0.25 0 A 0.25 C518R 0.501 0.003 benign 0 0.23 0 0.77 T 0.23 F520S 0.673 0.997 probably damaging 0 1 0 0 C 1 L526P 0.836 1 probably damaging 0 1 0 0 C 1 F528L 0.72 0.996 probably damaging 0 1 0 0 C 0.97 S531N 0.298 0.002 benign 0.62 0 0.38 0 A 0.62 T556P 0.556 0.901 possibly damaging 1 0 0 0 A 0.22 Stop NA 0 0.88 0 0.12 C 0.88 Codon->G I168V 0.534 0.997 probably damaging 0 1 0 0 C 1 syn NA 0.1 0 0.9 0 G 0.6 syn NA 0 1 0 0 C 1 A29T 0.391 0 benign 0.29 0 0.71 0 G 0.29 G34S 0.846 1 probably damaging 1 0 0 0 A 1 G48E 0.825 1 probably damaging 0.653061224 0 0.346938776 0 A 0.653061224 R80H 0.833 1 probably damaging 0.961538462 0 0.038461538 0 A 0.961538462 I98T 0.669 0.997 probably damaging 0 1 0 0 C 1 R100Q 0.824 1 probably damaging 1 0 0 0 A 1 R100Q 0.824 1 probably damaging 0.492063492 0 0.507936508 0 G 0.492063492 syn NA 0 0.07 0 0.93 T 0.64 A193T 0.517 0.001 benign 0.66 0 0.34 0 A 0.65 G210E 0.68 1 probably damaging 0.24 0 0.76 0 G 0.24 L234F 0.217 1 probably damaging 0 0.13 0 0.87 T 0.39 G251D 0.502 0.972 probably damaging 0.25 0 0.75 0 G 0.25 syn NA 1 1 0 1 T 1 S321N 0.709 0.996 probably damaging 0.587301587 0 0.412698413 0 A 0.587301587 A329T 0.323 0 benign 0.826666667 0 0.173333333 0 A 0.826666667 G339E 0.87 1 probably damaging 1 0 0 0 A 1 syn NA 0.083333333 0 0.916666667 0 G 0.746666667 A380T 0.204 0 benign 1 0 0 0 A 0.84 NA 1 0 0 0 A 0.24 NA 1 0 0 0 A 1 NA NA 0.07 0 0.93 0 G 0.27 NA NA 0 0.28 0 0.72 T 0.28 NA NA 0.39 0 0.61 0 G 0.61 NA 0 1 0 0 C 1 NA 0.270588235 0 0.729411765 0 G 0.270588235 NA NA 0.22 0 0.78 0 G 0.22 NA 0.076666667 0 0.926666667 0 G 0.346666667 NA 0 0 1 0 G 0.77 NA 0 0.626506024 0 0.361445783 C 0.373493976 NA 0 0.101304348 0 0.898695652 T 0.858695652 NA 0 0.626666667 0 0.373333333 C 0.333333333 NA 0 0 0 1 T 0.99 NA 0 0 0 1 T 0.45 NA 0 0.16 0 0.84 T 0.77 NA 0 0.69 0 0.31 C 0.27 NA 0 0.03 0 0.97 T 0.91 NA NA 0 0.56 0 0.44 C 0.38 NA NA 0 0.12 0 0.88 T 0.78 NA NA 0 0.2 0 0.8 T 0.78 NA 0 0.675714286 0 0.328571429 C 0.314285714 NA 0 0.29 0 0.71 T 0.71 NA 0.943820225 0 0.056179775 0 A 0.943820225 NA 0 0 1 0 G 0.28 NA NA 0 1 0 0 C 0.99 NA 0.08 0.82 0.1 0 C 0.38 NA 0 1 0 0 C 0.95 NA 0 0 0 1 T 1 NA 0 0.735632184 0 0.264367816 C 0.264367816 NA 0 0 0 1 T 0.75 NA 0 0 0 1 T 1 NA 0 0.371363636 0 0.628636364 T 0.261363636 NA NA 0 0.42 0 0.58 T 0.32 NA NA 0.27 0 0.73 0 G 0.33 NA 0 0.5 0 0.5 T 0.5 NA NA 0 0.34 0 0.66 T 0.66 NA NA 0 0.85 0 0.15 C 0.28 NA NA 0.86 0 0.14 0 A 0.62 NA NA 0 0.89 0 0.11 C 0.34

TABLE 6 Mitochondrial mutation recurrence for 41 nuclear genomic features Control patient_id region tRNA CYB RNR1 RNR2 ND1 ND2 ND3 ND4 ND4L ND5 ND6 CO1 CO2 CO3 ATP6 ATP8 OHR CSB1 CPCG0001 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0003 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0006 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0020 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0040 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 CPCG0046 1 0 0 0 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0 CPCG0047 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0048 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0057 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0063 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 CPCG0073 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 CPCG0078 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0081 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 CPCG0083 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0087 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0094 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0095 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 CPCG0098 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 CPCG0099 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0102 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 CPCG0114 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 CPCG0117 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0121 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0123 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 CPCG0124 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 CPCG0127 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0128 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0154 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0158 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 CPCG0166 1 0 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 CPCG0182 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0183 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0184 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0185 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0189 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 CPCG0190 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0191 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0196 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 CPCG0199 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0201 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0205 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 CPCG0206 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 CPCG0208 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0210 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0211 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 CPCG0212 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0213 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0217 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 1 0 0 0 CPCG0232 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0233 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0234 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 CPCG0236 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0238 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0241 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0242 1 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 1 1 CPCG0246 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0248 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0249 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 CPCG0250 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0251 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 CPCG0255 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0256 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 CPCG0258 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0259 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0260 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0262 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 CPCG0263 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0265 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0266 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 CPCG0267 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0268 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0269 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 CPCG0324 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 CPCG0331 0 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 0 0 CPCG0334 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0336 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0339 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0340 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 CPCG0341 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0342 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0344 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0345 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 CPCG0346 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0348 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0350 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 CPCG0352 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0353 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0354 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0355 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0356 0 0 1 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 CPCG0357 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0358 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0360 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0361 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0362 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0363 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0364 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0365 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0366 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0368 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0369 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0371 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0372 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 CPCG0373 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0374 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 CPCG0375 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0378 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 CPCG0379 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0380 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 CPCG0381 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0387 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0388 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0391 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0392 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0401 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0404 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0407 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 CPCG0409 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0410 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 CPCG0411 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0412 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0413 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0414 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0004 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0005 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0007 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0008 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0015 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0019 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0022 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0027 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0030 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0036 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0042 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0050 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 CPCG0070 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 CPCG0071 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0075 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0076 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 CPCG0082 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 CPCG0084 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0089 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 CPCG0090 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 CPCG0096 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 CPCG0097 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0120 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0122 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0126 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0194 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0198 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0204 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 CPCG0237 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 CPCG0243 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0257 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0067 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0103 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 CPCG0072 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 CPCG0100 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 CPCG0187 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0188 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0235 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0349 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 CPCG0377 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 CPCG0382 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CPCG0408 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Berger0508 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 Berger0581 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Berger1701 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Berger1783 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Berger2832 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Berger3027 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Berger3043 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 0 0 EOPC-02 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 EOPC-03 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 EOPC-04 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 EOPC-05 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 EOPC-06 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 EOPC-07 0 0 0 1 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 EOPC-08 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 EOPC-09 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 EOPC-010 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 EOPC-011 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Baca03-1426 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Baca05-1657 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 Baca05-3595 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 Baca05-3852 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Baca06-1749 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 Baca06-3199 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Baca07-4610 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 Baca07-4941 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Baca07-5037 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Baca08-4154 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Baca08-716 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Baca09-37 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 BacaSTID 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000000410 BacaSTID 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0000002872 TCGA-CH- 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 5750 TCGA-CH- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5763 TCGA-CH- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5771 TCGA-CH- 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5788 TCGA-CH- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5789 TCGA-EJ- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5503 TCGA-EJ- 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 5506 TCGA-EJ- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7791 TCGA-G9- 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 6336 TCGA-G9- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6365 TCGA-G9- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6370 TCGA-G9- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7522 TCGA-HC- 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7075 TCGA-HC- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7079 TCGA-HC- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7233 TCGA-HC- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7737 TCGA-HC- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7740 TCGA-HC- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7744 TCGA-HC- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 8258 TCGA-HI- 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7169 PGA nuclear (median SNV count mitro_SNV dichot- chromo- (median patient_id HV1 HV2 Count ETS omized) kataegis_ind thripsis_ind dichotomized) CPCG0001 1 0 1 1 1 0 0 1 CPCG0003 0 0 1 0 1 0 0 1 CPCG0006 0 0 0 0 1 1 0 1 CPCG0020 0 0 1 0 0 0 0 1 CPCG0040 1 0 3 0 1 1 0 1 CPCG0046 1 0 5 0 0 0 0 0 CPCG0047 0 0 0 1 1 0 0 1 CPCG0048 0 0 0 1 0 0 0 0 CPCG0057 0 0 1 1 1 0 0 1 CPCG0063 0 0 2 0 1 0 0 1 CPCG0073 0 1 2 1 1 0 0 1 CPCG0078 0 1 2 0 1 0 0 1 CPCG0081 0 1 2 1 1 1 0 1 CPCG0083 0 0 1 1 1 0 0 1 CPCG0087 0 0 0 1 1 1 0 1 CPCG0094 0 0 0 1 1 1 0 1 CPCG0095 0 0 1 1 1 0 0 0 CPCG0098 0 1 4 0 1 1 1 1 CPCG0099 0 0 0 0 1 0 0 1 CPCG0102 0 0 1 0 0 0 0 0 CPCG0114 1 1 4 1 0 0 0 0 CPCG0117 0 0 1 0 1 0 1 0 CPCG0121 0 0 0 1 1 0 0 0 CPCG0123 0 0 1 1 0 0 0 1 CPCG0124 0 0 2 1 0 0 0 1 CPCG0127 0 0 1 0 0 0 0 0 CPCG0128 1 0 2 0 0 0 1 1 CPCG0154 0 0 0 1 0 0 0 0 CPCG0158 0 1 1 1 1 0 0 1 CPCG0166 0 1 5 0 0 0 0 0 CPCG0182 0 0 0 1 0 0 0 0 CPCG0183 1 0 2 0 1 0 0 1 CPCG0184 0 0 0 0 1 0 0 0 CPCG0185 0 0 1 1 1 0 0 1 CPCG0189 1 0 5 1 1 0 1 1 CPCG0190 0 0 1 0 1 0 0 0 CPCG0191 0 0 0 1 1 0 1 0 CPCG0196 0 1 2 1 1 0 0 0 CPCG0199 0 0 0 0 0 0 0 0 CPCG0201 0 0 2 1 1 1 1 1 CPCG0205 0 1 1 0 0 0 0 0 CPCG0206 0 1 1 0 1 0 0 0 CPCG0208 0 0 0 0 0 0 1 1 CPCG0210 0 0 0 0 1 0 0 0 CPCG0211 0 0 3 1 1 0 0 1 CPCG0212 0 0 1 0 1 0 0 1 CPCG0213 0 0 3 1 1 0 0 0 CPCG0217 0 0 3 0 0 0 1 0 CPCG0232 0 0 1 1 1 0 1 1 CPCG0233 0 0 2 0 1 1 1 1 CPCG0234 0 0 2 0 0 0 0 0 CPCG0236 0 0 1 0 1 1 1 1 CPCG0238 0 0 0 1 1 0 1 0 CPCG0241 0 0 0 1 1 0 0 1 CPCG0242 0 1 3 1 1 0 0 1 CPCG0246 0 0 0 0 0 0 0 0 CPCG0248 0 0 1 1 1 1 0 1 CPCG0249 0 0 2 0 1 1 1 1 CPCG0250 1 0 1 1 0 0 0 0 CPCG0251 0 0 1 0 0 1 0 0 CPCG0255 0 0 0 0 1 1 1 1 CPCG0256 1 1 3 1 0 1 0 0 CPCG0258 0 0 0 1 0 0 0 0 CPCG0259 1 0 1 0 0 0 0 1 CPCG0260 0 0 0 1 1 0 1 1 CPCG0262 0 0 2 1 1 1 0 1 CPCG0263 0 1 1 0 1 0 1 0 CPCG0265 0 0 1 1 0 1 0 1 CPCG0266 0 0 1 1 1 0 0 1 CPCG0267 0 0 1 0 0 0 0 0 CPCG0268 0 0 1 0 1 1 1 0 CPCG0269 1 0 4 0 0 0 0 1 CPCG0324 0 0 2 1 1 1 1 1 CPCG0331 0 0 3 1 1 0 0 1 CPCG0334 0 0 0 0 1 0 0 1 CPCG0336 0 0 1 1 0 1 0 0 CPCG0339 0 0 2 0 0 0 0 0 CPCG0340 0 0 2 1 1 1 1 1 CPCG0341 0 0 0 1 1 0 0 1 CPCG0342 0 0 1 1 0 0 0 1 CPCG0344 0 0 1 0 1 0 0 0 CPCG0345 0 0 1 0 1 0 0 1 CPCG0346 0 0 2 1 1 0 0 0 CPCG0348 0 0 0 0 0 0 0 0 CPCG0350 0 0 1 1 1 1 1 1 CPCG0352 1 0 2 1 1 0 0 0 CPCG0353 0 0 0 0 0 0 0 0 CPCG0354 0 0 0 1 0 1 0 1 CPCG0355 1 0 2 0 0 0 0 0 CPCG0356 0 0 3 1 1 1 0 0 CPCG0357 0 0 0 1 1 0 0 1 CPCG0358 0 0 1 1 1 0 0 0 CPCG0360 0 0 0 0 1 0 0 0 CPCG0361 0 0 1 1 0 0 0 0 CPCG0362 0 0 0 1 0 0 0 0 CPCG0363 0 0 0 0 0 0 0 0 CPCG0364 0 0 0 1 0 0 1 1 CPCG0365 0 0 0 0 0 0 0 0 CPCG0366 0 0 0 1 1 0 0 0 CPCG0368 1 0 1 0 0 0 0 0 CPCG0369 0 0 0 1 1 0 0 1 CPCG0371 0 0 0 1 1 1 0 1 CPCG0372 0 0 1 1 1 1 0 1 CPCG0373 0 0 0 0 0 0 0 0 CPCG0374 0 0 1 0 1 1 0 0 CPCG0375 0 0 0 0 1 0 0 1 CPCG0378 0 0 1 0 1 0 0 1 CPCG0379 0 0 1 1 1 0 1 1 CPCG0380 0 0 1 1 1 0 0 1 CPCG0381 0 0 0 0 0 0 0 0 CPCG0387 0 0 2 0 0 0 0 1 CPCG0388 0 0 1 0 1 0 0 1 CPCG0391 0 0 0 0 0 0 0 0 CPCG0392 0 0 0 1 1 0 1 1 CPCG0401 0 0 0 0 0 0 0 0 CPCG0404 1 0 1 0 1 1 0 1 CPCG0407 0 0 2 1 1 0 0 1 CPCG0409 0 0 1 1 0 0 0 1 CPCG0410 0 0 3 1 1 0 1 0 CPCG0411 0 0 0 0 0 0 0 0 CPCG0412 0 0 3 1 1 1 0 1 CPCG0413 0 0 0 0 0 0 0 0 CPCG0414 0 0 0 0 0 1 0 0 CPCG0004 0 0 0 NA NA NA NA NA CPCG0005 0 0 1 NA NA NA NA NA CPCG0007 0 0 0 NA NA NA NA NA CPCG0008 0 0 0 NA NA NA NA NA CPCG0015 0 0 0 NA NA NA NA NA CPCG0019 0 0 1 NA NA NA NA NA CPCG0022 0 0 0 0 0 0 0 0 CPCG0027 0 0 2 0 0 0 0 0 CPCG0030 0 0 2 NA NA NA NA NA CPCG0036 0 0 0 NA NA NA NA NA CPCG0042 0 0 0 NA NA NA NA NA CPCG0050 0 0 1 0 0 0 0 1 CPCG0070 0 1 2 NA NA NA NA NA CPCG0071 0 0 2 NA NA NA NA NA CPCG0075 0 0 0 NA NA NA NA NA CPCG0076 0 0 1 NA NA NA NA NA CPCG0082 0 0 1 NA NA NA NA NA CPCG0084 1 0 1 NA NA NA NA NA CPCG0089 0 0 1 NA NA NA NA NA CPCG0090 0 0 2 0 0 0 0 1 CPCG0096 0 0 1 NA NA NA NA NA CPCG0097 1 0 2 NA NA NA NA NA CPCG0120 0 0 1 NA NA NA NA NA CPCG0122 0 0 0 1 0 1 0 0 CPCG0126 0 0 0 NA NA NA NA NA CPCG0194 0 0 0 NA NA NA NA NA CPCG0198 1 0 1 NA NA NA NA NA CPCG0204 0 1 3 NA 0 NA NA NA NA CPCG0237 0 0 1 0 0 0 0 0 CPCG0243 0 0 0 0 0 0 0 CPCG0257 0 0 0 NA NA NA NA NA CPCG0067 0 0 4 NA NA NA NA NA CPCG0103 0 0 2 NA NA NA NA NA CPCG0072 0 0 1 NA NA NA NA NA CPCG0100 0 1 2 NA NA NA NA NA CPCG0187 0 1 1 NA NA NA NA NA CPCG0188 0 0 0 NA NA NA NA NA CPCG0235 0 0 0 NA NA NA NA NA CPCG0349 0 0 1 NA NA NA NA NA CPCG0377 0 0 1 NA NA NA NA NA CPCG0382 0 0 0 NA NA NA NA NA CPCG0408 0 0 0 NA NA NA NA NA Berger0508 0 0 3 0 NA 1 NA 0 Berger0581 0 0 0 NA NA NA NA NA Berger1701 0 0 0 1 NA 0 NA 0 Berger1783 0 0 0 NA NA NA NA NA Berger2832 0 0 0 1 NA 0 NA 0 Berger3027 0 0 1 NA NA NA NA NA Berger3043 0 0 3 0 NA 0 NA 1 EOPC-02 0 0 0 0 NA 0 NA 0 EOPC-03 0 0 1 NA NA NA NA NA EOPC-04 1 0 2 0 NA 1 NA 1 EOPC-05 1 0 1 0 NA 0 NA 0 EOPC-06 0 0 0 0 NA 0 NA 0 EOPC-07 0 0 4 0 NA 0 NA 0 EOPC-08 0 0 0 0 NA 0 NA 0 EOPC-09 0 0 0 0 NA 0 NA 0 EOPC-010 0 0 2 0 NA 0 NA 0 EOPC-011 0 0 0 0 NA 0 NA 0 Baca03-1426 0 0 1 1 0 0 0 1 Baca05-1657 0 0 1 1 0 0 0 0 Baca05-3595 1 0 2 0 0 0 0 1 Baca05-3852 0 0 2 1 0 0 0 0 Baca06-1749 0 0 1 0 1 1 1 0 Baca06-3199 0 1 1 1 1 1 0 1 Baca07-4610 0 1 1 1 1 0 0 1 Baca07-4941 0 0 1 1 0 0 0 1 Baca07-5037 0 0 0 1 0 0 0 1 Baca08-4154 0 0 1 0 1 1 0 1 Baca08-716 0 0 0 0 0 1 0 1 Baca09-37 0 0 1 1 0 0 0 1 BacaSTID 0 0 0 0 0 0 0 0 0000000410 BacaSTID 0 0 1 1 0 1 0 0 0000002872 TCGA-CH- 0 0 2 0 0 1 0 1 5750 TCGA-CH- 0 0 0 NA NA NA NA NA 5763 TCGA-CH- 0 0 0 NA NA NA NA NA 5771 TCGA-CH- 1 0 1 0 1 1 1 1 5788 TCGA-CH- 0 0 0 0 0 0 0 0 5789 TCGA-EJ- 0 0 0 NA NA NA NA NA 5503 TCGA-EJ- 1 0 2 NA NA NA NA NA 5506 TCGA-EJ- 0 0 0 0 0 0 0 0 7791 TCGA-G9- 0 0 2 1 0 0 0 0 6336 TCGA-G9- 0 0 0 1 0 0 0 1 6365 TCGA-G9- 0 0 0 0 0 0 0 0 6370 TCGA-G9- 0 0 0 0 0 0 0 0 7522 TCGA-HC- 1 0 1 0 0 1 1 1 7075 TCGA-HC- 0 0 0 0 0 0 0 0 7079 TCGA-HC- 0 0 0 0 0 0 0 1 7233 TCGA-HC- 0 0 0 NA NA NA NA NA 7737 TCGA-HC- 0 0 0 0 0 0 0 0 7740 TCGA-HC- 0 0 0 1 0 1 1 1 7744 TCGA-HC- 0 0 0 0 0 0 0 0 8258 TCGA-HI- 0 0 0 0 0 0 0 1 7169 CDK chr7: chr16: chr13: chr2: GR (median CDH1_ N1B_ CHD1_ MYC_ NKX3-1_ PTEN_ RB1_ TP53_ 14501 6491 5805 13139 dichotomized) CNA CNA CNA CNA CNA CNA CNA CNA 9604 0033 5742 0479 0 0 0 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 1 −1 0 −1 0 0 0 0 0 0 −1 0 0 1 −1 0 0 0 0 0 0 0 0 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 −1 1 0 −1 −1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 −1 0 0 0 0 0 0 1 −1 0 0 0 0 0 −1 0 0 0 0 0 0 0 0 0 0 −1 0 −1 −1 0 0 1 0 0 0 0 0 1 −1 0 −1 0 0 0 0 0 0 0 0 0 1 −1 0 0 0 1 1 0 0 0 0 −1 0 1 −1 0 −1 0 0 0 0 0 1 −1 0 0 1 −1 0 0 −1 0 0 0 0 0 −1 0 0 1 −1 0 0 −1 0 0 0 0 1 0 0 −1 0 −1 −1 0 0 0 0 0 0 0 0 0 0 0 0 −1 −1 −1 0 0 0 0 0 0 0 0 0 0 −1 0 0 0 0 0 0 1 0 −1 0 1 −1 0 −1 0 1 0 0 0 1 0 0 −1 0 −1 −1 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 −1 0 0 0 0 0 0 0 −1 0 0 −1 −1 0 0 0 0 0 1 0 −1 −1 0 0 0 −1 0 0 0 0 0 0 −1 0 0 0 −1 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 −1 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 −1 0 0 −1 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 −1 0 −1 0 0 −1 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 −1 0 0 −1 0 0 0 0 0 0 1 −1 0 −1 0 −1 0 0 0 0 0 0 0 0 1 0 −1 1 −1 −1 −1 −1 0 1 0 0 1 0 0 0 0 −1 −1 0 0 0 0 1 0 1 0 0 0 0 −1 0 −1 −1 0 1 0 0 1 0 0 −1 0 0 −1 0 0 0 0 0 0 1 0 0 0 0 −1 −1 0 0 0 0 0 0 1 0 1 0 0 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 −1 0 −1 0 −1 0 0 0 0 0 0 0 0 0 0 −1 −1 0 0 0 0 0 0 1 0 0 0 1 −1 0 0 0 0 1 0 0 1 0 0 0 0 −1 0 0 0 0 0 0 0 1 0 0 0 0 −1 0 0 −1 0 0 0 0 1 0 −1 0 0 −1 −1 −1 0 0 0 0 0 0 0 −1 0 0 −1 0 0 −1 0 0 0 0 0 0 0 0 0 −1 −1 0 −1 0 0 0 0 0 −1 −1 0 0 0 0 0 0 0 0 0 0 1 −1 −1 0 0 −1 −1 0 −1 0 0 0 0 1 0 −1 −1 0 −1 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 −1 1 −1 0 0 0 0 0 0 0 1 0 0 0 0 0 −1 −1 0 0 0 0 0 1 0 0 0 0 −1 −1 0 0 0 0 0 0 1 0 0 0 1 −1 −1 0 0 0 0 0 0 0 0 −1 0 0 0 0 0 0 0 0 1 0 1 0 −1 0 0 −1 −1 0 −1 0 0 0 0 1 0 −1 −1 0 −1 0 −1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 −1 0 0 0 0 0 0 0 0 0 0 −1 −1 0 0 0 0 0 0 0 0 0 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 −1 0 0 0 0 −1 0 −1 0 0 0 0 1 −1 0 0 0 −1 0 0 0 0 0 1 0 1 −1 0 0 0 −1 −1 0 0 0 0 0 0 0 0 −1 0 0 −1 0 0 0 0 0 0 0 0 0 −1 0 0 −1 −1 0 0 0 0 0 0 1 0 −1 0 0 0 0 0 0 0 0 1 0 1 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 −1 0 0 −1 0 0 0 0 0 0 0 1 −1 0 0 0 −1 −1 0 −1 0 0 0 0 1 0 −1 0 0 −1 −1 0 0 0 0 0 0 1 0 −1 0 0 −1 0 −1 0 0 0 0 1 1 0 0 0 0 0 0 0 −1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 −1 −1 0 −1 −1 −1 0 0 0 0 0 0 −1 0 0 0 −1 0 −1 0 0 1 0 0 1 0 0 0 0 0 −1 −1 −1 0 0 1 0 1 0 0 0 0 0 0 −1 0 0 0 0 0 0 0 1 0 1 1 0 −1 0 1 0 0 0 1 0 −1 0 0 0 −1 −1 0 0 0 0 0 0 −1 0 0 0 −1 0 −1 −1 0 0 0 0 1 0 −1 0 0 −1 −1 0 0 0 1 0 0 0 0 0 0 0 −1 −1 −1 0 0 0 0 0 0 0 0 0 0 0 −1 −1 0 0 0 0 0 1 0 −1 0 0 −1 −1 0 −1 0 0 0 1 1 0 0 0 0 0 0 0 −1 0 0 0 0 0 −1 0 0 0 −1 0 0 0 0 0 0 0 1 0 0 0 0 0 −1 −1 −1 0 0 0 0 0 −1 0 0 0 0 0 −1 −1 0 0 0 0 1 0 −1 −1 0 −1 0 0 0 1 0 0 0 0 0 0 0 0 −1 −1 0 −1 0 0 0 0 0 0 0 0 0 0 −1 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 −1 −1 0 1 −1 0 0 −1 0 0 0 0 1 −1 −1 0 0 −1 0 0 0 0 0 0 0 1 0 −1 0 0 0 −1 −1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 −1 0 0 0 0 0 0 0 0 0 1 −1 −1 0 0 −1 −1 0 0 0 0 0 0 1 −1 0 0 1 −1 0 −1 −1 0 0 0 0 1 0 0 0 1 −1 −1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 −1 0 0 0 0 0 0 1 0 −1 −1 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 −1 −1 0 0 −1 −1 −1 0 0 0 0 0 0 −1 0 0 0 −1 0 0 0 0 0 0 1 0 0 −1 0 0 0 0 0 0 0 0 0 1 0 0 −1 0 −1 0 −1 −1 0 0 0 0 1 0 0 0 0 −1 −1 0 0 0 0 0 0 1 0 −1 0 0 −1 −1 0 −1 0 0 0 0 0 0 0 0 0 0 −1 0 0 0 0 0 1 1 −1 0 0 0 −1 −1 −1 −1 0 0 0 1 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA 0 0 0 0 −1 0 0 −1 NA NA NA NA NA 0 0 0 0 0 0 0 0 NA NA NA NA NA 0 −1 0 0 −1 0 −1 0 NA NA NA NA NA −1 0 0 1 0 0 0 0 NA NA NA NA NA 0 0 0 0 −1 −1 0 0 NA NA NA NA NA 0 0 0 0 0 −1 −1 0 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA 0 0 0 0 1 0 0 1 NA NA NA NA NA 0 0 0 0 0 0 0 0 NA NA NA NA NA −1 0 −1 0 −1 −1 0 0 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 NA 0 0 0 0 0 0 0 0 NA NA NA NA NA 0 0 0 0 0 0 0 0 NA NA NA NA NA −1 0 0 0 0 −1 0 0 NA NA NA NA NA 0 0 0 0 0 −1 0 0 NA NA NA NA NA −1 0 0 1 −1 0 0 0 NA NA NA NA NA 0 0 0 0 0 0 0 1 NA NA NA NA NA 0 0 0 0 0 0 0 0 NA NA NA NA 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 0 0 0 0 0 −1 −1 0 NA NA NA NA NA 0 0 0 0 0 0 0 0 NA NA NA NA NA −1 0 0 1 1 0 −1 0 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 NA 0 1 0 0 −1 0 −1 0 NA NA NA NA NA −1 0 0 0 −1 0 0 0 NA NA NA NA NA 0 0 0 0 0 0 0 0 NA NA NA NA NA 0 0 0 0 −1 0 0 −1 NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 NA 0 0 0 0 −1 0 0 0 NA NA NA NA NA 0 0 0 0 0 0 0 0 NA NA NA NA NA 0 0 0 0 0 0 0 −1 NA NA NA NA NA 0 0 0 1 −1 0 0 0 NA NA NA NA NA −1 0 −1 1 −1 −1 0 −1 NA NA NA NA NA 1 0 0 1 −1 0 0 −1 NA NA NA NA NA 0 0 0 0 −1 0 −1 −1 NA NA NA NA NA −1 0 −1 1 −1 0 −1 0 NA NA NA NA NA 0 0 −1 0 −1 0 −1 0 NA NA NA NA NA 0 0 0 0 −1 0 0 0 NA NA NA NA NA −1 0 −1 1 −1 0 −1 0 NA NA NA NA NA 0 −1 0 0 −1 −1 0 0 NA NA NA NA 1 NA NA NA NA NA NA NA NA 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 1 NA NA NA NA NA NA NA NA 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 1 NA NA NA NA NA NA NA NA 0 0 0 0 0 NA NA NA 0 −1 NA NA NA 0 0 0 0 NA NA NA NA 1 −1 NA NA NA NA NA NA NA 0 NA NA NA 0 0 NA NA NA 0 0 0 0 0 NA NA NA 0 0 NA NA NA 0 0 0 0 0 NA NA NA 0 0 NA NA NA 0 0 0 0 0 NA NA NA 0 −1 NA NA NA 0 0 0 0 0 NA NA NA 0 0 NA NA NA 0 0 0 0 0 NA NA NA 0 0 NA NA NA 0 0 0 0 0 NA NA NA NA NA NA NA NA 0 0 0 0 0 NA NA NA 0 0 NA NA NA 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 −1 −1 0 0 0 0 0 0 1 0 0 0 1 −1 0 0 −1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 −1 0 0 1 0 −1 0 0 0 0 0 0 1 0 0 0 0 0 −1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 −1 −1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1 −1 0 −1 0 −1 1 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 −1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 chr22: chr4: 3182 3968 ATM_ FOXA1_ MED12_ SPOP_ TP53_ 6396 4557 SNV SNV SNV SNV SNV 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 1 0 NA NA NA NA NA NA NA 0 0 0 0 0 0 0 NA NA NA NA NA NA NA 0 0 0 0 0 0 0 NA NA NA NA NA NA NA 0 0 0 0 0 1 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 1 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 chr3: chr3: chr3: chr10: chr21: chr4: chr6: chr7: chr17: 125Mbp_ 129Mbp_ 195Mbp_ 89Mbp_ 42Mbp_ 148Mbp_ 97Mbp_ 61Mbp_ 25Mbp_ Inv Inv Inv Inv Inv Ctx Ctx Ctx Ctx 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 1 1 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 1 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1 1 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA 0 0 0 1 0 0 0 0 0 NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 NA NA NA NA NA NA NA NA NA 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 chr21: 42Mbp_ TCERG1L- TCERG1L- TUBA3C_ SOX14_ ACTL6B_ MIR129-2_ Ctx 5′_Meth 3′_Meth Meth Meth Meth Meth 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 0 1 0 0 1 1 0 NA NA NA NA NA NA 0 0 1 0 0 1 1 0 0 0 0 0 1 1 0 1 1 0 0 1 0 0 NA NA NA NA NA NA 1 0 0 1 1 1 0 0 1 1 0 1 1 1 1 NA NA NA NA NA NA 0 0 1 0 0 1 1 1 0 1 0 1 1 1 0 0 1 0 0 1 1 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 0 1 0 0 1 1 0 0 1 0 1 0 1 0 1 0 1 0 0 1 0 0 1 0 0 1 0 1 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 1 0 0 0 0 0 0 NA NA NA NA NA NA 0 1 0 1 1 0 1 0 1 0 0 0 1 1 0 NA NA NA NA NA NA 0 1 0 1 1 0 0 0 1 0 0 0 0 1 0 0 1 0 0 1 1 0 0 1 1 1 0 1 0 1 0 1 1 1 0 0 0 1 0 0 1 1 0 0 1 0 0 1 1 0 0 1 0 1 1 1 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 1 0 0 1 1 1 0 0 1 0 0 0 1 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 0 0 1 1 1 0 0 1 0 1 1 0 0 0 1 1 0 1 0 0 0 0 1 0 0 0 0 0 NA NA NA NA NA NA 0 1 1 0 0 1 1 0 0 1 0 0 1 1 0 0 1 0 0 1 1 0 0 0 0 0 1 1 0 0 1 1 0 0 1 1 1 0 1 1 1 1 0 0 1 0 0 1 0 0 1 0 1 1 1 0 1 1 0 1 0 1 0 0 0 1 1 1 1 1 1 0 1 0 1 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 1 0 1 1 0 0 0 1 1 0 1 1 1 1 1 1 0 1 1 1 1 0 0 0 1 1 0 0 0 1 1 1 1 1 0 0 0 1 0 0 1 1 0 1 0 0 1 0 1 0 0 0 0 1 1 1 0 1 0 1 0 0 1 0 0 1 1 1 1 0 0 1 0 0 1 0 0 0 1 0 1 1 1 0 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 0 0 0 1 0 1 0 0 0 1 0 1 1 1 1 0 1 1 0 0 0 1 1 0 1 0 1 1 0 0 1 0 1 0 0 0 1 0 0 0 0 1 0 0 1 0 0 1 0 0 0 1 1 0 0 1 0 1 0 0 1 0 0 0 0 1 0 1 0 0 0 1 0 1 0 1 0 0 0 0 1 0 0 0 0 0 1 0 1 1 1 0 0 0 1 0 1 0 0 1 0 0 1 1 1 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 1 0 1 1 1 1 0 0 0 1 1 0 0 0 1 0 1 0 0 0 0 1 1 0 1 0 0 1 1 1 1 0 1 1 0 1 0 0 1 0 1 0 1 0 0 1 0 0 0 1 1 1 1 0 0 0 0 1 0 0 0 1 0 0 1 0 1 1 1 0 0 1 0 0 1 1 0 0 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 1 0 1 0 0 0 0 0 0 1 1 1 1 0 0 1 0 1 1 0 0 0 1 1 1 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 1 0 1 0 1 0 1 0 1 1 1 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 0 1 0 0 1 1 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 1 1 1 1 1 1 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 1 NA NA NA NA NA NA 1 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA NA NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA 0 NA NA NA NA NA NA

TABLE 7 Table of mtSNVs with AHF values between 0.1 and 0.2 Tumour Tumour Tumour Tumour Normal Normal Normal Normal Tumour Normal mtDNA Difference Patient Position Reference Tumour HF-A HF-C HF-G HF-T Normal HF-A HF-C HF-G HF-T Coverage Coverage Locus in HF CPCG0120 61 C C 0 0.88 0.04 0.08 C 0 1 0 0 2414 1066 CR 0.12 ICGC_PCA087 72 T T 0 0.13 0 0.87 T 0 0 0 1 1733 1357 CR 0.13 ICCC_PCA161 146 C T 0 0.01 0 0.99 T 0 0.17 0 0.83 2239 839 CR 0.16 ICGC_PCA053 152 C T 0 0.13 0 0.87 T 0 0 0 1 3817 3423 CR 0.13 ICCC_PCA130 203 G G 0.14 0 0.86 0 G 0 0 1 0 5419 597 CR 0.14 CPCG0211 204 T C 0 0.99 0 0.01 C 0 0.65 0 0.15 6273 732 CR 0.14 CPCG0128 249 A A 1 0 0 0 A 0.89 0 0.11 0 6347 859 CR 0.11 CPCG0126 291 A A 0.88 0 0 0.12 A 1 0 0 0 6805 1010 CR 0.12 CPCG0126 294 T T 0 0.13 0 0.87 T 0 0 0 1 6536 916 CR 0.13 CPCG0126 296 C C 0 0.88 0.12 0 C 0 1 0 0 6269 678 CR 0.12 CPCG0126 297 A G 0 0.15 0.85 0 G 0 0 1 0 5914 543 CR 0.15 CPCG0126 299 C C 0.11 0.89 0 0 C 0 1 0 0 7035 1001 CR 0.11 CPCG0267 302 A A 0.99 0.01 0 0 A 0.86 0.14 0 0 2788 429 CR 0.13 CPCG0371 302 A A 0.99 0.01 0 0 A 0.89 0.11 0 0 3650 1316 CR 0.1 CPCG0071 302 A A 0.87 0.12 0.01 0 A 0.98 0.02 0 0 2725 1059 CR 0.1 CPCG0126 302 A A 0.84 0.16 0 0 A 0.98 0.01 0 0 5384 584 CR 0.15 Baca05-3595 303 C C 0.02 0.97 0 0 C 0.2 0.8 0 0 4713 210 CR 0.17 Baca05-3595 309 C T 0 0.24 0 0.76 T 0 0.12 0 0.88 3340 1188 CR 0.13 Baca05-3595 460 T T 0.11 0 0 0.88 T 0.27 0 0 0.73 6244 2829 CR 0.15 CPCG0204 529 G G 0 0 1 0 G 0.11 0 0.89 0 6579 2313 CR 0.11 CPCG0089 545 G G 0.12 0.01 0.87 0 G 0 0 1 0 1106 2018 CR 0.13 ICGC_PCA184 586 G G 0.19 0 0.81 0 G 0 0 1 0 6197 3270 TF 0.19 CPCG0096 653 G G 0 0 1 0 G 0.11 0 0.89 0 7418 1911 RNR1 0.1 CPCG0036 709 G G 0.19 0 0.81 0 G 0 0 1 0 7241 777 RNR1 0.19 ICGC_PCA053 827 A A 0.88 0 0.12 0 A 1 0 0 0 5176 5170 RNR1 0.12 ICCC_PCA094 953 T T 0 0.14 0 0.86 T 0 0 0 1 4544 1383 RNR1 0.14 CPCG0084 1072 G G 0.19 0 0.81 0 G 0 0 1 0 5886 1888 RNR1 0.19 ICGC_PCA064 1252 G G 0.19 0 0.81 0 G 0 0 1 0 7649 6466 RNR1 0.19 CPCG0070 1324 T T 0 0 0 1 T 0 0.16 0 0.84 7774 3376 RNR1 0.16 ICCC_PCA124 1454 G G 0.16 0 0.84 0 G 0 0 1 0 7325 2704 RNR1 0.16 ICGC_PCA132 1485 G G 0.13 0 0.87 0 G 0 0 1 0 6697 2019 RNR1 0.13 CPCG0005 1826 G G 0.15 0 0.85 0 G 0 0 1 0 7673 1994 RNR2 0.15 CPCG0089 1906 G G 0.07 0.04 0.88 0 G 0 0 1 0 2144 3082 RNR2 0.11 CPCG0067 2203 G G 0.04 0.01 0.9 0.06 G 0 0 1 0 213 1286 RNR2 0.1 CPCG0368 2233 T T 0 0 0 1 T 0 0.16 0 0.84 7765 3094 RNR2 0.15 ICGC_PCA197 2296 T T 0 0.19 0 0.81 T 0 0 0 1 7371 2948 RNR2 0.19 CPCG0413 2321 A G 0.04 0 0.96 0 G 0.2 0 0.8 0 7059 3641 RNR2 0.15 CPCG0408 2345 G G 0.14 0 0.86 0 G 0 0 1 0 7306 6130 RNR2 0.14 CPCG0114 2487 A A 0.99 0.01 0 0 A 0.84 0.15 0 0.01 1953 252 RNR2 0.15 CPCG0123 2487 A A 0.99 0.01 0 0 A 0.85 0.12 0.01 0 6361 1104 RNR2 0.14 CPCG0166 2487 A A 1 0 0 0 A 1 0 0 0.01 126 1065 RNR2 0.13 CPCG0211 2487 A A 0.86 0.13 0.01 0 A 0.81 0.17 0.01 0 6421 605 RNR2 0.19 Berger3027 2487 A A 0.95 0.05 0 0 A 0.8 0.2 0 0 2734 7990 RNR2 0.15 CPCG0067 2536 G G 0.11 0 0.89 0 A 0 0 1 0 5891 2001 RNR2 0.11 Baca06-3199 2553 G G 0.12 0 0.88 0 G 0 0 1 0 6914 6249 RNR2 0.12 CPCG0361 2587 G G 0.15 0 0.85 0 G 0 0 1 1 7215 3708 RNR2 0.15 ICGC_PCA172 2609 T T 0 0.18 0 0.82 G 0 0 0 0 5372 5848 RNR2 0.18 Baca06-1749 2698 G G 0.15 0 0.85 0 T 0 0 1 0 6547 2793 RNR2 0.15 ICGC_PCA165 2698 G G 0 0 0.88 0 G 0 0 1 0 7239 1912 RNR2 0.12 CPCG0046 2700 G G 0.01 0 0.88 0.11 G 0 0 1 0 379 1626 RNR2 0.12 CPCG0201 2702 G G 0.13 0 0.87 0 G 0 0 1 0 7436 2468 RNR2 0.13 ICGC_PCA059 2916 G G 0.16 0 0.84 0 G 0 0 1 0 4442 2547 RNR2 0.16 TCGA-CH-5789 3243 A A 0.89 0 0.11 0 G 1 0 0 0 7105 6797 TL1 0.1 ICGC_PCA034 3358 G G 0.13 0 0.87 0 A 0 0 1 0 5359 2244 ND1 0.13 CPCG0094 3447 A A 0.88 0.1 0.01 0.01 A 1 0 0 0 4366 939 ND1 0.12 CPCG0123 3447 A A 1 0 0 0 A 0.84 0.12 0.02 0.02 5662 1018 ND1 0.16 CPCG0183 3447 A A 1 0 0 0 A 0.85 0.11 0.02 0.02 6238 951 ND1 0.15 CPCG0211 3447 A A 1 0 0 0 A 0.88 0.1 0.02 0 6535 637 ND1 0.12 CPCG0071 3447 A A 0.85 0.14 0.01 0.01 A 0.95 0.05 0 0 4372 1535 ND1 0.11 BacaSTID0000002872 3447 A A 1 0 0 0 A 0.88 0.1 0.01 0.01 4415 1634 ND1 0.12 Berger3043 3452 T T 0 0.19 0 0.81 T 0 0 0 1 4071 795 ND1 0.19 ICGC_PCA023 3457 G G 0.13 0 0.87 0 G 0 0 1 0 5304 5385 ND1 0.13 CPCG0089 3464 T T 0.07 0.06 0 0.87 T 0 0 0 1 4676 3687 ND1 0.13 CPCG0123 3468 A A 1 0 0 0 A 0.85 0.12 0.01 0.02 5725 954 ND1 0.14 CPCG0183 3468 A A 0.99 0.01 0 0 A 0.87 0.09 0.01 0.02 6470 924 ND1 0.12 CPCG0071 3468 A A 0.86 0.12 0 0.01 A 0.96 0.04 0 0 4425 1497 ND1 0.1 CPCG0123 3475 A A 1 0 0 0 A 0.88 0.11 0 0.01 5599 907 ND1 0.12 ICGC_PCA173 3483 G G 0 0 1 0 G 0.12 0 0.88 0 7586 4617 ND1 0.12 CPCG0089 3488 T T 0.06 0.07 0.01 0.87 T 0 0 0 1 3368 3131 ND1 0.13 CPCG0123 3492 A A 0.97 0.02 0 0 A 0.82 0.16 0.01 0 5220 813 ND1 0.15 CPCG0183 3492 A A 1 0 0 0 A 0.81 0.18 0.01 0 5640 720 ND1 0.19 CPCG0211 3492 A A 0.99 0.01 0 0 A 0.81 0.18 0 0 6252 475 ND1 0.18 CPCG0067 3531 G G 0.08 0.02 0.89 0 G 0 0 1 0 2461 766 ND1 0.1 Baca09-37 3567 C C 0 0.82 0 0.17 C 0 1 0 0 6043 4943 ND1 0.17 CPCG0127 3592 G G 0.1 0 0.9 0 G 0 0 1 0 6787 1064 ND1 0.1 CPCG0210 3614 T T 0 0.11 0 0.89 T 0 0 0 1 7477 1319 ND1 0.11 ICGC_PCA184 3715 G G 0.12 0 0.88 0 G 0 0 1 0 6406 3722 ND1 0.12 CPCG0189 3834 G G 0.2 0 0.8 0 G 0 0 1 0 7677 1734 ND1 0.2 ICGC_PCA048 4142 G G 0.2 0 0.8 0 G 0 0 1 0 3163 2816 ND1 0.2 CPCG0346 4153 G G 0.16 0 0.84 0 G 0 0 1 0 5516 1739 ND1 0.16 CPCG0267 4226 T T 0 0.04 0 0.96 T 0 0.17 0 0.83 6856 1733 ND1 0.13 ICGC_PCA192 4408 G G 0.1 0 0.9 0 G 0 0 1 0 3913 2915 TM 0.1 ICGC_PCA132 4412 G G 0.11 0 0.89 0 G 0 0 1 0 6704 2125 TM 0.11 CPCG0378 4428 G G 0.18 0 0.82 0 G 0 0 1 0 7468 4250 TM 0.18 Baca07-5037 4762 T T 0 0.17 0 0.83 T 0 0 0 1 7290 7502 ND2 0.17 CPCG0022 4848 G G 0 0 0.87 0.13 G 0 0 0.98 0.02 1236 3356 ND2 0.11 CPCG0126 4969 G G 0.19 0 0.81 0 G 0 0 1 0 7426 1891 ND2 0.19 CPCG0236 5177 G G 0.14 0 0.86 0 G 0 0 1 0 7524 2322 ND2 0.13 CPCG0123 5208 A A 1 0 0 0 A 0.88 0.09 0.01 0.02 5545 1037 ND2 0.12 CPCG0183 5208 A A 1 0 0 0 A 0.88 0.09 0.01 0.02 6415 831 ND2 0.12 CPCG0211 5208 A A 1 0 0 0 A 0.89 0.08 0.02 0 6277 413 ND2 0.11 CPCG0122 5208 A A 1 0 0 0 A 0.89 0.09 0.01 0.01 6710 621 ND2 0.11 ICGC_PCA184 5476 T T 0 0.19 0 0.81 T 0 0 0 1 7121 4051 ND2 0.19 CPCG0234 5511 T T 0.02 0.08 0 0.9 T 0 0 0 1 106 1613 ND2 0.1 CPCG0344 5511 T T 0 0.19 0 0.81 T 0 0 0 1 7434 2172 ND2 0.19 ICGC_PCA103 5521 G G 0.14 0 0.86 0 G 0 0 1 0 6905 3724 TW 0.14 CPCG0071 5734 T T 0 0.11 0 0.88 T 0 0 0 1 4363 1110 OLR 0.12 CPCG0346 5801 T T 0 0.12 0 0.88 T 0 0 0 1 7580 3087 TC 0.12 CPCG0089 6054 G G 0.08 0.03 0.88 0 G 0 0 1 0 3712 3366 CO1 0.12 ICGC_PCA131 6128 C C 0 0.6 0 0.4 T 0 0.4 0 0.6 7042 2821 CO1 0.2 ICGC_PCA069 6164 C C 0.13 0.87 0 0 C 0 1 0 0 5295 2424 CO1 0.13 ICGC_PCA001 6221 T C 0 1 0 0 C 0 0.89 0 0.11 4346 1283 CO1 0.11 ICGC_PCA017 6366 G G 0.13 0 0.87 0 G 0 0 1 0 3616 4404 CO1 0.13 CPCG0048 6419 A A 1 0 0 0 A 0.88 0.11 0 0 6135 1051 CO1 0.11 CPCG0005 6419 A A 0.99 0.01 0 0 A 0.86 0.14 0 0 6158 1041 CO1 0.13 CPCG0084 6419 A A 0.99 0.01 0 0 A 0.84 0.15 0 0 6190 1189 CO1 0.15 CPCG0100 6419 A A 0.98 0.01 0 0 A 0.88 0.11 0 0 5818 896 CO1 0.1 CPCG0089 6430 T T 0.06 0.04 0.01 0.9 T 0 0 0 1 3642 5059 CO1 0.1 CPCG0089 6438 T T 0.05 0.05 0 0.9 T 0 0 0 1 3156 4906 CO1 0.1 CPCG0166 6480 G G 0.24 0 0.76 0 G 0.43 0 0.57 0 6847 1518 CO1 0.19 CPCG0362 6532 T T 0 0.11 0 0.89 T 0 0 0 1 7341 3512 CO1 0.11 CPCG0122 6555 A A 1 0 0 0 A 0.9 0.07 0.03 0.01 7189 686 CO1 0.1 ICGC_PCA070 6627 G G 0.17 0 0.83 0 G 0 0 1 0 5014 3745 CO1 0.19 CPCG0183 6819 A A 1 0 0 0 A 0.89 0.08 0.01 0.01 6151 618 CO1 0.11 CPCG0122 6819 A A 1 0 0 0 A 0.87 0.1 0.02 0 5544 369 CO1 0.13 Berger1701 6819 A A 1 0 0 0 A 0.81 0.16 0.01 0.01 1949 371 CO1 0.18 Berger2832 6819 A A 0.87 0.12 0.01 0 A 0.99 0.01 0 0 2556 356 CO1 0.11 TCGA-CH-5763 6819 A A 1 0 0 0 A 0.88 0.1 0.01 0.01 2450 1031 CO1 0.12 ICGC_PCA189 6991 T T 0 0.12 0 0.88 T 0 0 0 1 7055 7399 CO1 0.12 CPCG0020 7020 G G 0.15 0 0.85 0 G 0 0 1 0 4448 711 CO1 0.15 CPCG0042 7102 T T 0 0 0 1 T 0 0.1 0 0.9 6816 1647 CO1 0.1 CPCG0211 7236 G G 0 0 1 0 G 0.12 0 0.88 0 6411 889 CO1 0.12 ICGC_PCA152 7391 T T 0 0.11 0 0.89 T 0 0 0 1 6554 3031 CO1 0.1 TCGA-EJ-5506 7566 G G 0.2 0 0.8 0 G 0 0 0.99 0 7401 4137 TD 0.19 ICGC_PCA129 7859 G G 0.04 0 0.96 0 G 0.22 0 0.78 0 7117 4475 CO2 0.18 ICGC_PCA132 7923 A A 0.88 0 0.12 0 A 1 0 0 0 6656 2270 CO2 0.12 CPCG0166 8088 T T 0 0.1 0 0.9 T 0 0 0 1 108 1604 CO2 0.1 CPCG0117 8403 T T 0 0.18 0 0.82 T 0 0 0 1 7413 1495 ATP8 0.18 CPCG0183 8577 A A 1 0 0 0 A 0.89 0.09 0.01 0.01 6412 1054 ATP6 0.11 ICGC_PCA145 8752 A A 0.87 0 0.13 0 A 1 0 0 0 5177 1819 ATP6 0.13 CPCG0089 8959 G G 0.07 0.03 0.89 0.01 G 0 0 1 0 3013 2740 ATP6 0.1 CPCG0243 8995 G G 0 0 1 0 G 0.12 0 0.88 0 7381 1823 ATP6 0.12 CPCG0081 9035 T T 0 0 0 1 T 0 0.16 0 0.84 7716 1845 ATP6 0.16 ICCC_PCA172 9165 T T 0 0.14 0 0.86 T 0 0 0 1 5046 5174 ATP6 0.14 CPCG0050 9276 G G 0.16 0 0.84 0 G 0 0 1 0 7018 1577 CO3 0.16 ICGC_PCA034 9552 G T 0 0.12 0 0.88 T 0 0 0 1 5171 2128 CO3 0.12 CPCG0123 9726 A A 1 0 0 0 A 0.88 0.08 0.01 0.02 6869 1607 CO3 0.12 CPCG0067 9744 G G 0.11 0 0.89 0 G 0 0 1 0 6386 2243 CO3 0.11 TCCA-HC-7740 9746 G G 0.46 0 0.54 0 G 0.27 0 0.73 0 6363 2884 CO3 0.19 ICGC_PCA174 9931 G G 0.17 0 0.83 0 G 0 0 1 0 7355 4095 CO3 0.17 ICCC_PCA170 9942 G G 0.1 0 0.9 0 G 0 0 1 0 7249 2955 CO3 0.1 CPCG0126 10197 G G 0.15 0 0.85 0 G 0 0 1 0 5271 1260 ND3 0.14 Baca05-3595 10203 G G 0 0 1 0 G 0.2 0 0.8 0 2812 112 ND3 0.19 CPCG0324 10237 T T 0 0 0 1 T 0 0.18 0 0.82 7346 1476 ND3 0.18 CPCG0123 10277 A A 1 0 0 0 A 0.88 0.11 0 0 6675 1499 ND3 0.12 CPCG0183 10277 A A 0.99 0 0 0 A 0.86 0.12 0.01 0.01 7016 1350 ND3 0.13 CPCG0184 10277 A A 1 0 0 0 A 0.9 0.09 0 0 6598 1654 ND3 0.1 CPCG0234 10277 A A 0.8 0.18 0.02 0 A 0.99 0.01 0 0 138 921 ND3 0.19 CPCG0097 10277 A A 0.87 0.12 0 0 A 0.99 0.01 0 0 583 1107 ND3 0.12 CPCG0100 10277 A A 0.99 0.01 0 0 A 0.89 0.1 0 0 6041 1016 ND3 0.1 CPCG0183 10283 A A 1 0 0 0 A 0.88 0.1 0.01 0.01 6903 1395 ND3 0.12 CPCG0211 10283 A A 1 0 0 0 A 0.89 0.1 0.01 0 6495 540 ND3 0.11 CPCG0048 10306 A A 0.99 0.01 0 0 A 0.86 0.13 0 0 6152 1091 ND3 0.13 CPCG0081 10306 A A 1 0 0 0 A 0.89 0.1 0 0 7641 1378 ND3 0.11 CPCG0123 10306 A A 1 0 0 0 A 0.83 0.16 0 0.01 6752 1535 ND3 0.17 CPCG0183 10306 A A 1 0 0 0 A 0.86 0.12 0.01 0 7275 1419 ND3 0.14 CPCG0211 10306 A A 0.99 0.01 0 0 A 0.87 0.12 0 0 6406 556 ND3 0.12 CPCG0015 10306 A A 0.99 0.01 0 0 A 0.88 0.12 0 0 5306 1884 ND3 0.11 Baca08-4154 10306 A A 0.84 0.16 0 0 A 0.95 0.05 0 0 249 3705 ND3 0.11 BacaSTID0000002872 10306 A A 1 0 0 0 A 0.86 0.13 0 0 4051 1542 ND3 0.13 CPCG0194 10326 T T 0 0 0 1 T 0 0.2 0 0.8 5883 1053 ND3 0.19 ICGC_PCA138 10373 G A 0.94 0 0.06 0 A 0.77 0 0.23 0 3764 1249 ND3 0.17 CPCG0212 10453 A A 0.94 0 0.16 0 A 1 0 0 0 6070 1936 TR 0.16 CPCG0234 10454 T T 0 0.16 0 0.84 T 0 0 0 1 148 1705 TR 0.16 CPCG0408 10591 T T 0 0 0 1 T 0 0.14 0 0.86 7721 6744 ND4L 0.14 EOPC-04 10603 C C 0.15 0.85 0 0 C 0 0.99 0 0 3530 5885 ND4L 0.14 CPCG0361 10677 G G 0.1 0 0.89 0 G 0 0 1 0 5789 3685 ND4L 0.11 CPCG0391 10686 G G 0.12 0 0.88 0 G 0 0 1 0 7276 6103 ND4L 0.12 ICGC_PCA053 10731 G G 0.11 0 0.89 0 G 0 0 1 0 6919 6480 ND4L 0.11 ICGC_PCA102 10768 A A 0.74 0 0.26 0 A 0.61 0 0.39 0 4758 2928 ND4 0.14 CPCG0089 10934 G G 0.07 0.03 0.89 0 G 0 0 1 0 2594 2217 ND4 0.11 CPCG0089 11031 G G 0.08 0.03 0.89 0 G 0 0 1 0 2913 3705 ND4 0.11 CPCG0257 11124 T T 0 0.18 0 0.82 T 0 0 0 1 7628 1926 ND4 0.18 ICGC-PCA192 11126 G G 0.12 0 0.88 0 G 0 0 1 0 3845 2760 ND4 0.12 ICGC_PCA040 11166 G G 0.03 0 0.97 0 G 0.14 0 0.86 0 5903 5831 ND4 0.1 CPCG0346 11223 T T 0 0.13 0 0.87 T 0 0 0 1 7478 2780 ND4 0.12 CPCG0067 11225 G G 0.11 0 0.89 0 G 0 0 1 0 6154 1591 ND4 0.11 CPCG0340 11250 T T 0 0.19 0 0.81 T 0 0 0 1 7525 3514 ND4 0.19 CPCG0078 11557 A A 0.94 0 0.06 0 A 0.82 0 0.18 0 7451 100 ND4 0.12 CPCG0072 11914 A G 0.11 0 0.89 0 G 0 0 1 0 4976 1962 ND4 0.11 CPCG0046 12125 G G 0 0 0.88 0.11 G 0 0 1 0 389 1921 ND4 0.11 CPCG0392 12134 T T 0 0 0 1 T 0 0.14 0 0.86 7599 1948 ND4 0.14 CPCG0241 12235 T T 0 0.15 0 0.85 T 0 0 0 1 7385 1447 TS2 0.15 CPCG0084 12457 G G 0.13 0 0.87 0 G 0.01 0 0.99 0 3270 1337 ND5 0.12 CPCG0166 12471 T T 0 0.2 0 0.8 T 0 0 0 1 193 1606 ND5 0.2 CPCG0388 12541 G G 0.13 0 0.87 0 G 0 0 1 0 7537 2422 ND5 0.13 Baca05-3852 12631 T T 0 0.15 0 0.85 T 0 0 0 1 6577 1992 ND5 0.15 CPCG0187 12772 G G 0 0 1 0 G 0.17 0 0.83 0 7180 891 ND5 0.17 Berger1701 12775 G G 0.16 0 0.84 0 G 0 0 0.99 0 2788 841 ND5 0.15 ICGC_PCA156 12977 T T 0 0.18 0 0.82 T 0 0 0 1 6751 3729 ND5 0.18 ICGC_PCA127 13042 G G 0.17 0 0.83 0 G 0 0 1 0 6856 3318 ND5 0.17 CPCG-0122 13094 T T 0 0.12 0 0.88 T 0 0 0 0.99 7441 983 ND5 0.11 ICGC_PCA172 13105 G G 0.09 0 0.91 0 G 0.23 0 0.77 0 5389 5714 ND5 0.14 TCGA-EJ-7791 13376 T T 0 0 0 0.99 T 0 0.14 0 0.86 6535 2460 ND5 0.13 Baca06-1749 13424 T T 0 0.16 0 0.84 T 0 0 0 1 7371 3119 ND5 0.15 ICGC_PCA031 13466 G G 0 0 1 01 3 0.17 0 0.83 0 5931 5521 ND5 0.17 CPCG0020 13590 G G 0.16 0 0.84 0 G 0 0 1 0 7611 1841 ND5 0.16 CPCG0089 13674 T T 0.05 0.07 0.01 0.87 T 0 0 0 1 3237 4163 ND5 0.13 CPCG0353 13708 G G 0.1 0 0.9 0 G 0 0 1 0 6663 3432 ND5 0.1 CPCG0046 13940 G G 0.06 0 0.89 0.05 G 0 0 1 0 318 1344 ND5 0.11 CPCG0123 14102 T T 0 0.19 0 0.81 T 0 0 0 0.99 7411 2392 ND5 0.18 ICGC_PCA024 14311 T T 0 0.14 0 0.86 T 0 0 0 1 4940 2480 ND6 0.14 CPCG0030 14423 G G 0.15 0 0.84 0 G 0.02 0 0.98 0 7206 1664 ND6 0.14 CPCG0072 14470 T T 0 0.12 0 0.88 T 0 0 0 1 6689 2084 ND6 0.12 CPCG0234 14560 G G 0 0 0.89 0.1 G 0 0 1 0 997 1290 ND6 0.11 CPCG0234 14698 G G 0 0 0.9 0.1 G 0 0 1 0 1360 1364 TE 0.1 ICGC_PCA143 14798 T C 0 0.85 0 0.15 C 0 0.7 0 0.3 7083 4223 CYB 0.15 CPCG0236 14859 G G 0.18 0 0.82 0 G 0 0 1 0 7208 2114 CYB 0.18 ICGC_PCA055 14985 G G 0.12 0 0.88 0 G 0 0 1 0 7069 4679 CYB 0.12 CPCG0046 15200 G G 0.01 0 0.9 0.09 G 0 0 1 0 424 1479 CYB 0.1 EOPC-07 15211 C T 0 0.01 0 0.99 T 0 0.11 0 0.89 5386 1718 CYB 0.11 CPCG0363 15216 G G 0.11 0 0.89 0.01 G 0 0 1 0 6276 3366 CYB 0.11 ICGC_PCA022 15228 T T 0 0.18 0 0.82 T 0 0 0 1 4273 6156 CYB 0.18 ICGC_PCA137 15255 T T 0 0.11 0 0.89 T 0 0 0 1 6969 2363 CYB 0.11 ICGC_PCA035 15356 G G 0.15 0 0.84 0 G 0 0 1 0 7076 4723 CYB 0.15 EOPC-02 15458 T C 0 0.71 0 0.28 C 0 0.91 0 0.09 4983 3285 CYB 0.19 CPCG0183 15536 A A 1 0 0 0 A 0.89 0.07 0.01 0.02 7009 1083 CYB 0.11 CPCG0211 15536 A A 1 0 0 0 A 0.89 0.08 0.02 0.01 6942 570 CYB 0.11 ICGC_PCA118 15614 G G 0.15 0 0.85 0 G 0 0 1 0 7135 3573 CYB 0.15 ICGC_PCA172 15825 C T 0 0.1 0 0.9 T 0 0.25 0 0.75 5181 5498 CYB 0.15 ICGC_PCA078 15900 T T 0 0.14 0 0.86 T 0 0 0 1 3010 3847 TT 0.14 CPCG0046 15927 G G 0.1 0 0.85 0.05 G 0 0 1 0 419 1717 TT 0.15 CPCG0235 15976 T T 0 0.2 0 0.8 T 0 0 0 1 7757 2096 TP 0.2 CPCG0048 16092 T C 0 0.85 0 0.15 C 0 0.96 0 0.04 7162 1622 CR 0.11 CPCG0057 16093 T C 0 0.87 0 0.13 C 0 0.97 0 0.03 7070 246 CR 0.11 CPCG0199 16093 T C 0 0.8 0 0.2 C 0 0.94 0 0.06 7365 2534 CR 0.13 CPCG0250 16093 T C 0 0.84 0 0.16 C 0 0.96 0 0.04 7176 2788 CR 0.13 CPCG0259 16093 T C 0 0.85 0 0.15 C 0 0.97 0 0.03 7063 2312 CR 0.12 CPCG0354 16093 T C 0 0.87 0 0.13 C 0 0.98 0 0.02 7123 4981 CR 0.11 Baca08-4154 16093 T C 0 0.92 0 0.08 C 0 0.73 0 0.27 104 6163 CR 0.19 ICGC_PCA053 16093 T C 0 0.79 0 0.21 C 0 0.98 0 0.02 6911 7080 CR 0.19 ICGC_PCA095 16093 T C 0 0.81 0 0.19 C 0 0.97 0 0.03 4785 2264 CR 0.16 ICGC_PCA151 16093 T C 0 0.88 0 0.12 C 0 0.98 0 0.01 5414 1639 CR 0.11 CPCG0378 16117 T T 0 0.16 0 0.84 T 0 0 0 1 7660 7058 CR 0.16 CPCG0194 16129 A G 0 0 1 0 G 0.14 0 0.85 0 3933 498 CR 0.14 CPCG0346 16145 G G 0.12 0 0.88 0 G 0 0 1 0 7495 3317 CR 0.12 ICGC_PCA153 16147 C C 0 0.87 0 0.13 C 0 1 0 0 6929 2343 CR 0.13 CPCG0122 16175 A A 1 0 0 0 A 0.9 0.1 0.01 0 5458 475 CR 0.1 CPCG0194 16183 A C 0.17 0.83 0 0 C 0.27 0.73 0 0 1329 490 CR 0.1 ICGC_PCA127 16184 C C 0 0.89 0 0.11 C 0 1 0 0 6185 3060 CR 0.11 CPCG0007 16187 T T 0 0.02 0 0.98 T 0 0.14 0 0.86 6350 1529 CR 0.11 Baca05-3852 16187 T C 0 0.98 0 0.02 C 0 0.86 0 0.14 6536 1173 CR 0.12 CPCG0070 16189 C T 0 0.03 0 0.97 T 0.01 0.14 0 0.86 7212 2311 CR 0.11 CPCG0194 16189 C C 0 0.98 0 0.01 C 0 0.87 0 0.12 1847 550 CR 0.11 EOPC-02 16189 C T 0 0.16 0 0.84 T 0.01 0.03 0 0.96 2314 1217 CR 0.12 BacaSTID0000000410 16189 C T 0 0.28 0 0.72 T 0 0.12 0 0.87 6024 402 CR 0.16 BacaSTID0000002872 16189 C C 0 0.86 0 0.14 C 0 1 0 0 3393 2188 CR 0.13 CPCG0194 16223 T T 0 0.01 0 0.99 T 0 0.14 0 0.86 3820 597 CR 0.13 ICGC_PCA001 16223 T T 0 0 0 1 T 0 0.12 0 0.88 5297 1828 CR 0.12 EOPC-02 16231 T C 0 0.86 0 0.14 C 0 1 0 0 2802 1558 CR 0.14 ICGC_PCA171 16247 A A 0.96 0 0.04 0 A 0.86 0 0.14 0 4771 2537 CR 0.1 ICGC_PCA026 16258 A A 0.81 0 0.19 0 A 1 0 0 0 4236 1740 CR 0.19 EOPC-02 16261 C T 0 0.13 0 0.87 T 0 0.01 0 0.99 3465 2005 CR 0.12 EOPC-02 16265 A C 0.11 0.89 0 0 C 0 1 0 0 3807 2232 CR 0.1 CPCG0363 16266 C C 0 0.9 0 0.1 C 0 1 0 0 6878 2983 CR 0.1 CPCG0194 16266 C T 0 0.01 0 0.99 T 0 0.13 0 0.87 4844 875 CR 0.12 CPCG0194 16274 G A 1 0 0 0 A 0.89 0 0.11 0 5382 956 CR 0.1 CPCG0260 16278 T C 0 0.88 0 0.11 C 0 1 0 0 6258 1496 CR 0.11 CPCG0349 16296 C T 0 0.01 0 0.99 T 0 0.18 0 0.82 7025 3138 CR 0.16 TCGA-HC-7233 16311 C T 0 0.01 0 0.99 T 0 0.13 0 0.87 3246 1622 CR 0.12 CPCG0183 16318 A A 1 0 0 0 A 0.86 0 0.14 0 7392 1684 CR 0.14 CPCG0194 16390 G A 1 0 0 0 A 0.89 0 0.11 0 5047 1010 CR 0.1 CPCG0382 16519 C C 0 1 0 0 C 0 0.9 0 0.1 4052 1521 CR 0.1 CPCG0089 16522 T T 0.06 0.05 0 0.89 T 0 0 0 1 2521 2119 CR 0.11 CPCG0256 16527 C T 0 0.16 0 0.84 T 0 0.06 0 0.94 2232 692 CR 0.1 

The invention claimed is:
 1. A method of detecting one or more mitochondrial single nucleotide variations (mtSNVs) in a human subject with prostate cancer, the method comprising: detecting a single nucleotide variation at position 8393 or 8433 of a mitochondrial genome with respect to the Reconstructed Sapiens Reference Sequence (RSRS) reference genome by sequencing mitochondrial genetic material from prostate cancer cells from the subject, wherein the single nucleotide variation is a C>T substitution at position 8393 or a T>C substitution at position
 8433. 2. The method of claim 1, wherein the prostate cancer is localized prostate cancer.
 3. The method of claim 1, further comprising treating the subject with hormone therapy, chemotherapy, or radiotherapy.
 4. The method of claim 1, wherein the method further comprises detecting single nucleotide variations at one or more of positions 146, 152, 183, 195, 199, 207, 215, 227, 234, 248, 255, 307, and
 309. 5. The method of claim 1, wherein the method further comprises detecting a single nucleotide variation at one or more of positions 146, 152, 183, 195, 199, 207, 215, 227, 234, 248, 255, 307, 7772, 7803, 7919, 7929, 7997, 8078, 8391, 8547, 9378, 9380, 9504, 9516, 9628, 9673, 9786, 9797, 9840, 9891, 9977, 10558, 10586, 16027, 16035, 16048, 16051, 16086, 16092, 16093, 16147, 16148, 16153, 16162, 16169, 16182, 16183, 16184, 16188, 16189, 16192, 16213, 16278, 16304, and
 16342. 6. The method of claim 1, wherein the single nucleotide variation is a C>T substitution at position
 8393. 7. The method of claim 1, wherein the single nucleotide variation is a T>C substitution at position
 8433. 8. A method for treating a human subject for prostate cancer, the method comprising treating the subject with surgery, hormone therapy, chemotherapy, or radiotherapy, wherein the subject was determined to have a mitochondrial single nucleotide variation (mtSNV) at position 8393 or 8433 of a mitochondrial genome from prostate cancer cells from the subject with respect to the RSRS reference genome, wherein the single nucleotide variation is a C>T substitution at position 8393 or a T>C substitution at position
 8433. 9. The method of claim 8, wherein the subject was further determined to have a mutation in a region of a MYC gene from the prostate cancer cells.
 10. The method of claim 8, wherein the subject was further determined to have a mtSNV at one or more of positions 146, 152, 183, 195, 199, 207, 215, 227, 234, 248, 255, 307, and
 309. 11. The method of claim 8, wherein the subject was further determined to have a mtSNV at one or more of positions 146, 152, 183, 195, 199, 207, 215, 227, 234, 248, 255, 307, 309, 8391, 8547, 10558, 10586, 16027, 16035, 16048, 16051, 16086, 16092, 16093, 16147, 16148, 16153, 16162, 16169, 16182, 16183, 16184, 16188, 16189, 16192, 16213, 16278, 16304, and
 16342. 12. The method of claim 8, wherein the single nucleotide variation is a C>T substitution at position
 8393. 13. The method of claim 8, wherein the single nucleotide variation is a T>C substitution at position
 8433. 